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A B S T R A C T
Background
Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) in terms of reducing the
risk of joint damage, improving physical function and improving quality of life. This Cochrane review is an update of a review of the
treatment of RA with certolizumab pegol that was first published in 2011.
Objectives
To assess the clinical benefits and harms of certolizumab pegol (CDP870) in patients with RA who have not responded well to
conventional disease-modifying anti-rheumatic drugs (DMARDs).
Search methods
We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library 2014, Issue 5), MEDLINE, EMBASE, Scopus,
TOXLINE,Web of Knowledge; websites of the US Food and Drug Administration (FDA) and EuropeanMedicines Evaluation Agency
(EMEA); reference lists of articles; and searched http/clinicaltrials.gov. The searches were updated from 2009 (date of last search for
the original review) to 5 June 2014.
Selection criteria
Randomised controlled trials that compared certolizumab pegol with any other agent including placebo or methotrexate (MTX) in
adult patients with active RA despite current or prior treatment with conventional disease-modifying anti-rheumatic drugs (DMARDs),
such as MTX.
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Data collection and analysis
Two authors independently assessed search results, trial quality and extracted data. Disagreements were resolved by discussion or referral
to a third author.
Main results
Eleven trials were included in this update. Ten (4324 patients) were included in the pooled analysis for benefits, five more than
previously, and 10 (3711 patients) in the pooled analysis for harms, four more trials (1930 patients) than previously. The duration of
follow-up varied from 12 to 52 weeks and the range of doses of certolizumab pegol varied from 50 to 400 mg given subcutaneously
(sc). In phase III trials, the control was placebo plus MTX in five trials and placebo in four trials. The risk of bias of the included studies
was assessed as low but there may have been a risk of attrition bias.
Statistically significant improvements were observed at 24 weeks with the approved dose of 200 mg certolizumab pegol every other
week, in 1) American College of Rheumatology (ACR) 50% improvement: 27% absolute improvement (95% CI 20% to 33%), NNT
of 4 (95% CI 3 to 8), risk ratio (RR) 3.80 (95% CI 2.42 to 5.95); 2) the Health Assessment Questionnaire (HAQ): -12% absolute
improvement (95% CI -9% to -14%), NNT of 6 (95% CI 5 to 8), mean difference (MD) - 0.35 (95% CI -0.43 to -0.26) (scale 0 to
3); 3) Disease Activity Score (DAS) remission improvement: absolute improvement 11% (95% CI 8% to 15%), NNT of 9 (95% CI 4
to 20), RR 8.47 (95% CI 4.15-17.28); and 4) radiological changes: erosion score (ES) absolute improvement -0.29% (95% CI -0.42%
to -0.17%), NNT of 6 (95% CI 4 to 10), MD -0.67 (95% CI -0.96 to -0.38) (scale 0 to 230). Serious adverse events were statistically
significantly more frequent for certolizumab pegol (200 mg every other week) with an absolute rate difference of 4% (95% CI 2% to
6%), NNTH of 32 (95% CI 17 to 88), Peto odds ratio (OR) 1.77 (95% CI 1.27 to 2.46). There was a statistically significant increase
in all withdrawals in the placebo groups (for all doses and all follow-ups) with an absolute rate difference of -34% (95% CI -18% to
-50%), NNTH of 4 (95% CI 3 to 5), NNTH of 4 (95% CI 3 to 5), RR 0.42 (95% CI 0.36 to 0.50); and there was a statistically
significant increase in all withdrawals due to adverse events in the certolizumab groups (for all doses and all follow-up) with an absolute
rate difference of 2% (95% CI 1% to 3%), NNTH of 55 (95% CI 27 to 238), Peto OR 1.66 (95% CI 1.15 to 2.37).
The risk of bias was low and the quality of evidence was downgraded to moderate because of high rates of dropouts (> 20%) in most
of the trials. We did not find any problems with inconsistency, indirectness, imprecision or publication bias.
Authors’ conclusions
The results and conclusions did not change from the previous review. There is moderate-level evidence from randomised controlled
trials that certolizumab pegol alone or combined with methotrexate is beneficial in the treatment of RA. Adverse events were more
frequent with active treatment. We found a potential risk of serious adverse events.
P L A I N L A N G U A G E S U M M A R Y
Certolizumab pegol for treating adults with rheumatoid arthritis
We conducted an updated review of the effect of certolizumab pegol for adults with RA. We searched all relevant studies until June
2014 and found 11 studies with 4324 people.
In people with rheumatoid arthritis:
- certolizumab pegol probably improved the American College of Rheumatology ACR50 (pain, function and other symptoms of RA),
health-related quality of life, and the chance of remission of RA,
- certolizumab pegol probably reduced joint damage as seen on the x-ray,
- certolizumab pegol probably increased serious adverse events,
- with certolizumab pegol fewer people stopped taking their treatment, but most of these people stopped due to serious adverse events.
What is rheumatoid arthritis and what is certolizumab pegol?
When you have RA your immune system becomes overactive and attacks the lining of your joints. This makes your joints swollen, stiff
and painful. There is no cure for RA at present, so the treatments aim is to relieve pain and stiffness and improve your ability to move.
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Certolizumab pegol works by blocking a substance produced by the body known as tumour necrosis factor alpha (TNF). Certolizumab
pegol is given by injections under the skin, either by patients themselves or someone else.
What happens to people with rheumatoid arthritis who take certolizumab pegol 200 mg every other week after six months?
ACR50 (a 50% improvement in the number of tender or swollen joints and other outcomes such as pain and disability):
- 27more people out of 100 experienced improvement in the symptoms of their rheumatoid arthritis after six months with certolizumab
pegol (absolute improvement 27%),
- 36 people out of 100 who took certolizumab pegol experienced improvement compared to 9 people out of 100 who took a placebo
(a fake injection).
Health-related quality of life (Health Assessment Questionnaire):
- the additional benefit on this questionnaire for people who took certolizumab pegol was a change of -0.35 units on a scale 0 to 3
units (with 3 indicating a worse health state, therefore a negative change indicates improvement) (absolute improvement 12%),
- people on certolizumab pegol who completed the Health Assessment Questionnaire (HAQ) had a change of -0.48 points on a scale
of 0 to 3 compared to a change of -0.13 points on a scale of 0 to 3 for people who took a placebo.
Remission (absence of clinical signs of inflammation):
- 11 more people out of 100 experienced remission with certolizumab pegol (absolute improvement 11%),
- 13 people out of 100 who took certolizumab pegol experienced remission compared to 2 people out of 100 who took a placebo.
Radiological changes (x-rays of the joints):
- the joint damage in people who took certolizumab pegol was 0.07 units less on a scale of 0 to 230 units (absolute improvement -
0.29%),
- the damage to joints in people who took certolizumab pegol was 0.04 units less on a scale of 0 to 230 units compared to people who
took a placebo whose joint damage was 0.7 units more on a scale of 0 to 230 units.
Serious adverse events:
- 4 more people out of 100 experienced serious adverse events with certolizumab pegol (4% absolute harm),
- 8 people out of 100 who took certolizumab pegol experienced serious adverse events compared to 4 people out of 100 who took a
placebo.
What happens after 52 weeks to people with rheumatoid arthritis who take certolizumab pegol 200 mg and certolizumab 400
mg?
All withdrawals:
- 33 less people out of 100 stopped taking their treatment after 52 weeks with certolizumab pegol compared with placebo (absolute
improvement 34%),
- 23 people out of 100 who took certolizumab pegol stopped taking their treatment compared to 56 people out of 100 who took
placebo.
Withdrawals due to adverse events:
- 2 more people out of 100 stopped taking their treatment due to adverse events after 52 weeks with certolizumab pegol compared with
placebo (absolute improvement 2%),
- 5 people out of 100 who took certolizumab pegol stopped taking their treatment due to adverse events compared to 3 people out of
100 who took placebo.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Certolizumab pegol 200 mg sc (with or without M TX) versus placebo (with or without M TX) for rheumatoid arthritis in adults
Patient or population: pat ients with rheumatoid arthrit is in adults
Settings: adults (18 years old or more) who have persistent disease act ivity despite current or previous use of convent ional disease modif ying ant i-rheumatic drugs (DMARDs)
Intervention: certolizumab pegol 200 mg sc (with or without MTX) versus placebo (with or without MTX)
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per cent change = 66%
(15% to 137%).
NNTH = 55 (27 to 238)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 High risk of bias due to > 20% dropout rate in 4 out 5 trials. 2 High risk of bias due to > 20% dropout rate in 3 out 4 trials. 3
High risk of bias due to > 20% dropout rate in 3 out 4 trials. 4 High risk of bias due to > 20% dropout rate in 2 out 2 trials. 5
High risk of bias due to > 20 % dropout rate in 6 out 7 trials. 6 High risk of bias due to > 20% dropout rate in 7 out 10 trials.


































































































B A C K G R O U N D
Description of the condition
Rheumatoid arthritis (RA) is a chronic inflammatory disease af-
fecting the synovium of joints and other structures like tendon
sheaths and bursas. RA typically causes a symmetrical polyarticu-
lar arthritis with pain, swelling and stiffness of the affected joints.
If disease is not controlled early, damage may become perma-
nent leading to significant disability. Patients commonly experi-
ence fatigue and show changes in the blood, such as anaemia due
to chronic inflammation, and an acute phase reaction. In some
patients organs such as the skin (as rheumatoid nodules), lungs
(pleural inflammation and alveolitis), heart (pericarditis), blood
vessels (vasculitis) and the eyes (dry eyes or inflammation) may
be affected (Tureson 2013). RA is also associated with reduced
life expectancy, which is particularly due to cardiovascular disease
(Meune 2009) but in the early years also due to pulmonary disease
and lymphoma (Young 2007).
Important genetic influences are recognised, in particular genes
linked to activation of the immune system (Barton 2009), how-
ever environmental factors such as an urban versus a rural envi-
ronment and smoking are also associated with an increased risk of
RA (Edwards 2005). People of all ages are affected but the disease
begins most commonly between the ages of 40 and 70 years and
the incidence rises with increasing age (Doran 2002). Three times
as many women as men are affected and the population prevalence
in Western countries is between 0.5% and 1%. Significant func-
tional limitations occur in 15% of patients five years after disease
onset and around a third of those in paid work experience work
disability (Young 2000). In Spain, RA causes around 10% of total
disability and 5% of transitory disability (Carmona 2002) includ-
ing occupational disability (Doeglas 1995). Moreover, rapid in-
duction of remission translates into maintenance of work capacity
(Puolakka 2005).
Description of the intervention
The management of RA has undergone dramatic changes during
the last decade. The European League Against Rheumatism has re-
cently released updated recommendations for the management of
RA (Smolen 2014). The goal of treatment is to induce remission,
defined as the absence of signs and symptoms of significant inflam-
matory disease activity (Felson 2011). This applies particularly to
patients with newer onset RA, whereas in long-standing and re-
fractory disease low disease activity may be acceptable. To meet
these objectives, and according to the latest guidance, treatment
with disease-modifying anti-rheumatic drugs (DMARDs) should
be initiated as soon as a diagnosis of RA is made, and methotrexate
(MTX) has been considered (Lopez Olivo 2014) the mainstay of
treatment of RA (Singh 2012). The application of new treatment
strategies, such as tight control using composite measures of dis-
ease activity and appropriate switching of drug treatment when
the objectives are not reached, are also highly beneficial approaches
(Smolen 2010).
Not infrequently people do not respond to or are unable to tolerate
DMARDs (Yee 2003). The newer biological drugs that have been
introduced and approved for the treatment of RA in recent decades
have been associated with clinical outcome improvement (Singh
2009) but also with higher rates of adverse events (Singh 2011).
How the intervention might work
RA is characterised by immunological activation of many cell
types and a network of cytokines, particularly tumour necrosis
factor alpha (TNF-alpha) (Brennan 2008). Inhibitors of TNF-
alpha have been a major development in the treatment of RA.
Randomised trials have shown that these drugs are highly bene-
ficial in patients with RA who have not responded well to con-
ventional DMARDs. TNF-alpha inhibitors have been shown to
reduce the risk of joint damage, improve physical function and
quality of life (Chen 2006). Five TNF-alpha inhibitors are cur-
rently licensed for use in RA in Europe and the US. These are
adalimumab (Navarro Sarabia 2005), etanercept (Lethaby 2013),
golimumab (Singh 2010), infliximab (Lethaby 2013) and cer-
tolizumab pegol (Ruiz Garcia 2011). Comparative efficacy stud-
ies to evaluate the potential differences between anti-TNF and
non-antiTNF biologics have shown little difference between them
(Navarro Millan 2013). One pragmatic, open-label, controlled
trial has directly compared etanercept and adalimumab and re-
ported similar persistence rates and efficacy and safety over two
years of treatment (Jobanputra 2012). Similar results have been
obtained with certolizumab pegol in extension studies, the Amer-
ican College of Rheumatology ACR20 57% and ACR50 27% at
8 years (NCT00160693) and ACR20 81% and ACR50 58% at
7 years (NCT00175877). An important limitation of the wider
use of TNF inhibitors is the high cost, between USD 10,000 and
USD 25,000 per patient a year.
A systematic review of infliximab and adalimumab showed that
the risks of malignancy and serious infection were increased, with
odds ratios of 3.3 (95%confidence interval (CI) 1.2 to 9.1) and2.0
(95% CI 1.3 to 3.1) respectively (Bongartz 2006). However, more
recent data showed that therapy with anti-TNF is not related to an
increased risk of malignancies (skin cancer, melanoma, lymphoma
or solid tumours) (Lopez Olivo 2012). A second review of nine
biologic drugs (the five TNF inhibitors etanercept, adalimumab,
infliximab, golimumab and certolizumab pegol; the interleukin
(IL)-1 antagonist anakinra; the IL-6 antagonist tocilizumab; the
anti-CD28 abatacept; and anti-B cell rituximab) showed that bi-
ologics as a group were associated with a statistically significant
higher rate of total adverse events (odds ratio (OR) 1.28, 95%
credible index (CrI) 1.09 to 1.50) and withdrawals due to adverse
events (OR 1.47, 95% CrI 1.20 to 1.86), and an increased risk of
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tuberculosis (TB) reactivation (OR 4.68, 95% CrI 1.18 to 18.60)
compared to control (Singh 2011).
Certolizumab pegol is an anti-TNF consisting of a humanised
immunoglobulin fragment (Fab) conjugated to polyethylene gly-
col (PEG), also termed pegylation. This unique molecular struc-
ture yields a longer half-life and reduces the need for frequent
dosing (Choy 2002). Certolizumab pegol in combination with
methotrexate (MTX) is indicated for the treatment of moder-
ate to severe active RA in adult patients when the response to
DMARDs including MTX has been inadequate. It also can be
given as monotherapy in the case of intolerance, side effects or
contraindications to MTX. The drug has been shown to reduce
the rate of progression of joint damage as measured by x-ray and
to improve physical function. Long-term studies also show persis-
tence rates of 88.9% at two years with 46.7% of patients in low
disease activity (Keystone 2012).
Why it is important to do this review
Biological treatment has led to a radical change in the prognosis
and quality of life of patients with RA, however clinicians need
to take into account the potential risks associated with their use.
This review summarises the current data available on the benefits
and harms of certolizumab pegol, on its own and in combination
with MTX, for the treatment of RA. New evidences concerning
efficacy, safety and long-term persistence have become available
since the previous review update. It is important to be sure that
clinicians choose the treatment for people with RA appropriately
using the best medical evidence available.
O B J E C T I V E S
To assess the clinical benefits and harms of certolizumab pe-
gol (CDP870) in patients with RA who have not responded
well to conventional disease-modifying anti-rheumatic drugs
(DMARDs).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
Adults (18 years of age and older) with RA who have persistent
disease activity despite current or previous use of conventional
DMARDs.
Patients with RA were defined as those meeting the American
College of Rheumatology (ACR) 1987 revised criteria (Arnett
1988) for RA. That is to say, they had to have an active form of the
disease as demonstrated by at least two of the following symptoms:
1. three or more tender joint areas as observed by a physician;
2. three or more swollen joint areas as observed by a physician;
3. early morning stiffness with a duration > 30 minutes;
4. acute phase reactants such as a Westergren erythrocyte
sedimentation rate (ESR) more than 30 mm/hour or C-reactive
protein (CRP) more than 10 mg/mL.
Types of interventions
The intervention was certolizumab pegol (CDP870) at any dose.
The comparators were placebo or any DMARD including other
biologic agents used to treat RA.
Types of outcome measures
Major outcomes
• The proportion of patients achieving an ACR50
• Health-related quality of life, such as the Health Assessment
Questionnaire (HAQ) or Short Form Health Survey (SF-36)
• Disease Activity Score (DAS28 or other versions of DAS)
• Radiological changes (erosion score (ES), modified total
Sharp score, joint space narrowing)
• Serious adverse events
• All withdrawals
• Withdrawals due to adverse events
The ACR50 is defined as a 50% improvement in the number of
tender and swollen joints and a 50% improvement in at least three
of the following items: observer evaluation of overall disease activ-
ity, patient evaluation of overall disease activity, patient evaluation
of pain, a score of physical disability, or improvements in blood
acute-phase responses.
Scores in the HAQ range from 0 to 3, with 3 indicating a worse
health state, therefore a negative change indicates improvement.
The SF-36 is a scale from 0 to 100 where 0 is the worst and 100
the best health state.
Serious adverse effects were defined as malignancies and all infec-
tions, especially tuberculosis and death.
All causes of withdrawals from the medication were sought.
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Minor outcomes
• ACR20 and ACR70 (a 20% or 70% improvement
respectively in the parameters described above)
• Frequency of adverse events
The following adverse events were sought: headache, fever, blood
disorders, laboratory disorders, abdominal pain, nasopharyngitis,
nausea, respiratory tract infections, urinary tract infections, neck
pain, congestive heart failure, pruritus and anaphylaxis.
Search methods for identification of studies
Electronic searches
The search strategy used the revision of the Cochrane highly sen-
sitive search strategy (HSSS) for PubMed (Glanville 2006), the
best sensitivity filter developed by theHedges Team (Wong 2006a;
Wong 2006b) and followed the Cochrane Musculoskeletal Re-
view Group (CMSG) recommendations. Searches included both
MeSH headings and text terms for CDP870 and rheumatoid
arthritis. The searches were done byMsTamaraRader, Trial Search
Co-ordinator of the CMSG. These searches included: Cochrane
Database of Systematic Reviews (CDSR) and Cochrane Central
Register of Controlled Trials (CENTRAL), HTA, DARE, NHS
EED(The Cochrane Library) (Appendix4);MEDLINE (Appendix
1); EMBASE (Appendix 2); CINAHL (Appendix 3); SCOPUS
(Appendix 5); TOXLINE (TOXNET) (Appendix 6).
Safety data were obtained from clinical trials.
We updated the searches in CENTRAL (The Cochrane Library
2014, Issue 5), MEDLINE (2009 to 5 June 2014), EMBASE
(2009 to 5 June 2014), SCOPUS (2009 to 5 June 2014), TOX-
LINE (2009 to 5 June 2014), Web of Knowledge (2009 to 5 June
2014) and the websites of the US Food and Drug Administra-
tion (FDA) and EuropeanMedicines Evaluation Agency (EMEA)
(2009 to 5 June 2014).
Searching other resources
1. We examined the information made available by the main
researchers and sponsors in www.clinicaltrials.org
2. We reviewed information on the clinical trial meta-register
database (www.controlled-trials.com/mrct/)
3. We looked for health technology assessment reports from
the European, Canadian, North American and Australian
national agencies to identify further trials
4. The reference lists of all identified studies were inspected
for more trials
5. When published data were missing, incomplete, or
inconsistent with the trial protocols, further information was
sought from the authors and manufacturers (UCB)
Data collection and analysis
Selection of studies
Two authors independently assessed search results for potential
studies that met the inclusion criteria and disagreements were re-
solved by discussion or referral to a third author.
Inclusion criteria
1. RCTs that compared certolizumab pegol with any other
agent including placebo in adult RA patients with active RA
despite current or prior treatment with DMARDs
2. Trials that were fully published as a paper or available as a
complete trial report. Where published only as abstracts the trial
reports were requested from the manufacturers
3. Studies having at least three months of follow-up to assess
benefits
To assess harms we also sought studies having a suboptimal length
of follow-up, from eight weeks.
Exclusion criteria
1. Trials of certolizumab pegol in juvenile arthritis, Crohn’s
disease, psoriatic arthritis and other forms of spondyloarthritis
2. Trials of certolizumab pegol comparing different doses or
routes of administration without another active or placebo
control group (except for assessing harm outcomes)
3. Studies reporting solely on laboratory measures aimed at
investigating disease or treatment mechanisms and which did not
report relevant clinical outcomes
4. Observational studies of certolizumab pegol
5. Interim results of trials
Data extraction and management
Two review authors independently reviewed titles and abstracts
of studies identified in the search to assess which studies might
potentially meet the inclusion criteria; where there was doubt, the
full article was acquired for further inspection. Potential studies
identified by this process were then obtained and two authors
independently screened them to see if they met the review criteria
using aWeb interface. A final table was produced in Excel. We did
not need to resolve any disagreements through discussion.
Data were extracted, when possible for intention-to-treat popula-
tions, as raw numbers plus any summary measures with the stan-
dard deviations, confidence intervals and P values of the outcomes
reported. These were compiled in an Excel spreadsheet. Differ-
ences of opinion and data discrepancies were to be resolved by
reference to a third review author (Sylvia Bort) but that did not
happen.
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Assessment of risk of bias in included studies
According to the recommendations in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011), the risk of bias
was assessed by creating a ’risk of bias’ table for each study. A
summary is presented below as a risk of bias graph.
The main criteria used to assess the risk of bias included: blinding
of participants, allocation concealment, random sequence gener-
ation, incomplete outcome data, selective reporting of outcomes,
and other biases (such as fraud or imbalance in the groups, or the
sponsor either owns the data or needed to approve themanuscript).
The risk of bias in each study was explicitly judged on the basis
of each criterion using the following: low risk of bias, high risk of
bias, unclear risk of bias (either lack of information or uncertainty
over the potential bias). These criteria were included in the ta-
bles. Disagreements were resolved by discussion between the two
review authors. If needed a third review author was available for
discussion, but there were no disagreements.
Measures of treatment effect
The risk difference was used to quantify the number needed to
treat (NNT) (Laupacis 1988). We calculated the NNT from the
risk ratio according to the formulaNNT= 1/ACR*(1 - RR), where
ACR = assumed control risk and RR = risk ratio. When events
were very rare (< 10%) we used the Peto odds ratio (Peto OR).
For continuous data we used mean differences (MDs) when the
results were measured in the same way in the different studies.
We used standardised mean differences (SMDs) when the results
obtained were conceptually the same but used different measure-
ment scales. The central estimate (mean) and standard deviation
were recorded. Where these were not directly stated they were cal-
culated from the standard error or the different means and their
respective confidence intervals (CIs) or P values. When medians
and interquartile ranges were the only data provided, the median
was used as a proxy measure of the mean and the difference be-
tween the first and third interquartile was considered equivalent
to 1.35 of the SD.
Unit of analysis issues
Most of the clinical trials had a simple parallel group design with
participants individually randomised to one of two intervention
groups. The unit of analysis was not an issue in this review.
Dealing with missing data
We carried out an intention-to-treat analysis. Every individual
allocated to the intervention was counted whether they completed
the follow-up or not.Wehave assumed that thosewhodroppedout
had no change in their outcome. This rule is conservative for the
response to treatment because it assumes that those discontinuing
the studies would not have responded. It is not conservative for
adverse effects. However, assuming that all those leaving early had
developed side effects could overestimate risk.
When published data were missing, incomplete or inconsistent
with the RCT protocols or meeting abstracts, we asked for fur-
ther information from the authors and manufacturers. We only
excluded abstracts of studies that were interim reports of studies
that had not yet finished recruiting.
Assessment of heterogeneity
We have explored heterogeneity between the trials using the Chi
2 test for heterogeneity, with a 10% level of significance, and the
I2 statistic. We interpreted the ranges of I2 according to the rec-
ommendations in the Cochrane Handbook for Systematic Reviews of
Interventions: 0% to 40% might not be important; 30% to 60%
may represent moderate heterogeneity; 50% to 90% may repre-
sent substantial heterogeneity; and 75% to 100% considerable
heterogeneity (Higgins 2011).
Assessment of reporting biases
We planned to explore reporting bias using funnel plots when
doing a meta-analysis for 10 or more studies.
Data synthesis
The need to pool the results according to a fixed-effect or random-
effects model analysis was explored (Laird 1990). We planned
to use the fixed-effect model to pool the data because statistical
heterogeneity in our preview review was not high.However, finally
we decided toperforma random-effectsmodel despite the I2 values
being low. Although it was the same drug, there was a clear clinical
heterogeneity (different doses, allowing MTX or not, different
follow-up, different duration of RA, etc.).
The number needed to treat to benefit (NNTB) and the number
needed treat to harm (NNTH) were calculated. The mean differ-
ence was used to calculate the benefit (absolute change expressed
as both a percentage and in its original units) for continuous out-
comes such as HAQ, SF-36 and radiological changes.
Subgroup analysis and investigation of heterogeneity
Subgroup analyses were planned for the duration of the illness
(approximately three years evolution), patients’ sex, drug dose and
administration, and methodological quality. If heterogeneity had
been detected then a subgroup analysis (Yusuf 1991), or a meta-
regression (Thompson 1999), would have been carried out to see
if it could be explained.
Sensitivity analysis
We a priori planned the following sensitivity analyses in order to
explore effect size differences and the robustness of conclusions.
10Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1. Effect of study quality, dened as blinding of participants, al-
location concealment, random sequence generation, incomplete
outcome data, selective outcome reporting and other sources of
bias.
2. Effect of imputation, size of trials, use of concomitant
methotrexate, and doses of certolizumab pegol.
Summary of findings table
We used the ’Grades of Recommendation, Assessment, Develop-
ment and Evaluation’ developed by the GRADE working group
to provide an overall grading of the quality of the evidence by out-
come. The GRADE approach specifies four levels of quality. The
highest quality rating is for RCT. Review authors can, however,
downgrade randomised trial evidence from ’high’ to ’moderate’,
’low’ or even ’very low’ quality evidence depending on the presence
of specific factors: design or implementation, imprecision, incon-
sistency, indirectness, or reporting bias (see Cochrane Handbook
for Systematic Reviews of Interventions Chapter XII (section 12.2)
(Higgins 2011)).
R E S U L T S
Description of studies
Results of the search
See the flow chart (Figure 1) and ’Results of searches’ in Appendix
8.
11Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
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In this update we found 1703 records identified through database
searching on 12 February 2013. Five more trials were identified
through other sources. Finally we assessed 118 papers and 7 full-
text articles for eligibility. As a result five new trials were included
for analysis in this updated review.
According to the Cochrane MECIR standards, CMSG updated
the searches on 5 June 2014. However, no more trials were found,
only two proceedings of two Japanese trials that we found in clin-
icaltrials.org, with all of their results. The results, therefore, re-
mained unchanged. The description and the results of this second
search are in Appendix 9.
Included studies
In total 11 trials were included: 10 of them involving 4324 peo-
ple were included in the beneficial assessment (CDP870-004
2001; CDP870-014 2009; CERTAIN 2008; FAST4WARD
2005; NCT00791921 HIKARI; NCT00791999 JRAPID;
NCT00993317; RAPID1 2005; RAPID2 2007; REALISTIC
2008) and 10 trials with 3711 people in the assessment of harm (
CDP870-014 2009;CERTAIN2008;Choy 2002; FAST4WARD
2005; NCT00791921 HIKARI; NCT00791999 JRAPID;
NCT00993317; RAPID1 2005; RAPID2 2007; REALISTIC
2008). See the Characteristics of included studies and the demo-
graphics and flow of patients in Table 1 and Table 2 for details.
Only Choy 2002 and CDP870-004 2001 were phase II studies.
We found a third phase II study (Kaushik 2005) but we were
advised by UCB that: “this publication refers to the 2 previous
phase II”. All phase III studies were used to assess both benefits
and harms. CDP870-004 2001 only contributed data on benefits
as it did not report any data on harms. Due to the short follow-
up for assessing benefits, Choy 2002 was only included for safety
data. The data from the two phase II studies (CDP870-004 2001;
Choy 2002) were not pooled with the rest of the studies due to
the different follow-ups and doses used.
We retrieved nine phase III trials (CDP870-014 2009;
CERTAIN2008; FAST4WARD2005;NCT00791921 HIKARI;
NCT00791999 JRAPID; NCT00993317; RAPID1 2005;
RAPID2 2007; REALISTIC 2008). All trials were funded by
UCB.Data fromCDP870-014 2009 were provided byUCB from
the clinical study summary (www.clinicalstudyresults.org/docu-
ments/company-study˙4348˙0.pdf ) and the EMEA 2009 reports;
they were finally published in 2012 (the study was completed in
2004).
Table 1 shows the demographic and baseline characteristics for
the phase III trials: age, gender, rheumatoid factor (RF) positivity,
MTX concomitant dose, number of previous DMARDs, basal
HAQ and basal DAS28 among other outcomes. Table 2 provides
the flow chart of patients in the phase III studies.
Excluded studies
Themain reasons for exclusionwere: 1) reviews, 2) different drugs,
and 3) another outcome reported. See the table Characteristics of
excluded studies.
Risk of bias in included studies
The judgements about each risk of bias item were presented as
percentages across all included studies (Figure 2).Most of the trials
were rated as low risk of bias. The overall possibility of bias seemed
to be low.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
All studies but CDP870-004 2001 reported adequate meth-
ods of randomisation and allocation concealment. Six studies
(CDP870-014 2009; CERTAIN 2008; FAST4WARD 2005;
RAPID1 2005; RAPID2 2007; REALISTIC 2008) used the inter-
active voice response system (IVRS) method of allocation conceal-
ment. TheAsian trials (NCT00791921 HIKARI;NCT00791999
JRAPID; NCT00993317) were described as: “External central
of randomisation. Randomization by blocks”; so the risk of bias
seemed to be low.
Blinding
All studies but CDP870-004 2001 reported adequate blinding.
Refer to Figure 3.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Phase II:
• CDP870-004 2001 did not disclose the methods of
blinding and finally UCB explained to us: “CPD-870 and the
placebo utilized in this study (saline) did not have the same
viscosity therefore full blinding was not possible. Study drug was
to be prepared by a pharmacist having no other involvement in
the study; injections of study medications were given by a nurse
or physician who had no other involvement in the study...”;
• Choy 2002 disclosed the methods of blinding: “Placebo
(sodium acetate buffer) was given similarly as a single
intravenous infusion of 100 ml over 60 min”. It was unlikely that
the blinding could have been broken. UCB explained to us: “all
data were entered and Database locked after completion of the
clinical phase for the first study period and before ESR and CRP
were entered into the database. ESR and CRP data were
withheld from investigator and sponsor study personal during
the course of the study because knowledge of patient’s profile
could potentially unblind the study..., auto AB, anti CZP level,
TNFalpha, IL6 and IL1b were transferred into the database after
Database lock.”
Phase III:
• UCB told us, “in FAST4WARD 2005, CDP870-014
2009, RAPID1 2005, RAPID2 2007, CERTAIN 2008,
REALISTIC 2008, all the study staff with the exception of the
unblinded dispenser, was blind to the treatment. Each study
center was required to have a written blinding plan in place
signed by the Principal Investigator, which detailed the study
center’s steps for ensuring that the double blind nature of the
study was maintained. All the studies were monitored by two
different independent teams from the sponsor, one devoted to
blind data and one devoted to possibly unblinded information
(such as study medications related topics) and completely
separate documentation/filing systems were maintained for the
duration of the trials”;
• RAPID1 2005, “Radiographs were read at a central location
by 3 independent readers. Readers were blinded as to the
patient’s identity, clinical data, treatment, and time point
(sequence) at which the radiograph was taken”;
• RAPID2 2007, “Radiographs were read centrally and
blinded (for treatment, visit and patient identification) and
independently by two experienced readers”;
• FAST4WARD 2005 disclosed methods of blinding,
“Solutions of active drug or placebo were prepared by the
pharmacist or other unblinded, qualified site personnel, before
distributing to blinded study personnel for administration”.
• in the Japanese and Korean trials (NCT00791921
HIKARI; NCT00791999 JRAPID; NCT00993317) “All study
staff with the exception of the unblinded dispenser were blind to
the treatment, ... These unblinded personnel were not allowed to
engage in any other study activities”.
For these reasons we rated the risk of bias for blinding as low.
Incomplete outcome data
All studies except the small phase II trial (CDP870-004 2001)
reported adequate methods of handling missing outcome data. All
other studies had a full account of all withdrawals and reasons
for withdrawals. Where possible, we extracted data to allow an
intention-to-treat analysis in CDP870-014 2009; FAST4WARD
2005;NCT00993317.We considered a less than 80%completion
rate in the treatment group as a high risk of bias; 8 out of 11 studies
reported less than 80% completion rates.
The completion rates in the certolizumab pegol group ranged from
68% in FAST4WARD 2005 to 90% in REALISTIC 2008. In
all trials, fewer patients in the placebo-treated group completed
the trial compared to the treatment arm. More patients who were
treated with placebo withdrew due to lack of efficacy. The per-
centage of those completing the trial in the placebo group ranged
from 15% in the 12-month results of NCT00791921 HIKARI to
86% in the 12-weeks results of REALISTIC 2008. Missing data
were imputed using last observation carried forward in most trials.
The risk of bias appeared to be high. Refer to Figure 3.
Selective reporting
All studies showed planned outcomes, except NCT00791999
JRAPID. Finally ACR20/50/70 was reported by UCB as a figure
as well as providing the DAS, but we could not pool DAS data
and we had no information about the modified Total Sharp Score
(mTTS) for radiographic progression.
We changed the assessment of the bias in FAST4WARD 2005
because all the primary outcomes were described in the paper.
In our previous systematic review the trial CDP870-014 2009
only reported ACR20, but the ACR50, HAQ disability index and
acute phase reactant (CRP) are now available so we have changed
our likelihood of bias assessment to low.
In summary, we think the risk of reporting bias in this update is
low. Refer to Figure 3.
Other potential sources of bias
We did not detect potential threats to validity, such as fraud or
imbalance in the groups (relating to the baseline characteristics).
All studies included in this review were sponsored by the manu-
facturer of certolizumab pegol. There is evidence that industry-
sponsored trials may overestimate the treatment effect (Bhandari
2004) and there is also evidence that most of the authors of pub-
lished trials have a conflict of interest. However, there is a lack of
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consensus on whether these conflicts result in reduced quality of
the trials and, in view of this, we have decided to rate the risk of
bias of this domain as low.
We searched for more trials as well as for more information re-
garding those trials that we had found as unpublished trials during
the search (see Characteristics of ongoing studies table), but no
information was available either from the sponsors or from any
publication. UCB explained to us that the papers for these trials
have been accepted and are expected to be published.
In summary, we think the risk of other potential sources of bias is
low in this update. Refer to Figure 3.
Summary assessment of risk of bias by outcomes
Figure 2 and Figure 3 provide a graphical summary of the results
of the risk of bias assessments for the 11 included studies.
The main major outcomes
ACR 50 response at six months: the five studies included in the
meta-analysis were rated well in terms of adequate allocation con-
cealment, blinding and reporting of appropriate outcomes. How-
ever, there was a concern about bias in terms of incomplete out-
come data due to the high dropout rates in four of the five studies.
Another concern was that all studies were sponsored by the man-
ufacturer of certolizumab pegol.
HAQ change from baseline, response at six months: the four stud-
ies included in the meta-analysis were rated well in terms of ade-
quate allocation concealment, blinding and reporting of appropri-
ate outcomes. However, there was a concern about bias in terms of
incomplete outcome data due to the high dropout rates in three of
the four studies. Another concern was that all studies were spon-
sored by the manufacturer of certolizumab pegol.
Serious adverse events with certolizumab pegol 200mg at any time
of follow-up: the seven studies included in the meta-analysis were
rated well in terms of adequate allocation concealment, blinding
and reporting of appropriate outcomes. All of them were analysed
with ITT for all randomised patients who received at least one
dose, but in two out of seven studies the analysis was per protocol:
in RAPID2 2007 “two patients in the placebo group received cer-
tolizumab pegol 200 mg and were included in the certolizumab
pegol 200 mg group for safety evaluations”, and in REALISTIC
2008 nine patients less were analysed in the certolizumab pegol
arm and three patients less in the placebo group. Another concern
was that all studies were sponsored by the manufacturer of cer-
tolizumab pegol.
Effects of interventions
See: Summary of findings for the main comparison
Certolizumab pegol 200 mg sc (with or without MTX) versus
placebo (with or without MTX) for rheumatoid arthritis in adults
The analysis was performed depending on the drug exposure time
for subcutaneous (sc) doses of 200 mg and 400 mg, the doses
used in the trials. For 400 mg the most common was at four-
week intervals and for 200 mg sc the most frequently used was
every other week, but in some trials like RAPID1 and RAPID2
the interval was every two weeks for the 400 mg dose as well. As
we had two periods of follow-up (six months and one year) in one
study, we could not pool them thus we pooled each outcome at
each follow-up.Moreover, we had studies withmore than one dose
so we split the placebo arm to obtain pooled results. We did not
find strong differences that could justify not combining the results
for benefits and harms. We decided to perform a random-effects
model in spite of the low values of I2. Although it was the same
drug, there is clear clinical heterogeneity (different doses, allowing
MTX or not, different follow-up, different duration of RA, etc.).
Major outcomes
ACR50
Significant improvements were observed for all doses at any given
time for the ACR50 compared to placebo (see ’Benefits’ tables,
ACR Table 3, Data and analyses).
The ACR50with 200mg certolizumab pegol showed, at 24weeks,
a RR of 3.80 (95% CI 2.42 to 5.95), 5 out of 10 studies, involving
1445patients (Analysis 2.2); and at 52weeks aRRof 5.03 (95%CI
3.04 to 8.32), 1 out of 10 studies, involving 592 patients (Analysis
5.2).
The ACR50with 400mg certolizumab pegol showed, at 24weeks,
a RR of 4.65 (95% CI 3.09 to 6.99), 5 out of 10 studies, in-
volving 1591 patients (Analysis 3.2). The ACR50 with 400 mg
certolizumab pegol showed, at 52 weeks, a RR of 5.27 (95% CI
3.19 to 8.71), 1 out of 10 studies, involving 589 patients (Analysis
6.2).
The NNT was close to 4 for all the subanalyses (Table 3).
Health-related quality of life
An improvement in physical function and quality of life measured
as the HAQ and SF-36 (in the mental and physical components)
at all times of follow-up (see ’Health-related quality of life’ tables,
Table 4) was seen with certolizumab pegol compared to placebo.
HAQ, 24 weeks, 200 mg: MD -0.35 (95% CI -0.43 to -0.26), 4
out of 10 studies, involving 1268 patients (Analysis 11.1); HAQ,
24 weeks, 400 mg: MD -0.38 (95% CI -0.48 to -0.28), 4 out of
10 studies, involving 1425 patients (Analysis 11.2).
HAQ disability index (HAQ-DI), 24 weeks, any dose: MD -0.36
(95% CI -0.43 to -0.29), 5 out of 10 studies, involving 2246
patients (Analysis 12.1); HAQ-Di, 52 weeks, any dose: MD -
0.43 (95% CI -0.52 to -0.35), 1 out of 10 studies, involving 982
patients (Analysis 13.1).
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SF-36 physical component summary (PCS), 24 weeks, any dose:
MD 5.29 (95% CI 4.37 to 6.21), 3 out of 10 studies, involving
1765 patients (Analysis 18.1); SF-36 PCS, 52 weeks, any dose:
MD 6.47 (95% CI 5.13 to 7.81), 1 out of 10 studies, involving
982 patients (Analysis 20.1).
SF-36 mental component summary (MCS), 24 weeks, any dose:
MD 4.01 (95% CI 2.94 to 5.08), 4 out of 10 studies, involving
2012 patients (Analysis 19.1); SF-36 MCS, 52 weeks, any dose:
MD 4.30 (95% CI 2.57 to 6.03), 1 out of 10 studies, involving
982 patients (Analysis 21.1).
DAS-28
Significant improvements were observed for all doses and at any
given time compared to placebo.
The RR for patients achieving remission (DAS < 2.6) with 100
mg certolizumab pegol at 24 weeks was 2.82 (95% CI 1.6 to 5),
1 out of 10 studies, involving 1063 patients (Analysis 25.1).
The proportion of patients achieving remission (< 2.6) was higher
in the 200 mg certolizumab pegol group than in the placebo group
(RR 8.47, 95% CI 4.15 to 17.28) at 24 weeks, 4 out of 10 studies,
involving 1381 patients (Analysis 25.2); and RR of 10.36 (95%
CI 3.29 to 32.58) at 52 weeks, 1 out of 10 studies, involving 587
patients (Analysis 25.4).
The RR for patients achieving remission (< 2.6) with 400 mg
certolizumab pegol was 7.18 (95% CI 3.12 to 16.50) at 24 weeks,
3 out of 10 studies, involving 1201 patients (Analysis 25.3); and
at 52 weeks the RR was 12.49 (95% CI 3.99 to 39.12), 1 out of
10 studies, involving 583 patients (Analysis 25.5).
Radiological changes
Radiological changes were expressed as modified Total Sharp
Scores (mTSS), the erosion score (ES) and joint space narrowing
(JSN). All certolizumab pegol groups showed improvements com-
pared to placebo in the mean changes from baseline. There was
a clear radiological benefit, regardless of the dose, that was asso-
ciated with drug exposure time (see ’Radiological changes’, Table
5).
Erosion score (ES), 200 mg, 24 weeks: MD -0.67 (95% CI -0.96
to -0.38), 2 out of 10 studies, involving 859 patients (Analysis
33.1).
Erosion score (ES), any dose, 24 weeks: MD -0.70 (95% CI -0.98
to -0.42), 2 out of 10 studies, involving 1437 patients (Analysis
34.1).
Erosion score (ES), any dose, 52 weeks: MD -1.45 (95% CI -2.11
to -0.79), 1 out of 10 studies, involving 908 patients (Analysis
35.1).
Joint space narrowing (JSN), any dose, 24 weeks:MD -0.50 (95%
CI -0.79 to -0.21), 2 out of 10 studies, involving 1439 patients
(Analysis 37.1).
Joint space narrowing (JSN), any dose, 52 weeks:MD -1.10 (95%
CI -1.88 to -0.33), 1 out of 10 studies, involving 911 patients
(Analysis 38.1).
Modified Total Sharp Scores (mTSS), any dose, 24 weeks: MD -
1.18 (95% CI -1.67 to -0.69), 2 out of 10 studies, involving 1437
patients (Analysis 39.1).
Modified Total Sharp Scores (mTSS), any dose, 52 weeks: MD -
2.50 (95% CI -3.70 to -1.30), 1 out of 10 studies, involving 908
patients (Analysis 40.1).
Serious adverse events (SAEs) as defined in the studies
The clinical study summary of CDP870-004 2001 did not define
SAEs. All the new trials that were added in this update reported
on SAEs.
We reported adverse events depending on the doses:
SAE for certolizumab pegol 200 mg and any follow-up Peto OR
1.77 (95% CI 1.27 to 2.46), 7 out of 9 studies, involving 2729
patients (Analysis 8.6);
SAE for certolizumab pegol 400 mg and any follow-up Peto OR
1.98 (95%CI 1.36 to 2.90), 5 out of 9 studies, involving 1584 pa-
tients (Analysis 9.7); 240 events were reported in the certolizumab
pegol groups versus 69 events in the control groups.
All withdrawals
There were more withdrawals “at any dose and at any follow-up”
in placebo groups (56%) versus the certolizumab pegol groups
(23%) (Analysis 48.1).
There were more withdrawals “due to lack of efficacy” in placebo
groups (61%) versus the certolizumab pegol groups (19%) (
Analysis 48.2).
Withdrawals at any dose and at any follow-up: RR 0.42 (95%
CI 0.36 to 0.50), 10 out of 10 studies, involving 3962 patients
(Analysis 48.1).
Withdrawals at any dose and at any follow-up due to lack of effi-
cacy: RR 0.30 (95% CI 0.25 to 0.37), 5 out of 10 studies, involv-
ing 2195 patients (Analysis 48.2).
Withdrawals due to adverse events
There were more withdrawals “at any dose and at any follow-
up due to adverse events” in the certolizumab pegol groups (5%)
versus placebo groups (3%).
Withdrawals at any dose and at any follow-up due to adverse
events: Peto OR 1.66 (95% CI 1.15 to 2.37), 9 out of 10 studies,
involving 3998 patients (Analysis 48.3).
We have included all results in Summary of findings for the main
comparison.
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Minor outcomes
ACR20 and ACR70
We saw an improvement in ACR20 and ACR70 compared to
placebo for all doses and at any time.
ACR20 for any dose at 24 weeks: RR 2.76 (95% CI 2.29 to 3.33),
8 out of 10 studies, involving 2935 patients (Analysis 4.1); ACR20
for any dose at 52 weeks: RR 2.06 (95% CI 1.61 to 2.62), 1 out
of 10 studies, involving 982 patients (Analysis 7.1).
ACR70 for any dose at 24 weeks: RR 4.15 (95% CI 2.68 to 6.42),
7 out of 10 studies, involving 2705 patients (Analysis 4.3); ACR70
for any dose at 52 weeks: RR 3.14 (95% CI 1.86 to 5.29), 1 out
of 10 studies, involving 982 patients (Analysis 7.3).
Adverse events
We reported all adverse events in Data and analyses but not all of
them were commented on in the present section, only those that
we thought were the most interesting (see Table 6).
Any adverse event
We pooled the data for any adverse event from nine trials: 200
mg certolizumab pegol RR 1.18 (95% CI 1.10 to 1.27), 7 out
of 9 studies, involving 2739 patients (Analysis 8.1); and 400 mg
certolizumab pegol RR 1.21 (95% CI 1.11 to 1.31), 5 out of 9
studies, involving 1584 patients (Analysis 9.1).
We excluded Choy’s study because it showed more events than
patients in the certolizumab pegol group (62 events in 24 patients)
as well as in the placebo group (19 events in 12 patients). Thus
the RR could not be estimated.
Adverse events: severe intensity as defined in the studies
There were no differences in the number of SAEs between patients
treated with 200 mg (Peto OR 1.14, 95% CI 0.78 to 1.65), 4 out
of 9 studies, involving 2249 patients; and patients treated with
400 mg of certolizumab pegol (Peto OR 1.23, 95% CI 0.83 to
1.81), 4 out of 9 studies involving 1422 patients. See more details
in Analysis 8.4; Analysis 9.4.
Adverse events leading to death as defined in the studies
We did not find statistically significant differences in the num-
ber of adverse events leading to death between the placebo and
certolizumab pegol-treated groups. Eleven deaths due to adverse
events in the certolizumab pegol groups were reported versus one
death in the control groups: 200 mg certolizumab pegol Peto OR
2.34 (95% CI 0.46 to 11.84), 5 out of 9 studies involving 2443
patients (Analysis 8.8); 400 mg certolizumab pegol Peto OR 2.16
(95% CI 0.40 to 11.79), 3 out of 9 studies, involving 1179 pa-
tients (Analysis 9.8).
Death
In RAPID1 2005, in the placebo-treated group one patient died of
myocardial infarction. In the 200 mg certolizumab pegol-treated
group one patient died of hepatic neoplasm, another died of peri-
tonitis and cirrhosis, and one died during the post-treatment pe-
riod (> 84 days after the last injection). In the 400mg certolizumab
pegol-treated group one died of cerebral stroke, one of myocardial
necrosis, one of cardiac arrest and one of atrial fibrillation.
InRAPID2 2007, in the 200mg certolizumab pegol-treated group
one patient died of myocardial infarction; one patient died during
the study in the 400 mg certolizumab pegol-treated group (frac-
ture, shock), which was assessed as unlikely to be related to the
study medication.
In Choy 2002, in the open phase one patient in the certolizumab
pegol-treated group (20mg/kgCDP870) died from complications
following rapid drainage of a large, chronic rheumatoid pericardial
effusion. In the opinion of the investigator this event was unrelated
to treatment with CDP870.
In REALISTIC 2008, one patient died of sigmoid diverticulitis
and one of necrotizing pneumonia; both deaths were ruled out as
possibly related to certolizumab pegol.
In NCT00791921 HIKARI, one patient died of a rupture of a
dissecting aortic aneurysm in the thoracic region, but UCB con-
sidered that unlikely to have been related to the study medication.
CDP870-014 2009; CERTAIN 2008; FAST4WARD 2005;
NCT00791999 JRAPID did not report any deaths.
Overall certolizumab pegol deaths: PetoOR2.56 (95%CI 0.72 to
9.07), 9 out of 9 studies, involving 3866 patients (Analysis 49.8;
Figure 4).
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Figure 4. Forest plot of comparison: 49 Summary of findings: certolizumab (with or without MTX) versus
placebo (with or without MTX), outcome: 49.8 Deaths.
Serious adverse infections (SAI)
This composite outcome included any severe events of infec-
tions, infestations and tuberculous (disseminated tuberculosis,
peritoneal tuberculosis, pulmonary tuberculosis, lymph node tu-
berculosis, tuberculosis), lower respiratory tract infection, and ob-
structive chronic bronchitis with acute exacerbation. More SAIs
were reported in the 200 mg certolizumab pegol-treated group
(PetoOR3.30, 95%CI 1.45 to 7.51), 2 out of 9 studies, involving
964 patients; and in the 400 mg certolizumab pegol-treated group
(Peto OR 3.25, 95% CI 1.65 to 6.39), 4 out of 9 studies, involv-
ing 1422 patients; 58 events were reported in the certolizumab
pegol groups versus six events in the control groups. There were
no differences between the rates of SAIs in the 200 mg and 400
mg certolizumab pegol groups. See more details in Analysis 8.7;
Analysis 9.6.
Tuberculosis
A significant increase in the number of cases of tuberculosis was
observed in both of the certolizumab pegol-treated groups: seven
patients (0.8%) in the certolizumab pegol 200 mg group and five
patients (0.7%) in the certolizumab pegol 400 mg group versus
no cases in either placebo group: 200 mg certolizumab pegol Peto
OR 4.53 (95% CI 0.94 to 21.85), 5 out of 9 studies, involving
2340 patients (Analysis 8.11); 400 mg certolizumab pegol Peto
OR 4.55 (95% CI 0.71 to 29.11), 4 out of 9 studies, involving
1364 patients (Analysis 9.13). The overall analysis with both doses
(200 and 400 mg) did not reach statistical significance: Peto OR
3.71 (95% CI 0.94 to 14.61), 6 out of 9 studies, involving 3195
patients (Analysis 49.9). In RAPID2 2007, five patients in the
certolizumab pegol arms (three in certolizumab pegol 200 mg
and two in 400 mg) developed tuberculosis (three from Russia,
one each from Poland and Latvia). In NCT00993317 (200 mg
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certolizumab pegol) two patients developed tuberculosis.
Other infections
The types of different infections reported (pneumonitis, bacterial
arthritis, mastitis, urinary tract infection, herpes viral, bacterial
peritonitis, and opportunistic infection) are presented in ’Data
and analyses’.
Upper respiratory tract infection was more frequent with 200 mg
certolizumab pegol than in the placebo group (Peto OR 1.51,
95% CI 1.08 to 2.09), 7 out of 9 studies, involving 2729 patients
(Analysis 8.19); and 400 mg certolizumab pegol (Peto OR 1.42,
95%CI 0.77 2 to 2.61), 4 out of 9 studies, involving 1364 patients
(Analysis 9.28).
Nasopharyngitis was more frequent with both doses of cer-
tolizumab pegol than in the placebo group: 200 mg certolizumab
pegol Peto OR 1.46 (95% CI 1.02 to 2.09) (Analysis 8.23), 6 out
of 9 studies, involving 1674 patients; and 400 mg certolizumab
pegol Peto OR 1.98 (95% CI 1.26 to 3.11), 4 out of 9 studies, in-
volving 1364 patients (Analysis 9.41). However, neither upper nor
lower respiratory tract infections were more frequent compared to
placebo with both doses of certolizumab pegol: 200 mg (Peto OR
1.17, 95% CI 0.86 to 1.59), 8 out of 9 studies, involving 3692
patients; and 400 mg (Peto OR 1.66, 95% CI 0.77 to 3.58), 7
out of 9 studies, involving 3073 patients (Analysis 49.10; Analysis
49.11).
Pain
Pain at the site of injection was not statistically significant com-
pared with placebo: in the 200 mg certolizumab pegol-treated
group (Peto OR 1.85, 95% CI 0.49 to 6.92), 3 out of 9 stud-
ies, involving 1091 patients (Analysis 8.13); and the 400 mg cer-
tolizumab pegol-treated group (Peto OR 1.74, 95% CI 0.41 to
7.42), 3 out of 9 studies, involving 1179 patients (Analysis 9.21).
The wide CIs were due to the fact that pain was not observed in
any placebo group, surprisingly. Similar data were observed for
local reactions at the injection site.
Patients’ assessment of arthritis pain (visual analogue scale (VAS)
score 0 to 100 mm) improved at all doses and at all times. At week
24, the overall mean difference (MD) was -21.07 (95% CI -23.59
to -18.55), 4 out of 9 studies, involving 2064 patients (Analysis
42.1); and at week 52 the MD was -23.48 (95% CI -27.09 to -
19.88), 1 out of 9 studies, involving 982 patients (Analysis 43.1).
Other adverse events
Hypertension was more frequent with both doses of certolizumab
pegol than with placebo: 200 mg certolizumab pegol Peto OR of
3.09 (95%CI 1.64 to 5.84), 4 out of 9 studies, involving 1353 pa-
tients (Analysis 8.24); 400mg certolizumab pegol PetoORof 3.35
(95% CI 1.80 to 6.20), 3 out of 9 studies, involving 1121 patients
(Analysis 9.32). The secondary events for headache, fever, blood
disorders, laboratory disorders, abdominal pain, nasopharyngitis,
nausea, urinary tract infections, neck pain, congestive heart fail-
ure, pruritus and anaphylaxis are described in detail in Data and
analyses.
Despite the report from the EMEA (http://www.ema.europa.eu/
docs/en˙GB/document˙library/EPAR˙-
˙Public˙assessment˙report/human/001037/
WC500069735.pdf), we could not extract more data on adverse
events because these data were disclosed as combined data without
the number of events in each trial. Moreover, the adverse events
were grouped by ’primary system organ class’: cardiac disorders,
endocrine disorders, neoplasms benign, malignant and unspeci-
fied (excluding cysts and polyps).
Assessment of heterogeneity
Whenwe analysed the ACR50 (Analysis 4.2) we found a lowprob-
ability of statistical heterogeneity (I2 = 0%). When we reviewed
the demographics of phase III studies (Table 1) we found similar
proportions of females and males, similar mean ages, and similar
baseline HAQ-Di. We only found differences in the mean disease
duration in FAST4WARD 2005 and CDP870-014 2009, around
9.4 years compared with around 6 years in most arms of the other
studies where data were available (with low heterogeneity, I2 =
13 %). Disease duration was not available for CERTAIN 2008;
NCT00791921 HIKARI;NCT00791999 JRAPID (I2 = 6%, and
an overall I2 = 7%) (Analysis 50.5). Rheumatoid factor (RF) pos-
itivity varied from around 74% in the certolizumab pegol-treated
patients inREALISTIC 2008 up to100% inFAST4WARD 2005.
Similarly disease activity measures such as CRP and swollen joint
counts, but not DAS-28 and HAQ-D1, were generally lower in
REALISTIC 2008.
However, despite these differences there were no compelling rea-
sons for not combining the trial data for the most important vari-
ables.
Although 11 trials were included in this update no more than
seven trials were analysed in each forest plot, so a funnel plot was
not produced.
Subgroup analysis
Subgroup analyses were planned for the duration of the illness
(approximately three years evolution), patients’ sex, drug dose,
administration and methodological quality, but only subgroup
analysis regarding the dose of certolizumab pegol was performed.
All phase III trials were performed in patients with a high mean
duration of RA (from 6.1 to 9.5 years) and we could not obtain
any data categorized by sex. All phase III trials allowed previous
DMARD treatment (mean from 1.2 to 2 years). All phase III trials
included in the meta-analysis were rated as high quality, and so we
did not perform more subgroup analysis.
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Sensitivity analysis
We have done a sensitivity analysis with the major outcome
ACR50. In our previous systematic review we re-analysed quality
(adequate sequence generation, good allocation concealment, ad-
equate blinding, etc.) and did not show any changes. In this up-
date we have more information about the quality of the trials from
UCB and most trials were rated as high quality trials, so a sensi-
tivity analysis based on quality was not done. However, we sought
heterogeneity by analysing for doses of certolizumab pegol, size,
use of concomitant MTX, different populations (Japanese and
Korean trials versus other populations) and by published versus
unpublished trials, but found no statistical heterogeneity (Analysis
50.1; Analysis 50.2; Analysis 50.3; Analysis 50.4; Analysis 50.6).
D I S C U S S I O N
Summary of main results
Certolizumab pegol was FDA approved in 2008 for the treatment
of Crohn’s disease in adult patients with moderate to severe ac-
tive disease and who had an inadequate response to conventional
therapy. In 2009 the FDA approved certolizumab pegol for adult
patients suffering from moderate to severe rheumatoid arthritis.
The drug has been shown to reduce the rate of progression of joint
damage, as measured by X-ray, and to improve physical function.
Long-term follow-up studies of commercially sponsored RCTs
show persistence rates of 88.9% at two years, with 46.7% of pa-
tients having low disease activity (Keystone 2012). Whether such
rates can be replicated in routine care remains to be seen.
The purpose of this systematic review was to evaluate the benefits
and harms of certolizumab pegol for the treatment of people with
RA when compared to placebo. We only included RCTs with at
least three months of follow-up to assess benefits.
The duration of follow-up was from 12 to 52 weeks and the range
of doses of certolizumab pegol varied from 50 to 400 mg given
subcutaneously (sc).
Important differences between placebo and certolizumab pegol
were observed for measures of disease activity, in favour of cer-
tolizumab pegol. The differences were both statistically signifi-
cant and clinically important for the patient-reported outcomes
ACR50, HAQ, and SF-36 (physical (PCS) and mental (MCS)
component summary scores), and for structural damage measures.
Mean changes in HAQ that are > -0.22 are clinically meaningful,
although recent papers show that the cut-off could be higher (-
0.37) (Ward 2014). In addition, the results with SF-36 (physical
and mental components) can be considered relevant because in
patients with RA improvements in the SF-36 PCS and HAQDis-
ability Index (HAQ-DI) are associated with improved work pro-
ductivity and reduced long-term disability, healthcare utilization,
costs and mortality (Hazes 2010).
All certolizumab pegol groups showed improvements in radiologi-
cal outcomes compared to placebo, measured as the mean changes
from baseline. There was a clear radiological benefit although it
should be borne in mind that radiographic changes occur in a
relatively small proportion of patients in RA over the duration of
research studies.
Serious adverse events were more frequent in the certolizumab
pegol groups.
Statistically significant differences were observed in the overall
number of withdrawals. Patients in the placebo group were statis-
tically significantly more likely to discontinue treatment, probably
due to lack of beneficial effect, but more patients withdrew due to
adverse reactions in the certolizumab pegol group. The most fre-
quent side effects were infections, nasopharyngitis and hyperten-
sion. Tuberculosis and mortality were increased with certolizumab
pegol. These differences did not achieve statistical significance but
it should be noted that there was only one death in the placebo
group compared with 13 in the certolizumab pegol group. Sim-
ilarly, there were no cases of tuberculosis in the placebo group.
These cases of tuberculosis occurred despite precautions to screen
patients for tuberculosis before treatment.
In our previous review we stated we would compare our data
with data from the European Medicines Agency (EMEA) doc-
uments. We requested access to the drug company submissions
to the EMEA for marketing authorisation of certolizumab pegol.
Our request was denied despite an appeal. The EMEA stated that
“..in the course of emerging legal proceedings before the General
Court of the European Union, the Agency has been ordered to
suspend the implementation of the certain decisions granting ac-
cess to documents submitted by marketing authorisation holders
of medicinal products”.
No new or unexpected adverse events were associated with cer-
tolizumab pegol in the long-term analysis of harms. Among the
included trials the incidence rate (IR) of deaths was 0.84/100 pa-
tients-years (PY) in the certolizumab pegol-treated patients com-
pared to an IR of 0.27/100 PY in the placebo-treated patients.
Across all the trials and the open-label extensions, the IR was 0.63/
100 PY. Death was primarily related to cardiovascular events (IR
0.18/100 PY) (Bykerk 2013). No data regarding hypertension was
disclosed in Bykerk 2013. We observed an increase in the num-
ber of patients with hypertension among the certolizumab pegol-
treated patients (both 200 and 400 mg of certolizumab pegol).
This observation may be relevant to an increased rate of cardiovas-
cular events and deaths with certolizumab pegol. The described
deaths appear to be largely due to vascular disease and do not ap-
pear to be related to infection or immune suppression. Anti-TNFs
have been reported to reduce the risk of cardiovascular events in
patients with RA (Dixon 2007).
We found an increased risk of serious infections with certolizumab
pegol. This risk is recognised with anti-TNFs, both in randomised
trials and observational studies (FDA 2013). We did not find an
increased risk of malignancies or lymphoma, neither for 200 mg
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nor for 400 mg of certolizumab pegol, as shown in a previous
systematic review of anti-TNFs (Lopez Olivo 2012).
Overall completeness and applicability of
evidence
We have included all available RCTs for certolizumab pegol in pa-
tients with RA, with a June 2014 search date. This updated review
provides confirmatory evidence of the benefit of certolizumab pe-
gol for patients with RA.
It is important to state that only one study had a follow-up of
52 weeks. Thus there are important uncertainties about sustained
benefits and harms in a disease with a lifelong course and the need
for therapy over many years. An additional note of caution relates
to the population selection in terms of significant co-morbidities
and exclusion of patients with previous malignancy, for example.
In all trials except the CERTAIN 2008 trial (without a clear defi-
nition of its inclusion and exclusion criteria in clinical trials.org),
patients with previous neoplasia, any risk of infectious disease,
or previous tuberculosis, or prior treatment with any TNF-al-
pha inhibitor were excluded. In the NCT00791921 HIKARI;
NCT00791999 JRAPID and NCT00993317 trials, patients with
New York Heart Association (NYHA) class III or IV heart fail-
ure were also excluded. Moreover, in the RAPID1 2005 “Patients
who, in the investigator’s opinion, were at a high risk of infec-
tion were excluded, as were patients who had a history of malig-
nancy, demyelinating disease, blood dyscrasias, or severe, progres-
sive, and/or uncontrolled renal, hepatic, hematologic, gastroin-
testinal, endocrine, pulmonary, cardiac, neurologic, or cerebral
disease”. Thus, whilst it is clear that certolizumab pegol is bene-
ficial and has an acceptable safety profile in patients selected for
clinical trials, careful clinical judgement is needed to ensure bene-
fits in routine care particularly in patients susceptible to infections
such as those patients with chronic respiratory diseases.
Quality of the evidence
The quality of the evidence found in the trials included in this
review was high. Studies had high standards for treatment alloca-
tion, concealment and blinding, but there may have been a risk of
attrition bias. The quality of the evidence was downgraded for all
outcomes for this reason. However, other GRADE considerations
for downgrading, that is imprecision, indirectness and inconsis-
tency, were rated as ’no’, and publication bias was ’undetected’.
Despite differences in the importance of the outcomes (higher for
ACR50 and DAS remission, and lower for radiological changes)
we rated the quality of the evidence as moderate for all the out-
comes.
Outcome measures in favour of certolizumab pegol were statis-
tically significant in both random-effects and fixed-effect mod-
els. We chose to apply a random-effects model although statistical
heterogeneity was low. Clinical heterogeneity, however, was sub-
stantial (for example with varying follow-up times, doses, use of
methotrexate) and, as expected, pooling resulted in large confi-
dence intervals.
Potential biases in the review process
This updated systematic review has fewer limitations than our ear-
lier review primarily because key data from a greater number of
studies, including key study quality data, were available either as
published reports or directly from the pharmaceutical company.
From 11 included trials, 10 with over 4300 patients reported ben-
efits and 10 trials reported harms, indicating a substantial evidence
base. We lacked detail that may have been available in submissions
to the EMEA as part of this drug’s marketing authorisation and we
also did not have access to study protocols, so we were not able to
judge whether there was a concern about selective reporting. Lack
of availability of detailed study reports with individual patient data
denied us the opportunity of presenting a richer description of
adverse effects, particularly serious adverse reactions.
Agreements and disagreements with other
studies or reviews
The NICE 2009 and EMEA 2009 reports, performed as system-
atic reviews, have shown results quite similar to those in our review.
The beneficial effects (ACR50s) of other anti-TNF agents (goli-
mumab (Singh 2010), infliximab (Blumenauer 2002), etanercept
(Chen 2006; Lethaby 2013) and adalimumab (Navarro Sarabia
2005)) are also quite similar to that of certolizumab pegol. The
meta-analysis by Singh 2011 described the adverse effects of nine
biologics and included randomised controlled trials (RCTs), con-
trolled clinical trials (CCTs) and open-label extensions (OLEs) in
any indication (with the exception of HIV/AIDS) showing similar
overall results. Moreover, this study found similar results with cer-
tolizumab pegol for serious adverse events and serious infections
but failed to find an increased rate of withdrawals due to adverse
events. In this study the risk of serious infections was about four
times higher for certolizumab pegol and the authors performed
sensitivity analyses using different models to explain the results.
However, the significant differences between certolizumab pegol
and five other biologics as determined in the standard dose model
(main model) persisted in the unadjusted and dose-adjusted mod-
els for each comparison with one minor exception of certolizumab
pegol versus golimumab. Indirect comparisons between the bio-
logics suggested some differences in adverse events between drugs.
The authors concluded that there is a need for head-to-head trials
to verify these differences.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
Certolizumab pegol was the first pegylated anti-TNF agent ap-
proved by the FDA for the treatment of adult patients with mod-
erate to severe active RA.Our review confirms that the drug is clin-
ically beneficial, including a reduced risk of radiographic damage
compared with placebo. Adverse events were more frequent with
the active treatment. A potential risk of serious adverse events,
hypertension and tuberculosis in susceptible individuals needs to
be borne in mind when considering certolizumab pegol or other
anti-TNF drugs for active RA.
Implications for research
Treatment options for RA have expanded considerably in recent
years and include biologic agents targeting a variety of elements of
the inflammatory process. Once efficacy is established it is impor-
tant that studies focus on comparing agents in clinically relevant
populations. New agents continue to be targeted at patients who
have failed to respond to methotrexate, yet there are now many
established agents available for this population. Therefore, ethics
review boards need to consider whether studies which compare
agents with placebo or, at best, with background methotrexate
and active disease despite this therapy are justifiable. In this sit-
uation initial shorter-term studies may be justifiable to establish
efficacy, followed by longer-term studies looking at comparative
beneficial effects against drugs with known efficacy. Longer-term
randomised studies and observational data are clearly important
for the assessment of drug toxicity.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
CDP870-004 2001
Methods Double-blind, multiple dose, 12-week, placebo-controlled dose-ranging study
Participants 326 subjects with a history of inadequate response or intolerance to at least one DMARD
and active RA at screening
Interventions Patients received placebo, 50, 100, 200, 400, 600 and 800 mg sc q4w in two dose groups,
panel 1 and panel 2
Outcomes ACR20, ACR50, ACR70, subset of the ACR criterion, DAS responder rates at week 12
Follow-up 12 weeks
Notes We only have data from ACR20 at week 12
Funding sources: no data
Conflict of interest: no data
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk UCB reported: “Randomized code gener-
ated by Pharmaceutical Packaging Service
and based on instruction of the randomi-
sation procedure prepared by Celltech R&
D statistic”
Allocation concealment (selection bias) Unclear risk UCB reported: “Patients were randomly
assigned to treatment groups during the
DB phase (week 0 12) and received either
placebo or CDP-870 SC”
Blinding (performance bias and detection
bias)
ACR50
High risk UCB reported as blinded but they ex-
plained to us: “CPD-870 and the placebo
utilized in this study (saline) did not have
the same viscosity therefore full blinding
was not possible. Study drug was to be pre-
pared by a pharmacist having no other in-
volvement in the study; injections of study
medications were given by a nurse or physi-
cian who had no other involvement in the
study...”
Blinding (performance bias and detection
bias)
All outcomes
High risk See above
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CDP870-004 2001 (Continued)
Incomplete outcome data (attrition bias)
ACR50
High risk Data were not available
Incomplete outcome data (attrition bias)
All outcomes
High risk Data were not available
Selective reporting (reporting bias) Low risk Efficacy was defined as ACR improvement
in disease activity at week 12 and was de-
scribed
Other bias Unclear risk There were so few data that was impossible
to judge it
Blinding of participants and personnel
(performance bias)
All outcomes
High risk See above
Blinding of outcome assessment (detection
bias)
All outcomes
High risk See above
CDP870-014 2009
Methods Randomised double-blind placebo-controlled trial
Participants Patients with rheumatoid arthritis (RA) who are partial responders to MTX. RA defined
by the ACR classification criteria who had received MTX for ≥ 6 months (with at a
stable dose of ≥ 15 mg/week ) before baseline were included. At inclusion, patients had
to have active disease as defined by: Active disease was defined as ≥ 9 tender and 9
swollen joints at screening and at baseline, with either an erythrocyte sedimentation rate
(ESR; Westergen) ≥ 30 mm/hour or a C-reactive protein (CRP) level ≥ 15 mg/litre.
Other DMARDs had to be discontinued at least 28 days before baseline or five half-
lives,whatever longer, prior to first dose of study drug. We do not have more exclusion
criteria in the files reported from UCB but probably were similar to another Phase III
trial
It was a 24 weeks, phase III, double-blind, randomised, multicenter, placebo-controlled
study. 250 patients were randomised to one of two regimens of subcutaneous cer-
tolizumab pegol 400mg or placebo sc every 4weeks for a total of 6 injections. Methotrex-
ate treatment continue during the study taken prior to enrolment in the study. Subjects
who completed the current study or who withdrew on or after the Week 12 visit were
eligible to participate in the open-label safety study (CDP870-015)
The primary objective of this study was to compare the efficacy of certolizumab pegol
(CDP870 or CZP) in combination with methotrexate (MTX) toMTX alone in treating
the signs and symptoms of subjects with rheumatoid arthritis (RA) who are partial
responders to MTX. The study included 250 patients aged over 18 years with RA.
Inclusion and exclusion criteria were identical to RAPID1, but were discontinued all
DMARD at least 28 days or five half-lives, whatever longer, prior to first dose of study
drug. The primary endpoint was ACR20 response at week 24 and safety. Secondary
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CDP870-014 2009 (Continued)
efficacy endpoints at week 24 included ACR50, ACR70
Interventions Certolizumab pegol 400 mg plus MTX or placebo sc plus MTX every 4 weeks for a total
of 6 injections
Outcomes Primary: ACR20 and safety at 24 weeks. Secondary endpoints: Subject’s assessment
of pain (VAS), Subject’s global assessment of arthritis, Physician’s global assessment of
arthritis, Subject’s assessment of physical function by Health Assessment Questionnaire
- disability index (HAQ-DI), acute phase reactant value (only CRP for this study)
Follow-up 24 weeks
Notes NCT00544154. Clinical study summary provided by UCB
Funding sources: UCB
Conflict of interest: J.V. was a speaker at the meeting organized by UCB and is a
member of a UCB advisory board. E.C. has received grants/research support from Ab-
bott Laboratories, Allergan, Boehringer Ingelheim, Chelsea Therapeutics, GSK, Jazz
Pharmaceuticals, Merrimack Pharmaceutical, MSD, Pfizer, Pierre Fabre Medicament,
Roche, Chugai and Wyeth and UCB Pharma. E.C. has also received consultancy fees
from Abbott Laboratories, Allergan, Boehringer Ingelheim, Chelsea Therapeutics, Eli
Lilly, GSK, Jazz Pharmaceuticals, Merrimack Pharmaceutical, MSD, Pfizer, Pierre Fabre
Medicament, Roche, Schering Plough, Synovate, Chugai, MedImmune and Wyeth and
UCB Pharma. E.C. is a member of a Speaker’s Bureau for Abbott Laboratories, Aller-
gan, Boehringer Ingelheim, Chelsea Therapeutics, Eli Lilly, GSK, Jazz Pharmaceuticals,
Merrimack Pharmaceutical, MSD, Pfizer, Pierre Fabre Medicament, Roche, Schering
Plough, Chugai andWyeth and UCB Pharma. B.V. is a UCB Pharma employee and has
been granted UCB Pharma stock appreciation rights. N.G. is a former employee of UCB
Pharma, and is currently an employee of Array Biopharma, Inc. N.G. owns UCBPharma
stock. O.D. is an employee of UCB Pharma and holds stock options. R.A. has received
research grants from Abbott, BMS, Merck Pharma GmbH, Novartis, Pfizer, Roche and
UCB Pharma. R.A. is a member of a speaker’s bureau for Abbott Laboratories, BMS,
Horizon Pharma, Merck Pharma GmbH, Novartis, Roche, and has received consulting
fees from Abbott Laboratories, Horizon Pharma, Merck Pharma GmbH, Novartis and
Roche. R.A. has held non-remunerative positions of influence for Abbott Laboratories,
BMS, Novartis Pharmaceuticals Corporation and Roche. All other authors have declared
no conflicts of interest
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation code was generated by
an independent group following instruc-
tion of the randomisation procedures, pre-
pared by the project statistician (EMEA re-
port for the Phase III trial)
Allocation concealment (selection bias) Low risk Via Interactive voice recognition system
(IVRS)
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CDP870-014 2009 (Continued)
Blinding (performance bias and detection
bias)
ACR50
Low risk UCB explained us that: ”All the study staff
with the exception of the unblinded dis-
penser, was blind to the treatment“. ”Each
study center was required to have a written
blinding plan in place signed by the prin-
cipal investigator, which detailed the study
center’s steps for ensuring that the double
blind nature of the study was maintained“
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above paragraph
Incomplete outcome data (attrition bias)
ACR50
High risk Full account of all withdrawals and reasons
for withdrawals
77.8% of certolizumab pegol group and
53.7% of placebo completed 6 months of
treatment. Missing data were imputed for
analysis. Judged at high risk of bias due to >
20% dropout rate at 6 months in the treat-
ment group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analysis per protocol for HAQ and safety,
quote: “Of the 247 patients randomised,
124 patients in the CZP plus MTX group
(98%) and 119 in the placebo plus MTX
group (98%) received at least one injection
(243 total)”
Selective reporting (reporting bias) Low risk All the pre-specified outcomeswere studied
Other bias Low risk The study appears to be free of other
sources of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk See above paragraph. “To preserve the
blind to clinical research staff, the study
site pharmacist labelled clinical supplies
(study medication syringes), and a sorbitol
placebo was used to match the viscosity of
CZP”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above paragraph
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CERTAIN 2008
Methods A phase IIIB, multi-centre, double-blind, placebo-controlled, parallel group study to
evaluate the safety and efficacy of certolizumab pegol, administered with DMARD
Participants Patients with low tomoderate disease activity rheumatoid arthritis onDMARDs therapy
for at least six months
Interventions Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200
mg injections every 2 weeks until the last drug administration (Week 22) versus placebo
Outcomes Investigation of certolizumab pegol clinical efficacy in achieving clinical remission in





Conflict of interest: This study is not published. Despite this, paragraph was on the
web, “Principal Investigators are NOT employed by the organization sponsoring the
study”
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Well done
Allocation concealment (selection bias) Low risk Allocation by IVRS; so done remotely and
therefore concealment satisfactory
Blinding (performance bias and detection
bias)
ACR50
Low risk UCB stated: “All the study staff with the
exception of the unblinded dispenser, was
blind to the treatment. Each study center
was required tohave awritten blindingplan
inplace signedby the principal investigator,
which detailed the study center’s steps for
ensuring that the double blind nature of
the study was maintained”
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
ACR50
Low risk Full account of all withdrawals and reasons
for withdrawals
87.5% of certolizumab pegol group and
81% of placebo completed 6 months of
treatment. Missing data were imputed for
analysis. Judged at high risk of bias due to >
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CERTAIN 2008 (Continued)
20% dropout rate at 6 months in the treat-
ment group
Incomplete outcome data (attrition bias)
All outcomes
Low risk 85% in SF-36, 84% in Pain VAS, and 94%
inHAQ of certolizumab pegol group com-
pleted 24 months of treatment. Missing
data were imputed for analysis. Judged at
high risk of bias due to > 20% dropout rate
at 24 months in the treatment group
ITT in safety analysis
Selective reporting (reporting bias) Low risk All the pre-specified outcomeswere studied
Other bias Low risk The study appears to be free of other
sources of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Subject, caregiver, investigator and out-
come assessor”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Subject, caregiver, investigator and out-
come assessor”
Choy 2002
Methods Randomised double-blind placebo-controlled trial
Participants 36 patients with rheumatoid arthritis defined by the AmericanCollege for Rheumatology
(ACR) classification criteria. Patients with active diseased defined as having 3 or the
following 4 criteria: tender joint count (TJC)≥ 6, swollen joint count (SJC)≥ 3 (based
on 28 joint counts), morning stiffness of ≥ 45 minutes, and ESR≥ 28 mm/H. Patients
had to have failed treatment with at least one DMARD and have been off treatment for
at least 4 weeks
Interventions Ascending-dose group study of a single intravenous infusion of placebo (n = 12) or 1, 5
or 20 mg/kg of certolizumab pegol (each n = 8) for 8 weeks
Outcomes ACR20, ACR50, ACR70, Pain score (0-10 cm), Disease Activity Score (DAS), TJC,
SJC, Health Assessment Questionnaire (HAQ), C-reactive protein (CRP)
Follow-up 8 weeks
Notes This study was only considered to assess safety because follow-up was less than 8 weeks
Following the blinded dosing period of 8 weeks, 32 patients received a single open-label
infusion of either 5 or 20 mg/kg of certolizumab pegol
In the open phase, one patient who received 20mg/kg died from complications following
rapid drainage of a large, chronic rheumatoid pericardial effusion. No infective agent
was isolated from either the pericardial fluid or peripheral blood. In the opinion of the
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Choy 2002 (Continued)
investigator, this event was unrelated to treatment
Funding sources: no stated, but UCB had all the data and sent us details of how was
done
Conflict of interest: One author, DA Isenberg, worked for Celltech Research and De-
velopment, Slough, UK
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were divided into 4 groups. In each
group of 12 patients 8 received active treat-
ment and 4 received placebo. UCB explain
to us: “Methods for sequence generation
was randomised, DB, sequential ascending
dose”
Allocation concealment (selection bias) Low risk Central allocation
Blinding (performance bias and detection
bias)
ACR50
Low risk The study was blinded and UCB explained
to us: “all data were entered and Database
locked after completion of the clinical
phase for the first study period and be-
fore ESR and CRP were entered into the
database. ESR and CRP data were with-
held from investigator and sponsor study
personal during the course of the study be-
cause knowledge of patient’s profile could
potentially unblind the study..., auto AB,
anti CZP level, TNFalpha, IL6 and IL1b
were transferred into the database after DB
lock”
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
ACR50
Low risk Reasons for withdrawals were disclosed
92% of certolizumab pegol group and 50%
of placebo completed 8weeks of treatment.
Missing data were imputed for analysis.
Judged at high risk of bias due to > 20%
dropout rate at 8 weeks in the treatment
group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Safety analysis was also imputing missing
data
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Selective reporting (reporting bias) Low risk All the outcomes were available in the clin-
ical study report as figures
Other bias Low risk The study appears to be free of other
sources of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk UCB explained to us: “ the study pharma-
cist prepared for infusion the study medi-
cation and diluent, the pharmacy covered
the solution with an opaque material and
labelled it with “130mL CDP870 Engi-
neered Fab’ Conjugated to PEG or sodium
acetate placebo diluent” “For IV use only”,
administration details, the patient number,
patient initials, date and time to use the
medication by and name of investigator.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
FAST4WARD 2005
Methods Randomised double-blind trial
Participants 220 patients aged between 18 and 75 years and with RA defined by the ACR classifi-
cation criteria who had previously failed at least one disease modifying anti-rheumatic
drug (DMARD) were included. Patients previously treated with a TNF inhibitor were
excluded. Patients had to have a TJC of≥ 9 (out of 68), SJC of≥ 9 (out of 66) and one of
the following: morning stiffness of≥ 45 minutes; ESR≥ 28 mm/H; or CRP > 10 mg/L.
Patients with a previous history of a serious or life threatening infection were excluded.
Patients with a history of tuberculosis (TB), or evidence of TB on a chest radiograph,
or those with a positive reaction to purified protein derivative (PPD) reaction were also
excluded. Patients on concurrent corticosteroids were allowed entry provided the dose
was the equivalent of 10 mg or less of prednisolone. Parenteral corticosteroids were not
permitted
Interventions Certolizumab pegol 400 mg sc every four weeks (n=111) or placebo (n=109) for 24
weeks
Outcomes ACR20, 50, 70, HAQ-DI, Pain (VAS) and modified Brief Pain Inventory (mBPI), DAS-




Conflict of interest: JV has received a fee fromUCB for speaking at aNational Congress;
RFvV has received consulting fees from UCB; DB has received
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reimbursement from UCB for attending a symposium and funds for research; JB has
received reimbursement from UCB for attending a symposium and funds for research;
GC is a full time employee of and holds stocks in UCB; AI is a full time employee at
UCB and has shares in the company; NG is a full time employee of UCB and has shares
and stock options in the company; VS has worked as an independent biopharmaceutical
consultant in clinical development and regulatory affairs since September 1991 and is
currently a consultant to various companies, but has not and does not now hold stock in
any company. RF has received consulting fees and funds for clinical research from UCB
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Code list prepared by independent group
Allocation concealment (selection bias) Low risk Via interactive voice mail response (IVRS)
Blinding (performance bias and detection
bias)
ACR50
Low risk UCB stated: “All the study staff with the exception
of the unblinded dispenser, was blind to the treat-
ment”. “Each study center was required to have a writ-
ten blinding plan in place signed by the principal in-
vestigator, which detailed the study center’s steps for
ensuring that the double blind nature of the study was
maintained”
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above paragraph
Incomplete outcome data (attrition bias)
ACR50
High risk 68.5% of certolizumab pegol group and 25.7% of
placebo completed 6 months of treatment. Missing
data were imputed for analysis. Judged at high risk of
bias due to > 20% dropout rate at 6 months in the
treatment group
Incomplete outcome data (attrition bias)
All outcomes
High risk Full account of all withdrawals and reasons for with-
drawals
Quote: “All efficacy analyses were performed on the
modified intent to treat (mITT) population (all ran-
domised patientswhohad taken>1 dose of studymed-
ication). The actual number of subjects in the sum-
maries varies slightly from the mITT numbers due
to non-imputable missing data for each parameter.
For the primary analysis, patients were considered “re-
sponders” if they achieved anACR20 response vs base-
line at week 24. Patients who withdrew for any reason
were considered non responders.”
The safety analysis was based on the last observation
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carried forward approach
Selective reporting (reporting bias) Low risk All the outcomes were available
Other bias Low risk The study appears to be free of other sources of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk See above paragraph
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above paragraph
NCT00791921 HIKARI
Methods Treatment, randomised, double-blind
Participants Inclusion criteria:
• Subjects must have a diagnosis of adult-onset RA of at least 6 months but not
longer than 15 years in duration as defined by the 1987 American College of
Rheumatology classification criteria
• Subjects must have active RA disease as defined by:At least 6 tender joints and 6
swollen jointsESR of 28 mm/hour or CRP of 2.0 mg/dL
• Subjects who have failed to respond or have been resistant to at least one
DMARD (including MTX)
• Subjects in whom MTX cannot be administered for any of the reasons
(incomplete response/safety concerns
Exclusion criteria:
• Patients who have a diagnosis of any other inflammatory arthritisPatients who
have a secondary, non-inflammatory type of arthritis (e.g., osteoarthritis, fibromyalgia)
• Patients who currently have, or who have a history of, a demyelinating or
convulsive disease of the central nervous system (e.g., multiple sclerosis, epilepsy)
• Patients who have NYHA (New York Heart Association) Class III or IV
congestive heart failure
• Patients who currently have, or who have a history of, tuberculosis
• Patients who have a high risk of infection (with a current infectious disease, a
chronic infectious disease, a history of serious infectious disease)
• Patients who currently have, or who have a history of, malignancy
• Female patients who are breastfeeding or pregnant, who are of childbearing
potential
• Patients who previously received treatment with 2 or more anti-TNFα drugs or
who previously failed to respond to treatment with 1 or more anti-TNFα drugs
Less than 10 % of the patients were exposed to a previous a TNF with a wash-out period
of minimum of 3 months for etanercept or 6 months for other biologics
Interventions Patients received induction doses of 400 mg in weeks 0, 2 and 4 and thereafter 200mg
CDP870 given every 2 weeks until week 22 subcutaneously versus placebo
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Outcomes Primary outcome ACR20 at week 12; Secondary outcome ACR20 at week 24
Follow-up 24 weeks
Notes http://clinicaltrials.gov/ct2/show/NCT00791921?term=00791921&rank=1
Funding sources: Otsuka Pharmaceutical Co., Ltd. and UCB Japan
Conflict of interest: This study is already not published. Despite these paragraphs were
in the web: “Principal Investigators are NOT employed by the organization sponsoring
the study. There is NOT an agreement between Principal Investigators and the Sponsor
(or its agents) that restricts the PI’s rights to discuss or publish trial results after the trial
is completed”
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk External central of randomisation. Randomiza-
tion by blocks
Allocation concealment (selection bias) Low risk The allocation sequence was generate using
uniform randomnumbers fromSASRANUNI
function
Blinding (performance bias and detection
bias)
ACR50
Low risk “All study staff with the exception of the un-
blinded dispenser were blind to the treatment, .
.. These unblinded personnel were not allowed
to engage in any other study activities”
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
ACR50
High risk 71% of certolizumab pegol group and 15%
of placebo completed 6 months of treatment.
Missing data were imputed for analysis. Judged
at high risk of bias due to > 20% dropout rate
at 6 months in the treatment group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Full account of all withdrawals and reasons for
withdrawals
ITT analysis. Quote: “Of the 230 subjects in
the Full Analysis Set (FAS), 230 are included
in the adverse event reporting based upon the
Safety Set (SS) population. The Safety Set in-
cludes all subjects randomised who received at
least 1 dosing”
Selective reporting (reporting bias) Low risk The study protocol is available and all of the
study’s pre-specified (primary and secondary)
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outcomes that are of interest in the review have
been reported in the pre-specified way
Other bias Low risk The study appears to be free of other sources of
bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Without any details
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
NCT00791999 JRAPID
Methods Treatment, randomised, double-blind (subject, caregiver, investigator, outcomes assessor)
, dose comparison, parallel assignment, safety/efficacy study
Participants
Interventions Drug: CDP870 400mg
Drug: CDP870 200mg
Drug: CDP870 100mg
Drug: placebo of CDP870
Outcomes Primary outcome measures:
ACR20 responder rate (Time Frame: Week 12, 24) (Designated as safety issue: Yes)
Secondary outcome measures:
ACR20/50/70 responder rate (Time Frame: Week 1, 2, 4, 6, 8, 12, 14, 16, 20, 24)
DAS-28 (ESR) (Time Frame: Week 1, 2, 4, 6, 8, 12, 14, 16, 20, 24)
Modified Total Sharp Score (Time Frame: Week 24)
Follow-up 24 weeks
Notes http://clinicaltrials.gov/ct2/show/NCT00791999?term=NCT00791999&rank=1
Funding sources: Otsuka Pharmaceutical Co., Ltd; UCB Japan Co. Ltd
Conflict of interest: “Principal Investigators are NOT employed by the organization
sponsoring the study”. “There isNOT an agreement between Principal Investigators and
the Sponsor (or its agents) that restricts the PI’s rights to discuss or publish trial results
after the trial is completed”
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk External central of randomisation. Ran-
domization by blocks
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Allocation concealment (selection bias) Low risk The allocation sequence was generate using
uniform random numbers from SAS RA-
NUNI function
Blinding (performance bias and detection
bias)
ACR50
Low risk “All study staff with the exception of the
unblindeddispenserwere blind to the treat-
ment, ... These unblinded personnel were
not allowed to engage in any other study
activities”
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
ACR50
High risk 66% of certolizumab pegol 100 mg, 80%
of certolizumab pegol 200 mg and 76% of
certolizumab pegol 400 mg group (overall
74% in certolizumab pegol groups) and 32
% of placebo completed 6 months of treat-
ment. Missing data were imputed for anal-
ysis. Judged at high risk of bias due to >
20% dropout rate at 6 months in the treat-
ment group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Safety, quote: “Of the 316 subjects in the
Full Analysis Set (FAS), 316 are included
in the adverse event reporting based upon
the Safety Set (SS) population. The Safety
Set includes all subjects randomised who
received at least 1 dosing”
Selective reporting (reporting bias) High risk Subjects were recruited in Japan between
2008 and 2010. In 2008, DAS28 (ESR)
and Modified Total Sharp Score were sec-
ondary outcomes. In 2012 these outcomes




Other bias Low risk The study appears to be free of other
sources of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No details available
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
NCT00993317
Methods Treatment, randomised, double-blind (subject, investigator, outcomes assessor), placebo-
controlled, parallel assignment, safety/efficacy study
Participants Adult-onset RA of at least 6 months but not longer than 15 years in duration as defined
by the 1987 ARA criteria, with active disease
Interventions Drug: CDP870 200mg, 400mg CDP870 given at Week 0, 2, 4 and thereafter 200mg
CDP870 given every 2 weeks until week 22 (sc) plus MTX versus placebo plus MTX
with the same intervention
Outcomes ACR20 responder rate
Follow-up 24 weeks
Notes See http://clinicaltrials.gov/ct2/show/study/NCT00993317
Funding sources: Korea Otsuka Pharmaceutical Co Ltd
Conflict of interest: “Principal Investigators are NOT employed by the organization
sponsoring the study”. “There isNOT an agreement between Principal Investigators and
the Sponsor (or its agents) that restricts the PI’s rights to discuss or publish trial results
after the trial is completed”
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk External central randomisation
Allocation concealment (selection bias) Low risk The allocation sequence was generate using
uniform random numbers from SAS RA-
NUNI function
Blinding (performance bias and detection
bias)
ACR50
Low risk “All study staff with the exception of the
unblindeddispenserwere blind to the treat-
ment, ... These unblinded personnel were
not allowed to engage in any other study
activities”
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above
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Incomplete outcome data (attrition bias)
ACR50
High risk 70% of certolizumab pegol group and 50%
of placebo completed 6 months of treat-
ment. Missing data were imputed for anal-
ysis. Judged at high risk of bias due to >
20% dropout rate at 6 months in the treat-
ment group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Full account of all withdrawals and reasons
for withdrawals
Raw data
Per protocol analysis in change in (HAQ-
DI) 95% of certolizumab pegol group and
95% of placebo were imputed for analysis
Safety: ITT
Judged at high risk of bias due to > 20%
dropout rate at 24 months in the treatment
group
Selective reporting (reporting bias) Low risk The study protocol is available and all of
the study’s pre-specified (primary and sec-
ondary) outcomes that are of interest in the
review have been reported in the pre-spec-
ified way
Other bias Low risk The study appears to be free of other
sources of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk See above
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
RAPID1 2005
Methods Randomised double-blind trial
Participants 982 patients aged over 18 years and with RA defined by the ACR classification criteria
who had received MTX for ≥ 6 months (with at a stable dose of ≥ 10 mg/week for
at least 2 months) before baseline were included. Patients with a disease duration of
>15 years were excluded. Patients previously treated with a TNF inhibitor were also
excluded if they had previously failed to respond to treatment. Other DMARDs had
to be discontinued at least 28 days before baseline. At inclusion, patients had to have
active disease as defined by: Active disease was defined as ≥ 9 tender and 9 swollen
joints at screening and at baseline, with either an erythrocyte sedimentation rate (ESR;
Westergen) ≥ 30 mm/hour or a C-reactive protein (CRP) level ≥ 15 mg/L
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Interventions 982 patients were randomised 2:2:1 to receive treatmentwith subcutaneous certolizumab
pegol at an initial dosage of 400 mg given at weeks 0, 2, and 4, with a subsequent dosage
of 200 mg or 400 mg given every 2 weeks, plus MTX, or placebo plus MTX
Outcomes Co-primary endpoints were the ACR20 at week 24 and the mean change from baseline
in the modified Total Sharp Score at week 52. Major secondary end points were: the
change from baseline inmodified Total Sharp Score at week 24, the change from baseline
in the disability Index (DI) of the Health Assessment Questionnaire (HAQ) at weeks 24
and 52, the ACR20 responder rate at week 52, and the ACR50 and ACR70 responder
rates at weeks 24 and 52
Follow-up 24-52 weeks
Notes Patients with a history of tuberculosis or a chest radiograph showing active or latent
tuberculosis or those with a positive reaction to purified protein derivative (PPD) reaction
were also excluded
Funding sources: UCB
Conflict of interest: Dr. Keystone has received consulting fees, speaking fees, and/or
honoraria from Abbott, Amgen, Wyeth, Centocor, UCB, Roche, Genentech, Schering-
Plough, and Bristol-Myers Squibb (less than $10,000 each). Dr. van der Heijde has re-
ceived consulting fees, speaking fees, and/or honoraria from Abbott, Amgen, Centocor,
UCB, Roche, Schering-Plough, and Bristol-Myers Squibb (less than $10,000 each). Dr.
Landewe´ has received consulting fees, speaking fees, and/or honoraria from Abbott,
Amgen, Bristol-Myers Squibb, Centocor, Schering-Plough, UCB, and Wyeth (less than
$10,000 each). Dr. van Vollenhoven has received consulting fees, speaking fees, and/
or honoraria from UCB (more than $10,000). Dr. Combe has received consulting fees,
speaking fees, and/or honoraria from Abbott, Bristol-Myers Squibb, Merck, Sharp, &
Dohme, Roche, Schering, UCB, and Wyeth (less than $10,000 each). Dr. Emery has
received consulting fees from UCB (less than $10,000). Dr. Strand receives consulting
fees (her primary source of income) from Abbott Immunology, Allergan, Almirall, Al-
Pharma, Amgen, AstraZeneca, Bayhill, Bexel, Biogen Idec, Can-Fite, Centocor, Chelsea,
Cypress Bioscience, Dianippon
Sumitomo, Euro-Diagnostica, FibroGen, Forest, Genelabs, Genentech, Human
Genome Sciences, Idera, Incyte, Jazz, Lexicon Genetics Lux Biosciences, Merck Serono,
Novartis, Novo Nordisk, Noxxon Pharma, Nuon, Ono Pharmaceutical, Pfizer, Proc-
ter & Gamble, Rigel, RiGEN, Roche, Sanofi-Aventis, Savient, Schering-Plough, Scios,
SKK, UCB, VLST, Wyeth, XDx, and Zelos Therapeutics (less than $10,000 each) and
receives fees as a member of the advisory board for Abbott, Amgen, Biogen Idec, Bioseek,
Bristol-Myers Squibb, Can-Fite, Centocor, Chelsea, Cypress, Euro-Diagnostica, Forest,
Idera, Incyte, Jazz, Novartis, Pfizer, Rigel, RiGEN, Roche, Savient, Schering-Plough,
UCB, XDx, andWyeth (less than $10,000 each). Dr. Mease has received consulting fees,
speaking fees, and/or honoraria from UCB (less than $10,000). Mr. Desai owns stock
or stock options in UCB
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Code list prepared by independent group
Allocation concealment (selection bias) Low risk Interactive voice recognition system (IVRS) used to
allocate patient to treatment group (2:2:1 ratio)
Blinding (performance bias and detection
bias)
ACR50
Low risk UCB stated: “All the study staff with the exception of
the unblinded dispenser, was blind to the treatment.
Each study center was required to have awritten blind-
ing plan in place signed by the principal investigator,
which detailed the study center’s steps for ensuring
that the double blind nature of the study was main-
tained”
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above paragraph
Incomplete outcome data (attrition bias)
ACR50
High risk 65%of certolizumab200mgand70.3%certolizumab
400 mg of group and 22% of placebo completed 12
months of treatment. Missing data were imputed for
analysis. Judged at high risk of bias due to > 20%
dropout rate at 12 months in the treatment group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Full account of all withdrawals and reasons for with-
drawals
HAQ, quote: “Analyses were performed using the last
observation carried forward (LOCF) method for im-
putation of missing scores in the total ITT population
and the actual scores (observed) in those who with-
drew at week 16”
Safety: ITT analysis
Selective reporting (reporting bias) Low risk All the outcomes that are of interest in the review have
been reported in the pre-specified way
Other bias Low risk The study appears to be free of other sources of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk See above paragraph
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above paragraph
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RAPID2 2007
Methods Randomised double-blind trial
Participants 619 patients aged over 18 years and with RA of at least 6months and defined by the ACR
classification criteria who had received MTX for ≥ 6 months with at a stable dose of ≥
10 mg/week for at least 2 months before baseline were included. Patients with a disease
duration of > 15 years were excluded. At inclusion, patients had to have active disease as
defined by: TJC and SJC of ≥ 9, ESR ≥ 30 mm/H, and a CRP of ≥15 mg/L. Patients
previously treated with a TNF inhibitor were also excluded if they had previously failed
to respond to treatment
Interventions Patients were randomised 2:2:1 to one of two regimens of subcutaneous liquid cer-
tolizumab pegol (400 mg at weeks 0, 2 and 4, followed by 200 or 400 mg every 2 weeks)
plus MTX, or placebo (saline) plus MTX
Outcomes The primary endpoint was ACR20 response at week 24, and physician’s global assess-
ment of disease activity, patient’s assessment of pain, Health Assessment Questionnaire-
Disability Index (HAQ-DI) and serum CRP or ESR
Secondary efficacy endpoints at week 24 included ACR50, ACR70, mean change from
baseline in van der Heijde modified Total Sharp Scores (mTSS), Short Form-36 (SF-36)
Health Survey,and individual ACR core set variables. Disease activity was assessed using
the Disease Activity Score 28-joint assessment 4 (DAS-28 (ESR)
Follow-up 24 weeks
Notes Patients who did not show an ACR20 response at both weeks 12 and 14 were to be
withdrawn from the study, designated ACR20 non-responders in the primary analysis
and allowed to enter an open-label extension study at week 16 with certolizumab pegol
400 mg every 2 weeks
Patients with history of, or positive chest x-ray findings for, tuberculosis, or a positive pu-
rified protein derivative (PPD) skin test (defined as positive indurations per local medical
practice) were excluded. As per protocol, if a positive PPD skin test was assumed by the
local investigators to be related to previous bacille Calmette-Guerin (BCG) vaccination
and was not associated with clinical or radiographic suspicion of tuberculosis, patients
could be enrolled at the discretion of the investigator. In total, 101 patients (16%) were
enrolled with a PPD test > 5 mm at baseline
Funding sources: UCB
Conflict of interest: J Smolen, R B Landewé, P Mease, RF van Vollenhoven, A Ka-
vanaugh,M Schiff, GRBurmester, V Strand andD van derHeijde serve as consultants to
UCB, Inc. RB Landewé, A Kavanaugh, M Schiff and D van der Heijde receive research
funding from UCB, Inc and GR Burmester and J Vencovsky have received honorarium
from UCB, Inc for speaking. D Mason and K Luijtens are employees of UCB, Inc. J
Brzezicki has nothing to disclose
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Code list prepared by independent group
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Allocation concealment (selection bias) Low risk Interactive voice recognition system (IVRS) used to
allocate patient to treatment group (2:2:1 ratio)
Blinding (performance bias and detection
bias)
ACR50
Low risk UCB stated: “All the study staff with the exception of
the unblinded dispenser, was blind to the treatment.
Each study center was required to have awritten blind-
ing plan in place signed by the principal investigator,
which detailed the study center’s steps for ensuring
that the double blind nature of the study was main-
tained”
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above paragraph
Incomplete outcome data (attrition bias)
ACR50
High risk 71% and 74% of certolizumab pegol 200 mg and
certolizumab pegol 400 mg respectively and 13% of
placebo completed 6 months of treatment. Missing
data were imputed for analysis. Judged at high risk of
bias due to > 20% dropout rate at 6 months in the
treatment group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Full account of all withdrawals and reasons for with-
drawals
Safety: ITT analysis. Quote: “two patients in the
placebo group received certolizumab pegol 200 mg
and were included in the certolizumab pegol 200 mg
group for safety evaluations”
Selective reporting (reporting bias) Low risk All the outcomes that are of interest in the review have
been reported in the pre-specified way
Other bias Low risk The study appears to be free of other sources of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk See above paragraph
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Radiographswere read centrally andblinded (for treat-
ment, visit and patient identification) and indepen-
dently by two experienced readers
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Methods Treatment, randomised, double-blind (subject, outcomes assessor), parallel assignment,
safety/efficacy study
Participants Patients with established adult patients with moderate-to-severe rheumatoid arthritis
Interventions 400 mg CZP given as two 200 mg subcutaneous (sc) injections at Weeks 0, 2, and 4,
followed by 200 mg CZP given as 1 sc injection on Weeks 6, 8, and 10. At Week 12
subjects enter the open-label phase and receive 200 mg of CZP every other week for a
minimum 16 additional weeks until CZP is commercially available versus placebo (0.9%
saline) given as 2 subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by placebo
given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open-label
phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks
until CZP is commercially available
Outcomes To assess the clinical responses rate as measured by ACR20 response rate Week 12.
Other outcomes: responder rate, disease activity, fatigue, physical functioning. In the
group remaining in the study after week 12: responder rate, disease activity, fatigue,






Conflict of interest: “Principal Investigators are NOT employed by the organization
sponsoring the study.”. “ There IS an agreement between Principal Investigators and the
Sponsor (or its agents) that restricts the PI’s rights to discuss or publish trial results after
the trial is completed.” “ Restriction Description: UCB has > 60 but <= 180 days to
review results communications prior to public release and may delete information that is
confidential and compromises ongoing studies or is considered proprietary. This restric-
tion is not intended to compromise the objective scientific integrity of the manuscript,
it being understood that the results shall be published regardless of outcome”
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomised 4:1 via an inter-
active voice response system”
Allocation concealment (selection bias) Low risk “Patients were randomised 4:1 via an inter-
active voice response system”
Blinding (performance bias and detection
bias)
ACR50
Low risk Blinding of participants and key study per-
sonnel ensured, andunlikely that the blind-
ing could have been broken. UCB ex-
plained us that: “All the study staff with the
exception of the unblinded dispenser, was
blind to the treatment”. “Each study center
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was required tohave awritten blindingplan
in place signed by the principal investiga-
tor, which detailed the study center’s steps
for ensuring that the double blind nature
of the study was maintained”
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above paragraph
Incomplete outcome data (attrition bias)
ACR50
Low risk 90% of certolizumab pegol group and 86%
of placebo completed 12 weeks of treat-
ment. Missing data were imputed for anal-
ysis. Judged at high risk of bias due to >
20% dropout rate at 12 weeks in the treat-
ment group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Full account of all withdrawals and reasons
for withdrawals
ITT analysis for efficacy outcomes but per
protocol analysis in safety: 9 patients less in
arm of certolizumab pegol and 3 patients
less in placebo group
Selective reporting (reporting bias) Low risk All the outcomes that are of interest in the
review have been reported in the pre-spec-
ified way
Other bias Low risk The study appears to be free of other
sources of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Despite blinding is not described, Blinding
of participants and key study personnel en-
sured, and unlikely that the blinding could
have been broken
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and key study per-
sonnel ensured, andunlikely that the blind-
ing could have been broken
Choy’s study didn’t show number of patients in each arm, mean age (SD), percentage of females, previous DMARD, on steroids, on
NSAIDs; and DAS was reported as mean change from baseline without SD.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aaltonen 2012 Meta-analysis of randomised controlled trials
Alten 2013 OLE
Andreakos 2003 Different drug/agent studied
Anonymous 2003 Review; different drug/agent studied
Audrey 2010 Meta-analysis of randomised controlled trials
Bain 2003 Different drug/agent studied
Bansback 2005 Different drug/agent studied
Barnes 2007 Review
Baugh 2001 Review
Bayes M 2006 Review
Chang 2006 Different drug/agent studied
Chikanza 2000a Review in children
Chikanza 2000b Review
Deeks 2013 Review
Dose Flex 2007 Is a RCT that tested clinical efficacy of two dosing regimes of CZP (200 mg Q2W or 400 mg Q4W + MTX)
compared to MTX alone for maintenance of clinical response up to 34 weeks in patients who have achieved
ACR20 after a 16 week open-label run-in period of CZP treatment (CZP 200 mg Q2W + MTX). Reason for
exclusion is that patients are not with active disease at the moment of randomisation and so is a criterion of
out
Evans 2003 Different drug/agent studied
Fanet-Goguet 2004 Review
Fleischmann 2005 Review
Fleischmann 2013 Open-label extension study (OLE)
Gabay 2002 Review
Garber 2005 Different drug/agent studied
54Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)




Graninger 2002 Different drug/agent studied
Ingham 2010 Meta-analysis of randomised controlled trials
Janssen 2012 Meta-analysis of randomised controlled trials
Kathmann 2005 Review
Kaushik 2005 Review
Kavanaugh 2013 Open-label extension study (OLE)
Kavanaugh A Assessed in RAPID1 and RAPID2, a work productivity survey (WPS-RA)
Keystone 2013 Open-label extension
Keystone 2013a Open-label extension (OLE)
Kochbati 2004 Review
Launois 2011 Meta-analysis of randomised controlled trials
Launois 2011a Meta-analysis of randomised controlled trials
Le 2010 Meta-analysis of randomised controlled trials
Le 2012 Meta-analysis of randomised controlled trials
LE Blay P Meta-analysis of randomised controlled trials
Lopez-Olivo 2012 Meta-analysis of randomised controlled trials
Mealy 2005 Different drug/agent studied
Mok 2004 Review
Moulis 2012 Meta-analysis of randomised controlled trials
Mount 2005 Review
NCT00160641 Just one simple group
NCT00160693 Is an OLE with just one simple group
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(Continued)
NCT00175877 Just one simple group
NCT00753454 One simple group
NCT00843778 Just one simple group




Pierreisnard 2012 Meta-analysis of randomised controlled trials
Rose-John 2003 Review
Russo 2005 Different drug/agent studied
Sandborn 2003 Crohn’s disease review
Schreiber Crohn’s disease
Smolen 2013 Open-label extension (OLE)
Sorbera 2005 Review
Takeuchi 2005 Review
Tanaka 2013 Open-label extension (OLE)




Wang 2013 Meta-analysis of randomised controlled trials
Yamanaka Conference proceedings without useful data
Yamanaka a Conference proceedings without useful data
Zhu 2013 Meta-analysis of randomised controlled trials
56Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Zwerina 2005 Review
Characteristics of ongoing studies [ordered by study ID]
NCT00850343
Trial name or title Long-term Treatment Study of CDP870Without Coadministration ofMTX in Japanese Rheumatoid Arthri-
tis (RA) Patients
Methods Randomized, open-label, uncontrolled, parallel assignment
Participants Japanese RA patients who are transferred from the study (Study 275-08-003), as well as to evaluate the effects
of dosing regimens on safety and efficacy of CDP870 in the ACR20 responders who completed Study 275-
08-003
Interventions Drug: CDP870 200mg and CDP870 400mg
Outcomes Primary outcome: adverse events (Time Frame: At any time) (Designated as safety issue: Yes); Secondary
outcome: ACR20/50/70 responder rate
DAS-28 (ESR), Modified Total Sharp Score
Starting date Mar 2009; expected completed date: Mar 2012
Contact information Drug Information Centeropc ctr@otsuka.jp
Notes
NCT00851318
Trial name or title Long-term Treatment Study of CDP870 as Add-on Medication to MTX in Japanese Rheumatoid Arthritis
(RA) Patients
Methods Randomised, open-label, uncontrolled, parallel assignment, safety/efficacy study
Participants
Interventions Two arms: CDP870 200 mg given every 2 weeks, SC; CP870 400mg given every 2 weeks, sc
Outcomes ACR20/50/70 responder rate (Time Frame: Week 24, 52) ([Designated as safety issue: Yes)
DAS28 (ESR) (Time Frame: Week 24, 52) (Designated as safety issue: Yes)
Modified Total Sharp Score (Time Frame: Week 24) (Designated as safety issue: Yes)
Starting date Mar 2009; expected completion Mar 2011
Contact information Contact: Drug Information Centeropc ctr@otsuka.jp
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Trial name or title A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy
and Safety of CDP870 in Early MTX-naive Rheumatoid Arthritis Patients With Poor Prognosis
Methods Clinical trial randomised, double-blind
Participants Estimated enrolment 300
Interventions 400mg of CDP870 given at Week 0, 2. 4, and thereafter 200mg CDP870 given every q2 weeks versus placebo
given every q2 weeks
Outcomes Primary outcome measures:Inhibition of radiographic progression at week 52
Seconary outcomes measures:
Inhibition of radiographic progression at week 24
Clinical remission rate at week 24 and week 52
Starting date October 2011
Contact information Otsuka Pharmaceutical Co, Ltd
Notes Final data collection for primary outcomes measure
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D A T A A N D A N A L Y S E S
Comparison 1. Efficacy at 12 weeks, any dose




participants Statistical method Effect size
1 ACR20 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 certolizumab 50 mg sc 1 47 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.13, 0.57]
1.2 certolizumab 100 mg sc 2 145 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.09, 7.05]
1.3 certolizumab 200 mg sc 5 1577 Risk Ratio (M-H, Random, 95% CI) 1.84 [0.99, 3.40]
1.4 certolizumab 400 mg sc 2 161 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.38, 5.23]
1.5 certolizumab 600 mg sc 1 47 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.51, 0.90]
1.6 certolizumab 800 mg sc 1 46 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.66, 1.04]
2 ACR50 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 certolizumab 50 mg sc 1 47 Risk Ratio (M-H, Random, 95% CI) 1.58 [0.09, 27.88]
2.2 certolizumab 100 mg sc 1 48 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.06, 20.96]
2.3 certolizumab 200 mg sc 3 1239 Risk Ratio (M-H, Random, 95% CI) 2.57 [1.76, 3.75]
2.4 certolizumab 400 mg sc 1 50 Risk Ratio (M-H, Random, 95% CI) 7.33 [0.48, 110.96]
3 ACR70 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 certolizumab 50 mg sc 1 47 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.06, 21.47]
3.2 certolizumab 100 mg sc 1 48 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.03, 14.89]
3.3 certolizumab 200 mg sc 3 1239 Risk Ratio (M-H, Random, 95% CI) 4.52 [2.14, 9.57]
3.4 certolizumab 400 mg sc 1 50 Risk Ratio (M-H, Random, 95% CI) 5.23 [0.34, 80.54]
Comparison 2. Efficacy at 24 weeks, 200 mg certolizumab pegol




participants Statistical method Effect size
1 ACR 20 6 1675 Risk Ratio (M-H, Random, 95% CI) 3.71 [2.68, 5.13]
2 ACR 50 5 1445 Risk Ratio (M-H, Random, 95% CI) 3.80 [2.42, 5.95]
3 ACR 70 5 1445 Risk Ratio (M-H, Random, 95% CI) 7.26 [3.83, 13.76]
Comparison 3. Efficacy at 24 weeks, 400 mg certolizumab




participants Statistical method Effect size
1 ACR 20 5 1591 Risk Ratio (M-H, Random, 95% CI) 3.73 [2.43, 5.72]
2 ACR 50 5 1591 Risk Ratio (M-H, Random, 95% CI) 4.65 [3.09, 6.99]
3 ACR 70 5 1591 Risk Ratio (M-H, Random, 95% CI) 7.20 [2.25, 23.03]
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Comparison 4. Efficacy at 24 weeks, any dose




participants Statistical method Effect size
1 ACR20 8 2935 Risk Ratio (M-H, Random, 95% CI) 2.76 [2.29, 3.33]
1.1 certolizumab 100 mg sc 1 98 Risk Ratio (M-H, Random, 95% CI) 2.65 [1.28, 5.47]
1.2 certolizumab 200 mg sc 6 1462 Risk Ratio (M-H, Random, 95% CI) 2.92 [2.17, 3.95]
1.3 certolizumab 400 mg sc 5 1375 Risk Ratio (M-H, Random, 95% CI) 2.65 [1.98, 3.56]
2 ACR50 7 2705 Risk Ratio (M-H, Random, 95% CI) 2.95 [2.37, 3.68]
2.1 certolizumab 100 mg sc 1 98 Risk Ratio (M-H, Random, 95% CI) 2.89 [1.13, 7.38]
2.2 certolizumab 200 mg sc 5 1232 Risk Ratio (M-H, Random, 95% CI) 2.76 [2.02, 3.78]
2.3 certolizumab 400 mg sc 5 1375 Risk Ratio (M-H, Random, 95% CI) 3.18 [2.29, 4.41]
3 ACR70 7 2705 Risk Ratio (M-H, Random, 95% CI) 4.15 [2.68, 6.42]
3.1 certolizumab 100 mg sc 1 98 Risk Ratio (M-H, Random, 95% CI) 6.86 [0.97, 48.72]
3.2 certolizumab 200 mg sc 5 1232 Risk Ratio (M-H, Random, 95% CI) 4.29 [2.36, 7.77]
3.3 certolizumab 400 mg sc 5 1375 Risk Ratio (M-H, Random, 95% CI) 4.04 [1.37, 11.90]
Comparison 5. Efficacy at 52 weeks, 200 mg certolizumab




participants Statistical method Effect size
1 ACR 20 1 592 Risk Ratio (M-H, Fixed, 95% CI) 4.05 [2.80, 5.87]
2 ACR 50 1 592 Risk Ratio (M-H, Fixed, 95% CI) 5.03 [3.04, 8.32]
3 ACR 70 1 592 Risk Ratio (M-H, Fixed, 95% CI) 6.00 [2.83, 12.74]
Comparison 6. Efficacy at 52 weeks, 400 mg certolizumab




participants Statistical method Effect size
1 ACR 20 1 589 Risk Ratio (M-H, Fixed, 95% CI) 4.18 [2.89, 6.05]
2 ACR 50 1 589 Risk Ratio (M-H, Fixed, 95% CI) 5.27 [3.19, 8.71]
3 ACR 70 1 589 Risk Ratio (M-H, Fixed, 95% CI) 6.56 [3.10, 13.89]
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Comparison 7. Efficacy at 52 weeks, any dose




participants Statistical method Effect size
1 ACR20 1 982 Risk Ratio (M-H, Random, 95% CI) 2.06 [1.61, 2.62]
1.1 certolizumab 200 mg sc 1 493 Risk Ratio (M-H, Random, 95% CI) 2.04 [1.44, 2.87]
1.2 certolizumab 400 mg sc 1 489 Risk Ratio (M-H, Random, 95% CI) 2.08 [1.48, 2.93]
2 ACR50 1 982 Risk Ratio (M-H, Random, 95% CI) 2.58 [1.83, 3.62]
2.1 certolizumab 200 mg sc 1 493 Risk Ratio (M-H, Random, 95% CI) 2.53 [1.56, 4.10]
2.2 certolizumab 400 mg sc 1 489 Risk Ratio (M-H, Random, 95% CI) 2.62 [1.62, 4.25]
3 ACR70 1 982 Risk Ratio (M-H, Random, 95% CI) 3.14 [1.86, 5.29]
3.1 certolizumab 200 mg sc 1 493 Risk Ratio (M-H, Random, 95% CI) 3.02 [1.44, 6.32]
3.2 certolizumab 400 mg sc 1 489 Risk Ratio (M-H, Random, 95% CI) 3.26 [1.56, 6.82]
Comparison 8. Safety, certolizumab 200 mg




participants Statistical method Effect size
1 Any adverse event 7 2729 Risk Ratio (M-H, Random, 95% CI) 1.19 [1.07, 1.32]
2 Adverse events Intensity mild 4 2249 Risk Ratio (M-H, Random, 95% CI) 1.18 [1.00, 1.41]
3 Adverse events Intensity
moderate
4 2249 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.86, 1.32]
4 Adverse events Intensity severe 4 2249 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.14 [0.78, 1.65]
5 Adverse events related to study
drug
2 964 Risk Ratio (M-H, Random, 95% CI) 1.59 [1.27, 1.99]
6 Serious Adverse Events (SAE) 7 2729 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.77 [1.27, 2.46]
7 Serious Infections 2 964 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.30 [1.45, 7.51]
8 Adverse events leading to death 5 2443 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.34 [0.46, 11.84]
9 Adverse events leading to
withdrawal
7 2729 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.62 [1.07, 2.44]
10 Death 5 2441 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.56 [0.56, 11.59]
11 Tuberculosis 5 2340 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.53 [0.94, 21.85]
12 Malignancies included
lymphoma
6 2570 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.79 [0.29, 2.12]
13 Injection site pain 3 1091 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.85 [0.49, 6.92]
14 Injection side reactions 4 2178 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.28 [1.80, 5.99]
15 Neutralising Anti-certolizumab
pegol antibodies
1 373 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.57 [0.71, 29.59]
16 Systemic lupus erythematosus 2 567 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.50 [0.07, 286.06]
17 Prolonged activated partial
thromboplastin time (aPTT)
2 500 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.73 [0.98, 7.61]
18 Urinary tract infection 5 2340 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.83 [0.51, 1.36]
19 Upper respiratory tract
infection
7 2729 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.51 [1.08, 2.09]
20 Lower respiratory tract
infection/ lung infection
6 2356 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.12 [0.76, 5.95]
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21 Headache 5 2372 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.05 [0.67, 1.64]
22 Bacteriuria 1 373 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.01 [0.30, 3.40]
23 Nasopharyngitis/Pharyngitis 6 1674 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.46 [1.02, 2.09]
24 Hypertension 4 1353 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.09 [1.64, 5.84]
25 Hematuria 1 373 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.36 [0.09, 1.47]
26 Hepatic enzyme increased 2 532 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.49 [0.17, 1.48]
27 AST increased 1 373 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.18 [0.04, 0.86]
28 ALT increased 1 373 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.09 [0.02, 0.45]
29 Back pain 1 591 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.91 [1.11, 7.65]
30 Herpes viral infection 2 821 Peto Odds Ratio (Peto, Fixed, 95% CI) 5.80 [0.34, 100.23]
31 Bacterial peritonitis 1 591 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.52 [0.07, 285.70]
32 Opportunistic infections 4 2070 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.33 [0.46, 117.85]
33 Infections and infestations 7 2712 Risk Ratio (M-H, Random, 95% CI) 1.29 [1.07, 1.56]
34 Gastroenteritis 2 785 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.97 [0.33, 2.87]
35 Hematologic abnormalities 2 821 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.02 [0.27, 15.21]
36 Decreased haemoglobin 1 591 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.02 [0.09, 11.18]
37 Increased platelet count 1 591 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.05 [0.00, 3.25]
38 Pneumonia 4 1606 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.88 [0.51, 6.99]
39 Diarrhoea 2 321 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.64 [0.22, 1.90]
40 Cerebral haemorrhage
including subarachnoid
2 321 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.27 [0.12, 13.50]
41 Nausea/vomiting 2 1249 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.83 [0.45, 1.50]
42 Acute miocardial infarction 1 194 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
43 Constipation 1 230 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.46 [1.04, 53.63]
44 Skin and subcutaneous tissue
disorders
3 516 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.54 [1.81, 6.95]
45 Cough 1 127 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.84 [0.28, 12.22]
46 Pruritus 1 127 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.56 [0.40, 51.56]
47 Abdominal
pain/discomfort/dyspepsia
1 127 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.58 [0.80, 8.35]
48 Fatigue 1 127 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.45 [0.18, 11.96]
49 Periodontitis 1 162 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.80 [0.35, 9.16]
Comparison 9. Safety, certolizumab 400 mg




participants Statistical method Effect size
1 Any adverse events 5 1584 Risk Ratio (M-H, Random, 95% CI) 1.20 [1.06, 1.35]
2 Adverse events Intensity mild 4 1422 Risk Ratio (M-H, Random, 95% CI) 1.25 [1.04, 1.50]
3 Adverse events Intensity
moderate
4 1422 Risk Ratio (M-H, Random, 95% CI) 1.24 [1.06, 1.45]
4 Adverse events Intensity severe 4 1422 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.23 [0.83, 1.81]
5 Adverse events related to study
drug
3 1179 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [1.19, 1.80]
6 Serious infections 4 1422 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.25 [1.65, 6.39]
7 3Serious Adverse Events (SAE) 5 1584 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.98 [1.36, 2.90]
8 Adverse events leading to death 3 1179 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.16 [0.40, 11.79]
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9 Adverse events leading to
withdrawal
5 1584 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.01 [1.20, 3.36]
10 Death 4 1422 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.16 [0.40, 11.79]
11 Vomiting 1 220 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.13 [0.00, 6.70]
12 Pneumonitis 1 220 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.13 [0.00, 6.70]
13 Tuberculosis 3 1179 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.55 [0.71, 29.11]
14 Arthritis bacterial 1 220 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.26 [0.14, 365.79]
15 Mastitis 1 220 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.26 [0.14, 365.79]
16 Benign Tumour 1 220 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.32 [0.46, 117.84]
17 Ischaemeic stroke 1 220 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.26 [0.14, 365.79]
18 Dizziness postural 1 220 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.26 [0.14, 365.79]
19 Menorrhagia 1 220 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.26 [0.14, 365.79]
20 Malignancies included
lymphoma
3 1179 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.26 [0.26, 6.08]
21 Injection site pain 3 1179 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.74 [0.41, 7.42]
22 Injection side reactions 5 1584 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.34 [0.20, 0.56]
23 Anti-certolizumab pegol
antibodies
2 591 Peto Odds Ratio (Peto, Fixed, 95% CI) 6.70 [2.18, 20.55]
24 Antinuclear antibodies (ANA) 1 220 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.65 [0.77, 3.53]
25 Prolonged activated partial
thromboplastin time (aPTT)
1 371 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.46 [0.80, 7.60]
26 Urinary tract infection 2 959 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.87 [0.50, 1.52]
27 Back pain 2 831 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.11 [1.48, 6.55]
28 Upper respiratory tract
infection
4 1364 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.42 [0.77, 2.61]
29 Lower respiratory tract
infection/ lung infection
3 993 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.11 [0.75, 5.95]
30 Headache 4 1364 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.30 [0.76, 2.20]
31 Bacteriuria 1 371 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.75 [0.20, 2.82]
32 Hypertension 3 1121 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.35 [1.80, 6.20]
33 Hematuria 1 371 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.37 [0.09, 1.49]
34 Hepatic enzyme increased 2 533 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.69 [0.25, 1.92]
35 AST increased 1 371 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.58 [0.16, 2.07]
36 ALT increased 1 373 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.67 [0.22, 2.05]
37 Herpes viral infection 1 588 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.53 [0.07, 285.35]
38 Bacterial peritonitis 1 588 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
39 Opportunistic infections 1 588 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
40 Infections and infestations 4 1364 Risk Ratio (M-H, Random, 95% CI) 1.49 [1.11, 1.99]
41 Nasopharyngitis/Pharyngitis 4 1364 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.98 [1.26, 3.11]
42 Gastrointestinal disorders 2 831 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.05 [0.54, 2.03]
43 Hematologic abnormalities 2 750 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.13 [0.21, 6.07]
44 Decreased Haemoglobin 1 588 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.49 [0.03, 9.10]
45 Increased platelet count 1 588 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.02 [0.09, 11.23]
46 Skin and subcutaneous tissue
disorders
1 162 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.38 [0.38, 4.94]
47 Acute miocardial infarction 1 162 Peto Odds Ratio (Peto, Fixed, 95% CI) 6.73 [0.13, 340.56]
48 Corneal Perforation 1 162 Peto Odds Ratio (Peto, Fixed, 95% CI) 6.73 [0.13, 340.56]
49 Conjunctivitis allergic 1 162 Peto Odds Ratio (Peto, Fixed, 95% CI) 6.73 [0.13, 340.56]
50 Periodontitis 1 159 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.14, 6.50]
51 Fatigue 1 243 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.46 [0.52, 4.15]
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Comparison 10. Mean HAQ-DI from baseline at week 12




participants Statistical method Effect size
1 certolizumab pegol 200 mg sc 1 1063 Mean Difference (IV, Fixed, 95% CI) -0.22 [-0.23, -0.21]
Comparison 11. Mean HAQ-DI from baseline at week 24




participants Statistical method Effect size
1 certolizumab pegol 200 mg sc 4 1268 Mean Difference (IV, Random, 95% CI) -0.35 [-0.43, -0.26]
2 certolizumab 400 mg sc 4 1425 Mean Difference (IV, Random, 95% CI) -0.38 [-0.48, -0.28]
Comparison 12. HAQ-DI at 24 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 5 2246 Mean Difference (IV, Random, 95% CI) -0.36 [-0.43, -0.29]
1.1 certolizumab pegol 200
mg sc
3 985 Mean Difference (IV, Random, 95% CI) -0.33 [-0.44, -0.23]
1.2 certolizumab pegol 400
mg sc
4 1261 Mean Difference (IV, Random, 95% CI) -0.38 [-0.48, -0.27]
Comparison 13. HAQ-DI at 52 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 1 982 Mean Difference (IV, Fixed, 95% CI) -0.43 [-0.52, -0.35]
1.1 certolizumab pegol 200
mg sc
1 493 Mean Difference (IV, Fixed, 95% CI) -0.42 [-0.54, -0.30]
1.2 certolizumab pegol 400
mg sc
1 489 Mean Difference (IV, Fixed, 95% CI) -0.45 [-0.57, -0.33]
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Comparison 14. SF-36 Physical Component Summary (PCS), week 24




participants Statistical method Effect size
1 certolizumab pegol 200 mg sc 3 1129 Mean Difference (IV, Random, 95% CI) 5.03 [3.90, 6.16]
2 certolizumab pegol 400 mg sc 3 1205 Mean Difference (IV, Random, 95% CI) 5.54 [4.11, 6.97]
Comparison 15. SF-36 Mental Component Summary (MCS), week 24




participants Statistical method Effect size
1 certolizumab pegol 200 mg sc 2 965 Mean Difference (IV, Random, 95% CI) 4.18 [2.70, 5.66]
2 certolizumab pegol 400 mg sc 3 1205 Mean Difference (IV, Random, 95% CI) 4.05 [2.77, 5.34]
Comparison 16. SF-36 Physical Component Summary (PCS), week 52




participants Statistical method Effect size
1 certolizumab 200 mg sc 1 592 Mean Difference (IV, Fixed, 95% CI) 6.06 [4.59, 7.53]
2 certolizumab 400 mg sc 1 589 Mean Difference (IV, Fixed, 95% CI) 6.88 [5.42, 8.34]
Comparison 17. SF-36 Mental Component Summary (MCS), week 52




participants Statistical method Effect size
1 certolizumab pegol 200 mg sc 1 592 Mean Difference (IV, Fixed, 95% CI) 4.3 [2.40, 6.20]
2 certolizumab pegol 400 mg sc 1 589 Mean Difference (IV, Fixed, 95% CI) 4.3 [2.40, 6.20]
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Comparison 18. SF-36 Physical Component Summary (PCS) at week 24, any dose




participants Statistical method Effect size
1 Change from baseline 3 1765 Mean Difference (IV, Random, 95% CI) 5.29 [4.37, 6.21]
1.1 certolizumab pegol 200
mg sc
3 967 Mean Difference (IV, Random, 95% CI) 4.99 [3.79, 6.20]
1.2 certolizumab pegol 400
mg sc
2 798 Mean Difference (IV, Random, 95% CI) 5.62 [3.70, 7.54]
Comparison 19. SF-36 Mental Component Summary (MCS) at week 24, any dose




participants Statistical method Effect size
1 Change from baseline 4 2012 Mean Difference (IV, Random, 95% CI) 4.01 [2.94, 5.08]
1.1 certolizumab pegol 200
mg sc
3 971 Mean Difference (IV, Random, 95% CI) 4.11 [2.62, 5.61]
1.2 certolizumab pegol 400
mg sc
3 1041 Mean Difference (IV, Random, 95% CI) 3.91 [2.38, 5.44]
Comparison 20. SF-36 Physical Component Summary (PCS) at week 52, any dose




participants Statistical method Effect size
1 Change from baseline 1 982 Mean Difference (IV, Fixed, 95% CI) 6.47 [5.13, 7.81]
1.1 certolizumab pegol 200
mg sc
1 493 Mean Difference (IV, Fixed, 95% CI) 6.06 [4.17, 7.95]
1.2 certolizumab pegol 400
mg sc
1 489 Mean Difference (IV, Fixed, 95% CI) 6.88 [4.99, 8.77]
Comparison 21. SF-36 Mental Component Summary (MCS) at week 52, any dose




participants Statistical method Effect size
1 Change from baseline 1 982 Mean Difference (IV, Fixed, 95% CI) 4.3 [2.57, 6.03]
1.1 certolizumab pegol 200
mg sc
1 493 Mean Difference (IV, Fixed, 95% CI) 4.3 [1.86, 6.74]
1.2 certolizumab pegol 400
mg sc
1 489 Mean Difference (IV, Fixed, 95% CI) 4.3 [1.85, 6.75]
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Comparison 22. Disease Activity Score (DAS-28) (ESR) remission (< 2.6) at 12 weeks




participants Statistical method Effect size
1 Proportion of patients
achieving remission 12 weeks
certolizumab 200 mg
1 1063 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.36 [1.53, 3.65]
Comparison 23. Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any dose, 24 weeks




participants Statistical method Effect size
1 Proportion of patients achieving
remission 24 weeks
5 2264 Risk Ratio (M-H, Random, 95% CI) 5.28 [3.08, 9.05]
1.1 certolizumab pegol 200
mg sc
4 1222 Risk Ratio (M-H, Random, 95% CI) 5.97 [2.93, 12.17]
1.2 certolizumab pegol 400
mg sc
3 1042 Risk Ratio (M-H, Random, 95% CI) 4.46 [1.95, 10.21]
Comparison 24. Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any dose, 52 weeks




participants Statistical method Effect size
1 Proportion of patients achieving
remission 52 weeks
1 977 Risk Ratio (M-H, Fixed, 95% CI) 5.80 [2.60, 12.94]
1.1 certolizumab pegol 200
mg sc
1 491 Risk Ratio (M-H, Fixed, 95% CI) 5.29 [1.69, 16.49]
1.2 certolizumab pegol 400
mg sc
1 486 Risk Ratio (M-H, Fixed, 95% CI) 6.31 [2.03, 19.59]
Comparison 25. Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time




participants Statistical method Effect size
1 Proportion of patients
achieving remission 12 weeks
certolizumab 200 mg
1 1063 Risk Ratio (M-H, Fixed, 95% CI) 2.82 [1.60, 5.00]
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2 Proportion of patients
achieving remission 24 weeks
certolizumab 200 mg
4 1381 Risk Ratio (M-H, Random, 95% CI) 8.47 [4.15, 17.28]
3 Proportion of patients
achieving remission 24 weeks
certolizumab 400 mg
3 1201 Risk Ratio (M-H, Random, 95% CI) 7.18 [3.12, 16.50]
4 Proportion of patients
achieving remission 52 weeks
certolizumab 200 mg
1 587 Risk Ratio (M-H, Fixed, 95% CI) 10.36 [3.29, 32.58]
5 Proportion of patients
achieving remission 52 weeks
certolizumab 400 mg
1 583 Risk Ratio (M-H, Fixed, 95% CI) 12.49 [3.99, 39.12]
Comparison 26. DAS-28 at 12 weeks, 200 mg certolizumab




participants Statistical method Effect size
1 DAS 28 (ESR) change from
baseline
1 1063 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 27. DAS-28 at 24 weeks, 400 mg certolizumab




participants Statistical method Effect size
1 DAS 28 (ESR) change from
baseline
2 593 Mean Difference (IV, Random, 95% CI) -1.46 [-2.49, -0.42]
Comparison 28. DAS-28 at week 52, certolizumab 200 mg




participants Statistical method Effect size
1 DAS 28 (ESR) Change from
baseline
1 592 Mean Difference (IV, Fixed, 95% CI) -0.9 [-1.12, -0.68]
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Comparison 29. DAS-28 at week 52, certolizumab 400 mg




participants Statistical method Effect size
1 DAS 28 (ESR) Change from
baseline
1 589 Mean Difference (IV, Fixed, 95% CI) -1.0 [-1.23, -0.77]
Comparison 30. DAS-28 at 24 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 2 839 Mean Difference (IV, Random, 95% CI) -1.59 [-2.10, -1.08]
1.1 certolizumab pegol 200
mg sc
1 310 Mean Difference (IV, Random, 95% CI) -1.77 [-2.08, -1.46]
1.2 certolizumab pegol 400
mg sc
2 529 Mean Difference (IV, Random, 95% CI) -1.45 [-2.49, -0.41]
Comparison 31. DAS-28 at 52 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 1 982 Mean Difference (IV, Fixed, 95% CI) -0.95 [-1.15, -0.75]
1.1 certolizumab pegol 200
mg sc
1 493 Mean Difference (IV, Fixed, 95% CI) -0.90 [-1.19, -0.61]
1.2 certolizumab pegol 400
mg sc
1 489 Mean Difference (IV, Fixed, 95% CI) -1.0 [-1.29, -0.71]
Comparison 32. DAS-28 at 24 weeks, 200 mg certolizumab




participants Statistical method Effect size
1 DAS 28 (ESR) change from
baseline
1 373 Mean Difference (IV, Fixed, 95% CI) -1.77 [-2.02, -1.52]
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Comparison 33. Erosion score (ES)




participants Statistical method Effect size
1 Change from the baseline mean
ES at week 24, certolizumab
pegol 200 mg
2 859 Std. Mean Difference (IV, Fixed, 95% CI) -0.35 [-0.50, -0.21]
2 Change from the baseline mean
ES at week 24, certolizumab
pegol 400 mg
2 869 Mean Difference (IV, Random, 95% CI) -0.76 [-1.14, -0.37]
3 Change from the baseline mean
ES at week 52, certolizumab
pegol 200 mg
1 544 Mean Difference (IV, Fixed, 95% CI) -1.4 [-2.08, -0.72]
4 Change from the baseline mean
ES at week 52, certolizumab
pegol 400 mg
1 543 Mean Difference (IV, Fixed, 95% CI) -1.50 [-2.20, -0.80]
Comparison 34. Erosion score (ES) at 24 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 2 1437 Mean Difference (IV, Random, 95% CI) -0.70 [-0.98, -0.42]
1.1 certolizumab pegol 200
mg sc
2 714 Mean Difference (IV, Random, 95% CI) -0.67 [-1.06, -0.28]
1.2 certolizumab pegol 400
mg sc
2 723 Mean Difference (IV, Random, 95% CI) -0.73 [-1.14, -0.32]
Comparison 35. Erosion score (ES) at 52 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 1 908 Mean Difference (IV, Fixed, 95% CI) -1.45 [-2.11, -0.79]
1.1 certolizumab pegol 200
mg sc
1 455 Mean Difference (IV, Fixed, 95% CI) -1.4 [-2.32, -0.48]
1.2 certolizumab pegol 400
mg sc
1 453 Mean Difference (IV, Fixed, 95% CI) -1.5 [-2.44, -0.56]
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Comparison 36. Joint space narrowing (JSN)




participants Statistical method Effect size
1 Change from the baseline mean
JSN 24 weeks, certolizumab
pegol 200 mg
2 861 Mean Difference (IV, Random, 95% CI) -0.45 [-0.77, -0.13]
2 Change from the baseline mean
JSN 24 weeks,certolizumab
pegol 400 mg
2 869 Mean Difference (IV, Random, 95% CI) -0.55 [-0.86, -0.24]
3 Change from the baseline mean
JSN 52 weeks,certolizumab
pegol 200 mg
1 548 Mean Difference (IV, Fixed, 95% CI) 1.00 [-1.85, -0.15]
4 Change from the baseline mean
JSN 52 weeks, certolizumab
pegol 400 mg
1 544 Mean Difference (IV, Fixed, 95% CI) -1.2 [-1.98, -0.42]
Comparison 37. Joint space narrowing (JSN) at 24 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 2 1439 Mean Difference (IV, Random, 95% CI) -0.50 [-0.79, -0.21]
1.1 certolizumab pegol 200
mg sc
2 716 Mean Difference (IV, Random, 95% CI) -0.46 [-0.87, -0.04]
1.2 certolizumab pegol 400
mg sc
2 723 Mean Difference (IV, Random, 95% CI) -0.54 [-0.96, -0.13]
Comparison 38. Joint space narrowing (JSN) at 52 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 1 911 Mean Difference (IV, Fixed, 95% CI) -1.10 [-1.88, -0.33]
1.1 certolizumab pegol 200
mg sc
1 458 Mean Difference (IV, Fixed, 95% CI) 1.00 [-2.11, 0.11]
1.2 certolizumab pegol 400
mg sc
1 453 Mean Difference (IV, Fixed, 95% CI) -1.2 [-2.27, -0.13]
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Comparison 39. Modified Total Sharp Scores (mTSS) at 24 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 2 1437 Mean Difference (IV, Random, 95% CI) -1.18 [-1.67, -0.69]
1.1 certolizumab pegol 200
mg sc
2 713 Mean Difference (IV, Random, 95% CI) -1.06 [-1.75, -0.38]
1.2 certolizumab pegol 400
mg sc
2 724 Mean Difference (IV, Random, 95% CI) -1.30 [-1.99, -0.60]
Comparison 40. Modified Total Sharp Scores (mTSS) at 52 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 1 908 Mean Difference (IV, Fixed, 95% CI) -2.50 [-3.70, -1.30]
1.1 certolizumab pegol 200
mg sc
1 455 Mean Difference (IV, Fixed, 95% CI) -2.4 [-4.11, -0.69]
1.2 certolizumab pegol 400
mg sc
1 453 Mean Difference (IV, Fixed, 95% CI) -2.60 [-4.29, -0.91]
Comparison 41. Patient’s assessment of arthritis pain (VAS score 0 to 100 mm)




participants Statistical method Effect size
1 Mean change at 24 weeks
certolizumab pegol 200 mg
2 965 Mean Difference (IV, Random, 95% CI) -20.49 [-23.43, -17.
55]
2 Mean change at 24 weeks
certolizumab pegol 400 mg
3 1182 Mean Difference (IV, Random, 95% CI) -22.69 [-25.53, -19.
84]
3 Mean change at 52 weeks
certolizumab pegol 200 mg
1 592 Mean Difference (IV, Fixed, 95% CI) -22.2 [-26.19, -18.
21]
4 Mean change at 52 weeks
certolizumab pegol 400 mg
1 589 Mean Difference (IV, Fixed, 95% CI) -24.7 [-28.62, -20.
78]
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Comparison 42. Patient’s assessment of arthritis pain (VAS score 0 to 100 mm) at 24 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 4 2064 Mean Difference (IV, Random, 95% CI) -21.07 [-23.59, -18.
55]
1.1 certolizumab pegol 200
mg sc
2 803 Mean Difference (IV, Random, 95% CI) -20.48 [-24.26, -16.
69]
1.2 certolizumab pegol 400
mg sc
4 1261 Mean Difference (IV, Random, 95% CI) -21.35 [-25.08, -17.
61]
Comparison 43. Patient’s assessment of arthritis pain (VAS score 0 to 100 mm) at 52 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 1 982 Mean Difference (IV, Fixed, 95% CI) -23.48 [-27.09, -19.
88]
1.1 certolizumab pegol 200
mg sc
1 493 Mean Difference (IV, Fixed, 95% CI) -22.2 [-27.37, -17.
03]
1.2 certolizumab pegol 400
mg sc
1 489 Mean Difference (IV, Fixed, 95% CI) -24.7 [-29.73, -19.
67]
Comparison 44. Modified total Sharp scores (mTSS)




participants Statistical method Effect size
1 Change from the baseline mean
mTSS 24 weeks, certolizumab
pegol 200 mg.
2 859 Mean Difference (IV, Random, 95% CI) -1.06 [-1.58, -0.55]
2 Change from the baseline mean
mTSS 24 weeks, certolizumab
400 mg
2 869 Mean Difference (IV, Random, 95% CI) -1.32 [-1.85, -0.78]
3 Change from the baseline mean
mTSS 52 weeks, certolizumab
pegol 200 mg
1 545 Mean Difference (IV, Fixed, 95% CI) -2.4 [-3.68, -1.12]
4 Change from the baseline mean
mTSS 52 weeks, certolizumab
pegol 400 mg
1 544 Mean Difference (IV, Fixed, 95% CI) -2.60 [-3.84, -1.36]
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Comparison 45. Certolizumab pegol 1mg/kg/day sc




participants Statistical method Effect size
1 Headache 1 20 Risk Ratio (M-H, Fixed, 95% CI) 4.5 [0.56, 35.98]
2 Lower respiratory tract infection 1 20 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.02, 10.54]
3 Adverse events Intensity severe 1 20 Risk Ratio (M-H, Fixed, 95% CI) 4.33 [0.20, 94.83]
4 Antinuclear antibodies (ANA) 1 20 Risk Ratio (M-H, Fixed, 95% CI) 3.00 [0.32, 27.83]
5 Urinary tract infection 1 20 Risk Ratio (M-H, Fixed, 95% CI) 4.33 [0.20, 94.83]
Comparison 46. Certolizumab 5 mg/kg/day sc




participants Statistical method Effect size
1 Lower respiratory tract infection 1 20 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.11, 20.68]
2 Urinary tract infection 1 20 Risk Ratio (M-H, Fixed, 95% CI) 4.33 [0.20, 94.83]
Comparison 47. Certolizumab 20 mg/kg/day sc




participants Statistical method Effect size
1 Headache 1 20 Risk Ratio (M-H, Fixed, 95% CI) 4.5 [0.56, 35.98]
2 Lower respiratory tract infection 1 20 Risk Ratio (M-H, Fixed, 95% CI) 3.00 [0.32, 27.83]
3 Death 1 20 Risk Ratio (M-H, Fixed, 95% CI) 4.33 [0.20, 94.83]
4 Antinuclear antibodies (ANA) 1 20 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.11, 20.68]
5 Urinary tract infection 1 20 Risk Ratio (M-H, Fixed, 95% CI) 4.33 [0.20, 94.83]
Comparison 48. Withdrawals




participants Statistical method Effect size
1 All Withdrawn: any doses any
follow up
10 3962 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.36, 0.50]
2 Withdrawn due to lack of
efficacy: any doses any follow
up
5 2195 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.25, 0.37]
3 Withdrawals due to adverse
events
9 3998 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.66 [1.15, 2.37]
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Comparison 49. Summary of findings: certolizumab (with or without MTX) versus placebo (with or without
MTX)




participants Statistical method Effect size
1 ACR 50 200 mg certolizumab
24 weeks
5 1445 Risk Ratio (M-H, Random, 95% CI) 3.80 [2.42, 5.95]
2 HAQ change from baseline 200
mg certolizumab 24 weeks
4 1268 Mean Difference (IV, Random, 95% CI) -0.35 [-0.43, -0.26]
3 Serious adverse events
certolizumab 200 mg sc
7 2729 Risk Difference (M-H, Fixed, 95% CI) 0.04 [0.02, 0.06]
3.1 certolizumab 200 mg 7 2729 Risk Difference (M-H, Fixed, 95% CI) 0.04 [0.02, 0.06]
4 Proportion of patients
achieving remission 24 weeks
certolizumab 200 mg
4 1381 Risk Ratio (M-H, Random, 95% CI) 8.47 [4.15, 17.28]
5 Radiological changes: Erosion
Scores (ES) certolizumab 200
mg sc
2 859 Mean Difference (IV, Random, 95% CI) -0.67 [-0.96, -0.38]
5.1 certolizumab 200 mg sc
24 weeks
2 859 Mean Difference (IV, Random, 95% CI) -0.67 [-0.96, -0.38]
6 All Withdrawals: 10 3962 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.36, 0.50]
7 Withdrawals due to adverse
events
9 3998 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.66 [1.15, 2.37]
8 Deaths 9 3866 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.56 [0.72, 9.07]
8.1 Certolizumab pegol 200
mg
6 2387 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.94 [0.36, 10.32]
8.2 Certolizumab pegol 400
mg
5 1349 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.53 [0.40, 31.39]
8.3 Other doses 2 130 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.48 [0.07, 286.49]
9 Tuberculosis 6 3195 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.71 [0.94, 14.61]
9.1 Certolizumab pegol 200
mg
5 2179 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.85 [0.66, 22.30]
9.2 Certolizumab pegol 400
mg
3 1016 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.52 [0.40, 31.33]
10 Upper respiratory tract
infections
8 3692 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.17 [0.86, 1.59]
10.1 Certolizumab pegol 200
mg
7 2528 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.28 [0.91, 1.80]
10.2 Certolizumab pegol 400
mg
4 1164 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.81 [0.41, 1.61]
11 Lower respiratory tract
infections
7 3073 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.66 [0.77, 3.58]
11.1 Certolizumab pegol 200
mg
6 2218 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.81 [0.62, 5.26]
11.2 Certolizumab pegol 400
mg
3 855 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.52 [0.50, 4.59]
12 Malignancies including
lymphoma
7 3749 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.90 [0.39, 2.08]
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12.1 Certolizumab pegol 200
mg
6 2570 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.79 [0.29, 2.12]
12.2 Certolizumab pegol 400
mg
3 1179 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.26 [0.26, 6.08]
Comparison 50. Analysis of sensibility ACR50




participants Statistical method Effect size
1 Doses 8 3768 Risk Ratio (M-H, Random, 95% CI) 2.89 [2.38, 3.51]
1.1 certolizumab 100 mg sc 1 98 Risk Ratio (M-H, Random, 95% CI) 2.89 [1.13, 7.38]
1.2 certolizumab 200 mg sc 6 2295 Risk Ratio (M-H, Random, 95% CI) 2.73 [2.13, 3.51]
1.3 certolizumab 400 mg sc 5 1375 Risk Ratio (M-H, Random, 95% CI) 3.18 [2.29, 4.41]
2 Size 8 3768 Risk Ratio (M-H, Random, 95% CI) 2.89 [2.38, 3.51]
2.1 certolizumab < 200
patients
2 321 Risk Ratio (M-H, Random, 95% CI) 2.44 [1.45, 4.10]
2.2 certolizumab > 200
patients
6 3447 Risk Ratio (M-H, Random, 95% CI) 2.97 [2.41, 3.67]
3 Use of MTX 8 3768 Risk Ratio (M-H, Random, 95% CI) 2.89 [2.38, 3.51]
3.1 With MTX 5 3038 Risk Ratio (M-H, Random, 95% CI) 2.77 [2.21, 3.46]
3.2 Without MTX 3 730 Risk Ratio (M-H, Random, 95% CI) 3.32 [2.23, 4.95]
4 Population 8 3768 Risk Ratio (M-H, Random, 95% CI) 2.89 [2.38, 3.51]
4.1 Asian trials 2 443 Risk Ratio (M-H, Random, 95% CI) 2.66 [1.77, 4.00]
4.2 Other trials 6 3325 Risk Ratio (M-H, Random, 95% CI) 2.96 [2.37, 3.70]
5 Duration of previous disease 6 3258 Risk Ratio (M-H, Random, 95% CI) 2.87 [2.31, 3.57]
5.1 Long previous disease
duration (9 years or more)
2 467 Risk Ratio (M-H, Random, 95% CI) 4.02 [2.02, 7.98]
5.2 Short previous disease
duration (less than 7 years)
4 2791 Risk Ratio (M-H, Random, 95% CI) 2.75 [2.18, 3.47]
6 Published vs unpublished studies 8 3768 Risk Ratio (M-H, Random, 95% CI) 2.89 [2.38, 3.51]
6.1 Published studies 5 3131 Risk Ratio (M-H, Random, 95% CI) 2.97 [2.36, 3.73]
6.2 Unpublished studies 3 637 Risk Ratio (M-H, Random, 95% CI) 2.71 [1.89, 3.90]
76Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.1. Comparison 1 Efficacy at 12 weeks, any dose, Outcome 1 ACR20.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 1 Efficacy at 12 weeks, any dose
Outcome: 1 ACR20








1 certolizumab 50 mg sc
CDP870-004 2001 8/39 6/8 100.0 % 0.27 [ 0.13, 0.57 ]
Subtotal (95% CI) 39 8 100.0 % 0.27 [ 0.13, 0.57 ]
Total events: 8 (Certolizumab pegol), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.45 (P = 0.00056)
2 certolizumab 100 mg sc
CDP870-004 2001 8/40 6/8 49.7 % 0.27 [ 0.13, 0.56 ]
NCT00791999 JRAPID (1) 45/72 7/25 50.3 % 2.23 [ 1.16, 4.29 ]
Subtotal (95% CI) 112 33 100.0 % 0.78 [ 0.09, 7.05 ]
Total events: 53 (Certolizumab pegol), 13 (Control)
Heterogeneity: Tau2 = 2.41; Chi2 = 20.04, df = 1 (P<0.00001); I2 =95%
Test for overall effect: Z = 0.22 (P = 0.82)
3 certolizumab 200 mg sc
CDP870-004 2001 14/41 6/8 18.9 % 0.46 [ 0.25, 0.82 ]
NCT00791921 HIKARI 78/116 17/114 20.3 % 4.51 [ 2.86, 7.12 ]
NCT00791999 JRAPID 63/82 7/26 18.3 % 2.85 [ 1.50, 5.44 ]
NCT00993317 52/85 15/42 20.4 % 1.71 [ 1.10, 2.66 ]
REALISTIC 2008 435/851 55/212 22.1 % 1.97 [ 1.55, 2.50 ]
Subtotal (95% CI) 1175 402 100.0 % 1.84 [ 0.99, 3.40 ]
Total events: 642 (Certolizumab pegol), 100 (Control)
Heterogeneity: Tau2 = 0.43; Chi2 = 40.08, df = 4 (P<0.00001); I2 =90%
Test for overall effect: Z = 1.93 (P = 0.054)
4 certolizumab 400 mg sc
CDP870-004 2001 25/42 6/8 50.9 % 0.79 [ 0.50, 1.27 ]
NCT00791999 JRAPID 66/85 8/26 49.1 % 2.52 [ 1.40, 4.54 ]
Subtotal (95% CI) 127 34 100.0 % 1.40 [ 0.38, 5.23 ]
Total events: 91 (Certolizumab pegol), 14 (Control)
Heterogeneity: Tau2 = 0.83; Chi2 = 12.22, df = 1 (P = 0.00047); I2 =92%
Test for overall effect: Z = 0.50 (P = 0.62)
5 certolizumab 600 mg sc
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CDP870-004 2001 (2) 25/39 8/8 100.0 % 0.68 [ 0.51, 0.90 ]
Subtotal (95% CI) 39 8 100.0 % 0.68 [ 0.51, 0.90 ]
Total events: 25 (Certolizumab pegol), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.73 (P = 0.0064)
6 certolizumab 800 mg sc
CDP870-004 2001 (3) 30/38 8/8 100.0 % 0.83 [ 0.66, 1.04 ]
Subtotal (95% CI) 38 8 100.0 % 0.83 [ 0.66, 1.04 ]
Total events: 30 (Certolizumab pegol), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Chi2 = 17.21, df = 5 (P = 0.00), I2 =71%
0.05 0.2 1 5 20
Favours control Favours certolizumab pego
(1) We need to split the results in placebo 22 of 77 patients by 3
(2) From EMEA report, only data for ACR20
(3) From EMEA report, only data for ACR20
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Analysis 1.2. Comparison 1 Efficacy at 12 weeks, any dose, Outcome 2 ACR50.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 1 Efficacy at 12 weeks, any dose
Outcome: 2 ACR50








1 certolizumab 50 mg sc
CDP870-004 2001 3/39 0/8 100.0 % 1.58 [ 0.09, 27.88 ]
Subtotal (95% CI) 39 8 100.0 % 1.58 [ 0.09, 27.88 ]
Total events: 3 (Certolizumab pegol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
2 certolizumab 100 mg sc
CDP870-004 2001 2/40 0/8 100.0 % 1.10 [ 0.06, 20.96 ]
Subtotal (95% CI) 40 8 100.0 % 1.10 [ 0.06, 20.96 ]
Total events: 2 (Certolizumab pegol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
3 certolizumab 200 mg sc
CDP870-004 2001 7/41 0/8 1.9 % 3.21 [ 0.20, 51.33 ]
NCT00993317 21/85 5/42 17.5 % 2.08 [ 0.84, 5.12 ]
REALISTIC 2008 226/851 21/212 80.6 % 2.68 [ 1.76, 4.08 ]
Subtotal (95% CI) 977 262 100.0 % 2.57 [ 1.76, 3.75 ]
Total events: 254 (Certolizumab pegol), 26 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 4.90 (P < 0.00001)
4 certolizumab 400 mg sc
CDP870-004 2001 17/42 0/8 100.0 % 7.33 [ 0.48, 110.96 ]
Subtotal (95% CI) 42 8 100.0 % 7.33 [ 0.48, 110.96 ]
Total events: 17 (Certolizumab pegol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Chi2 = 1.00, df = 3 (P = 0.80), I2 =0.0%
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Analysis 1.3. Comparison 1 Efficacy at 12 weeks, any dose, Outcome 3 ACR70.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 1 Efficacy at 12 weeks, any dose
Outcome: 3 ACR70








1 certolizumab 50 mg sc
CDP870-004 2001 2/39 0/8 100.0 % 1.13 [ 0.06, 21.47 ]
Subtotal (95% CI) 39 8 100.0 % 1.13 [ 0.06, 21.47 ]
Total events: 2 (Certolizumab pegol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
2 certolizumab 100 mg sc
CDP870-004 2001 1/40 0/8 100.0 % 0.66 [ 0.03, 14.89 ]
Subtotal (95% CI) 40 8 100.0 % 0.66 [ 0.03, 14.89 ]
Total events: 1 (Certolizumab pegol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
3 certolizumab 200 mg sc
CDP870-004 2001 3/41 0/8 6.8 % 1.50 [ 0.08, 26.57 ]
NCT00993317 11/85 0/42 7.1 % 11.50 [ 0.69, 190.57 ]
REALISTIC 2008 110/851 6/212 86.1 % 4.57 [ 2.04, 10.24 ]
Subtotal (95% CI) 977 262 100.0 % 4.52 [ 2.14, 9.57 ]
Total events: 124 (Certolizumab pegol), 6 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.01, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.95 (P = 0.000079)
4 certolizumab 400 mg sc
CDP870-004 2001 12/42 0/8 100.0 % 5.23 [ 0.34, 80.54 ]
Subtotal (95% CI) 42 8 100.0 % 5.23 [ 0.34, 80.54 ]
Total events: 12 (Certolizumab pegol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.24)
Test for subgroup differences: Chi2 = 2.13, df = 3 (P = 0.55), I2 =0.0%
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Analysis 2.1. Comparison 2 Efficacy at 24 weeks, 200 mg certolizumab pegol, Outcome 1 ACR 20.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 2 Efficacy at 24 weeks, 200 mg certolizumab pegol
Outcome: 1 ACR 20
Study or subgroup
Certolizumab








CERTAIN 2008 35/96 15/98 15.5 % 2.38 [ 1.39, 4.07 ]
NCT00993317 54/85 11/42 15.5 % 2.43 [ 1.42, 4.13 ]
NCT00791999 JRAPID 60/82 19/77 18.7 % 2.97 [ 1.96, 4.48 ]
RAPID1 2005 228/393 27/199 20.1 % 4.28 [ 2.98, 6.13 ]
NCT00791921 HIKARI 74/116 13/114 15.6 % 5.59 [ 3.29, 9.50 ]
RAPID2 2007 141/246 11/127 14.5 % 6.62 [ 3.72, 11.76 ]
Total (95% CI) 1018 657 100.0 % 3.71 [ 2.68, 5.13 ]
Total events: 592 (Certolizumab pegol 200 mg), 96 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 13.68, df = 5 (P = 0.02); I2 =63%
Test for overall effect: Z = 7.92 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Efficacy at 24 weeks, 200 mg certolizumab pegol, Outcome 2 ACR 50.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 2 Efficacy at 24 weeks, 200 mg certolizumab pegol
Outcome: 2 ACR 50
Study or subgroup
Certolizumab








CERTAIN 2008 20/96 7/98 16.7 % 2.92 [ 1.29, 6.58 ]
NCT00791999 JRAPID 45/82 13/77 24.4 % 3.25 [ 1.91, 5.54 ]
NCT00993317 35/85 8/42 20.2 % 2.16 [ 1.10, 4.24 ]
RAPID1 2005 144/393 15/199 25.3 % 4.86 [ 2.94, 8.04 ]
RAPID2 2007 80/246 4/127 13.4 % 10.33 [ 3.87, 27.54 ]
Total (95% CI) 902 543 100.0 % 3.80 [ 2.42, 5.95 ]
Total events: 324 (Certolizumab pegol 200 mg), 47 (Placebo)
Heterogeneity: Tau2 = 0.14; Chi2 = 9.05, df = 4 (P = 0.06); I2 =56%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Efficacy at 24 weeks, 200 mg certolizumab pegol, Outcome 3 ACR 70.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 2 Efficacy at 24 weeks, 200 mg certolizumab pegol
Outcome: 3 ACR 70
Study or subgroup
Certolizumab








CERTAIN 2008 9/96 3/98 22.4 % 3.06 [ 0.85, 10.97 ]
NCT00791999 JRAPID 24/82 1/77 10.0 % 22.54 [ 3.12, 162.58 ]
NCT00993317 14/85 1/42 9.8 % 6.92 [ 0.94, 50.85 ]
RAPID1 2005 83/393 6/199 47.8 % 7.00 [ 3.11, 15.76 ]
RAPID2 2007 39/246 1/127 10.0 % 20.13 [ 2.80, 144.86 ]
Total (95% CI) 902 543 100.0 % 7.26 [ 3.83, 13.76 ]
Total events: 169 (Certolizumab pegol 200 mg), 12 (Placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.38, df = 4 (P = 0.36); I2 =9%
Test for overall effect: Z = 6.07 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Efficacy at 24 weeks, 400 mg certolizumab, Outcome 1 ACR 20.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 3 Efficacy at 24 weeks, 400 mg certolizumab
Outcome: 1 ACR 20








CDP870-014 2009 56/126 27/121 21.8 % 1.99 [ 1.35, 2.93 ]
FAST4WARD 2005 50/111 10/109 16.9 % 4.91 [ 2.63, 9.18 ]
NCT00791999 JRAPID 61/85 19/77 21.2 % 2.91 [ 1.93, 4.39 ]
RAPID1 2005 236/390 27/199 22.3 % 4.46 [ 3.11, 6.39 ]
RAPID2 2007 141/246 11/127 17.9 % 6.62 [ 3.72, 11.76 ]
Total (95% CI) 958 633 100.0 % 3.73 [ 2.43, 5.72 ]
Total events: 544 (Certolizumab pegol), 94 (Control)
Heterogeneity: Tau2 = 0.18; Chi2 = 17.77, df = 4 (P = 0.001); I2 =77%
Test for overall effect: Z = 6.03 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Efficacy at 24 weeks, 400 mg certolizumab, Outcome 2 ACR 50.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 3 Efficacy at 24 weeks, 400 mg certolizumab
Outcome: 2 ACR 50








CDP870-014 2009 (1) 22/126 7/121 17.1 % 3.02 [ 1.34, 6.81 ]
FAST4WARD 2005 25/111 4/109 12.3 % 6.14 [ 2.21, 17.05 ]
NCT00791999 JRAPID 46/85 13/77 27.9 % 3.21 [ 1.88, 5.46 ]
RAPID1 2005 155/390 15/199 29.5 % 5.27 [ 3.19, 8.71 ]
RAPID2 2007 81/246 4/127 13.1 % 10.45 [ 3.92, 27.88 ]
Total (95% CI) 958 633 100.0 % 4.65 [ 3.09, 6.99 ]
Total events: 329 (Certolizumab pegol), 43 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 6.53, df = 4 (P = 0.16); I2 =39%
Test for overall effect: Z = 7.37 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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certolizumab and placebo groups for safety.
(1) EMEA report quotes 126 and 121 patients in certoluzimab and placebo group. Clinical Study Summary (CSS) from UCB quotes n=125 for both groups for effectiveness
and 119 and 124 for
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Analysis 3.3. Comparison 3 Efficacy at 24 weeks, 400 mg certolizumab, Outcome 3 ACR 70.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 3 Efficacy at 24 weeks, 400 mg certolizumab
Outcome: 3 ACR 70








CDP870-014 2009 (1) 0/126 2/121 11.2 % 0.19 [ 0.01, 3.96 ]
FAST4WARD 2005 6/111 0/109 12.1 % 12.77 [ 0.73, 223.93 ]
NCT00791999 JRAPID 26/85 1/77 19.7 % 23.55 [ 3.27, 169.46 ]
RAPID1 2005 80/390 6/199 37.4 % 6.80 [ 3.02, 15.32 ]
RAPID2 2007 26/246 1/127 19.6 % 13.42 [ 1.84, 97.78 ]
Total (95% CI) 958 633 100.0 % 7.20 [ 2.25, 23.03 ]
Total events: 138 (Certolizumab pegol), 10 (Control)
Heterogeneity: Tau2 = 0.77; Chi2 = 7.46, df = 4 (P = 0.11); I2 =46%
Test for overall effect: Z = 3.33 (P = 0.00088)
Test for subgroup differences: Not applicable
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(1) From EMEA report
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Analysis 4.1. Comparison 4 Efficacy at 24 weeks, any dose, Outcome 1 ACR20.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 4 Efficacy at 24 weeks, any dose
Outcome: 1 ACR20








1 certolizumab 100 mg sc
NCT00791999 JRAPID 44/72 6/26 5.1 % 2.65 [ 1.28, 5.47 ]
Subtotal (95% CI) 72 26 5.1 % 2.65 [ 1.28, 5.47 ]
Total events: 44 (Certolizumab pegol), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.63 (P = 0.0085)
2 certolizumab 200 mg sc
CERTAIN 2008 35/96 15/98 7.9 % 2.38 [ 1.39, 4.07 ]
NCT00791921 HIKARI 74/116 13/114 8.0 % 5.59 [ 3.29, 9.50 ]
NCT00791999 JRAPID 60/82 6/26 5.3 % 3.17 [ 1.55, 6.47 ]
NCT00993317 54/85 11/42 8.0 % 2.43 [ 1.42, 4.13 ]
RAPID1 2005 228/393 27/100 13.1 % 2.15 [ 1.54, 3.00 ]
RAPID2 2007 141/246 11/64 7.7 % 3.33 [ 1.93, 5.77 ]
Subtotal (95% CI) 1018 444 50.0 % 2.92 [ 2.17, 3.95 ]
Total events: 592 (Certolizumab pegol), 83 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 10.25, df = 5 (P = 0.07); I2 =51%
Test for overall effect: Z = 7.01 (P < 0.00001)
3 certolizumab 400 mg sc
CDP870-014 2009 56/126 27/121 11.5 % 1.99 [ 1.35, 2.93 ]
FAST4WARD 2005 50/111 10/109 6.4 % 4.91 [ 2.63, 9.18 ]
NCT00791999 JRAPID 61/85 7/25 6.2 % 2.56 [ 1.35, 4.87 ]
RAPID1 2005 236/390 27/99 13.1 % 2.22 [ 1.59, 3.09 ]
RAPID2 2007 141/246 11/63 7.7 % 3.28 [ 1.90, 5.68 ]
Subtotal (95% CI) 958 417 44.9 % 2.65 [ 1.98, 3.56 ]
Total events: 544 (Certolizumab pegol), 82 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 7.42, df = 4 (P = 0.12); I2 =46%
Test for overall effect: Z = 6.53 (P < 0.00001)
Total (95% CI) 2048 887 100.0 % 2.76 [ 2.29, 3.33 ]
Total events: 1180 (Certolizumab pegol), 171 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 18.18, df = 11 (P = 0.08); I2 =39%
Test for overall effect: Z = 10.61 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.22, df = 2 (P = 0.89), I2 =0.0%
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Analysis 4.2. Comparison 4 Efficacy at 24 weeks, any dose, Outcome 2 ACR50.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 4 Efficacy at 24 weeks, any dose
Outcome: 2 ACR50








1 certolizumab 100 mg sc
NCT00791999 JRAPID 32/72 4/26 5.5 % 2.89 [ 1.13, 7.38 ]
Subtotal (95% CI) 72 26 5.5 % 2.89 [ 1.13, 7.38 ]
Total events: 32 (Certolizumab pegol), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.22 (P = 0.027)
2 certolizumab 200 mg sc
CERTAIN 2008 20/96 7/98 7.3 % 2.92 [ 1.29, 6.58 ]
NCT00791999 JRAPID 45/82 4/26 5.7 % 3.57 [ 1.42, 8.97 ]
NCT00993317 35/85 8/42 10.6 % 2.16 [ 1.10, 4.24 ]
RAPID1 2005 144/393 15/100 20.5 % 2.44 [ 1.50, 3.96 ]
RAPID2 2007 80/246 4/64 5.2 % 5.20 [ 1.98, 13.67 ]
Subtotal (95% CI) 902 330 49.3 % 2.76 [ 2.02, 3.78 ]
Total events: 324 (Certolizumab pegol), 38 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.81, df = 4 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 6.37 (P < 0.00001)
3 certolizumab 400 mg sc
CDP870-014 2009 22/126 7/121 7.3 % 3.02 [ 1.34, 6.81 ]
FAST4WARD 2005 25/111 4/109 4.6 % 6.14 [ 2.21, 17.05 ]
NCT00791999 JRAPID 46/85 5/25 7.4 % 2.71 [ 1.21, 6.07 ]
RAPID1 2005 155/390 15/99 20.8 % 2.62 [ 1.62, 4.25 ]
RAPID2 2007 81/246 4/63 5.2 % 5.19 [ 1.98, 13.61 ]
Subtotal (95% CI) 958 417 45.2 % 3.18 [ 2.29, 4.41 ]
Total events: 329 (Certolizumab pegol), 35 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.42, df = 4 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 6.94 (P < 0.00001)
Total (95% CI) 1932 773 100.0 % 2.95 [ 2.37, 3.68 ]
Total events: 685 (Certolizumab pegol), 77 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.62, df = 10 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 9.66 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.38, df = 2 (P = 0.83), I2 =0.0%
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Analysis 4.3. Comparison 4 Efficacy at 24 weeks, any dose, Outcome 3 ACR70.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 4 Efficacy at 24 weeks, any dose
Outcome: 3 ACR70








1 certolizumab 100 mg sc
NCT00791999 JRAPID 19/72 1/26 4.9 % 6.86 [ 0.97, 48.72 ]
Subtotal (95% CI) 72 26 4.9 % 6.86 [ 0.97, 48.72 ]
Total events: 19 (Certolizumab pegol), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.054)
2 certolizumab 200 mg sc
CERTAIN 2008 9/96 3/98 11.7 % 3.06 [ 0.85, 10.97 ]
NCT00791999 JRAPID 24/82 0/26 2.5 % 15.94 [ 1.00, 253.38 ]
NCT00993317 14/85 1/42 4.8 % 6.92 [ 0.94, 50.85 ]
RAPID1 2005 83/393 6/100 29.8 % 3.52 [ 1.58, 7.83 ]
RAPID2 2007 39/246 1/64 4.9 % 10.15 [ 1.42, 72.45 ]
Subtotal (95% CI) 902 330 53.6 % 4.29 [ 2.36, 7.77 ]
Total events: 169 (Certolizumab pegol), 11 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.55, df = 4 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 4.79 (P < 0.00001)
3 certolizumab 400 mg sc
CDP870-014 2009 0/126 2/121 2.1 % 0.19 [ 0.01, 3.96 ]
FAST4WARD 2005 6/111 0/109 2.3 % 12.77 [ 0.73, 223.93 ]
NCT00791999 JRAPID 26/85 0/25 2.5 % 16.02 [ 1.01, 253.98 ]
RAPID1 2005 80/390 6/99 29.7 % 3.38 [ 1.52, 7.53 ]
RAPID2 2007 26/246 1/63 4.9 % 6.66 [ 0.92, 48.13 ]
Subtotal (95% CI) 958 417 41.4 % 4.04 [ 1.37, 11.90 ]
Total events: 138 (Certolizumab pegol), 9 (Control)
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Heterogeneity: Tau2 = 0.50; Chi2 = 5.94, df = 4 (P = 0.20); I2 =33%
Test for overall effect: Z = 2.53 (P = 0.011)
Total (95% CI) 1932 773 100.0 % 4.15 [ 2.68, 6.42 ]
Total events: 326 (Certolizumab pegol), 21 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.81, df = 10 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 6.40 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.23, df = 2 (P = 0.89), I2 =0.0%
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Analysis 5.1. Comparison 5 Efficacy at 52 weeks, 200 mg certolizumab, Outcome 1 ACR 20.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 5 Efficacy at 52 weeks, 200 mg certolizumab
Outcome: 1 ACR 20
Study or subgroup Certolizumab pegol Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 208/393 26/199 100.0 % 4.05 [ 2.80, 5.87 ]
Total (95% CI) 393 199 100.0 % 4.05 [ 2.80, 5.87 ]
Total events: 208 (Certolizumab pegol), 26 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 7.40 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Efficacy at 52 weeks, 200 mg certolizumab, Outcome 2 ACR 50.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 5 Efficacy at 52 weeks, 200 mg certolizumab
Outcome: 2 ACR 50
Study or subgroup Certolizumab pegol Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 149/393 15/199 100.0 % 5.03 [ 3.04, 8.32 ]
Total (95% CI) 393 199 100.0 % 5.03 [ 3.04, 8.32 ]
Total events: 149 (Certolizumab pegol), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 6.30 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Efficacy at 52 weeks, 200 mg certolizumab, Outcome 3 ACR 70.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 5 Efficacy at 52 weeks, 200 mg certolizumab
Outcome: 3 ACR 70
Study or subgroup Certolizumab pegol Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 83/393 7/199 100.0 % 6.00 [ 2.83, 12.74 ]
Total (95% CI) 393 199 100.0 % 6.00 [ 2.83, 12.74 ]
Total events: 83 (Certolizumab pegol), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.67 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Efficacy at 52 weeks, 400 mg certolizumab, Outcome 1 ACR 20.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 6 Efficacy at 52 weeks, 400 mg certolizumab
Outcome: 1 ACR 20
Study or subgroup Certolizumab pegol Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 213/390 26/199 100.0 % 4.18 [ 2.89, 6.05 ]
Total (95% CI) 390 199 100.0 % 4.18 [ 2.89, 6.05 ]
Total events: 213 (Certolizumab pegol), 26 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 7.58 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Efficacy at 52 weeks, 400 mg certolizumab, Outcome 2 ACR 50.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 6 Efficacy at 52 weeks, 400 mg certolizumab
Outcome: 2 ACR 50
Study or subgroup Certolizumab pegol Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 155/390 15/199 100.0 % 5.27 [ 3.19, 8.71 ]
Total (95% CI) 390 199 100.0 % 5.27 [ 3.19, 8.71 ]
Total events: 155 (Certolizumab pegol), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 6.49 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 Efficacy at 52 weeks, 400 mg certolizumab, Outcome 3 ACR 70.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 6 Efficacy at 52 weeks, 400 mg certolizumab
Outcome: 3 ACR 70
Study or subgroup Certolizumab pegol Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 90/390 7/199 100.0 % 6.56 [ 3.10, 13.89 ]
Total (95% CI) 390 199 100.0 % 6.56 [ 3.10, 13.89 ]
Total events: 90 (Certolizumab pegol), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.92 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Efficacy at 52 weeks, any dose, Outcome 1 ACR20.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 7 Efficacy at 52 weeks, any dose
Outcome: 1 ACR20








1 certolizumab 200 mg sc
RAPID1 2005 208/393 26/100 49.8 % 2.04 [ 1.44, 2.87 ]
Subtotal (95% CI) 393 100 49.8 % 2.04 [ 1.44, 2.87 ]
Total events: 208 (Certolizumab pegol), 26 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.06 (P = 0.000050)
2 certolizumab 400 mg sc
RAPID1 2005 213/390 26/99 50.2 % 2.08 [ 1.48, 2.93 ]
Subtotal (95% CI) 390 99 50.2 % 2.08 [ 1.48, 2.93 ]
Total events: 213 (Certolizumab pegol), 26 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.19 (P = 0.000028)
Total (95% CI) 783 199 100.0 % 2.06 [ 1.61, 2.62 ]
Total events: 421 (Certolizumab pegol), 52 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 5.83 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
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Analysis 7.2. Comparison 7 Efficacy at 52 weeks, any dose, Outcome 2 ACR50.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 7 Efficacy at 52 weeks, any dose
Outcome: 2 ACR50








1 certolizumab 200 mg sc
RAPID1 2005 149/393 15/100 49.8 % 2.53 [ 1.56, 4.10 ]
Subtotal (95% CI) 393 100 49.8 % 2.53 [ 1.56, 4.10 ]
Total events: 149 (Certolizumab pegol), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.76 (P = 0.00017)
2 certolizumab 400 mg sc
RAPID1 2005 155/390 15/99 50.2 % 2.62 [ 1.62, 4.25 ]
Subtotal (95% CI) 390 99 50.2 % 2.62 [ 1.62, 4.25 ]
Total events: 155 (Certolizumab pegol), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.92 (P = 0.000088)
Total (95% CI) 783 199 100.0 % 2.58 [ 1.83, 3.62 ]
Total events: 304 (Certolizumab pegol), 30 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 5.43 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.92), I2 =0.0%
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Analysis 7.3. Comparison 7 Efficacy at 52 weeks, any dose, Outcome 3 ACR70.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 7 Efficacy at 52 weeks, any dose
Outcome: 3 ACR70








1 certolizumab 200 mg sc
RAPID1 2005 83/393 7/100 49.8 % 3.02 [ 1.44, 6.32 ]
Subtotal (95% CI) 393 100 49.8 % 3.02 [ 1.44, 6.32 ]
Total events: 83 (Certolizumab pegol), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.93 (P = 0.0034)
2 certolizumab 400 mg sc
RAPID1 2005 90/390 7/99 50.2 % 3.26 [ 1.56, 6.82 ]
Subtotal (95% CI) 390 99 50.2 % 3.26 [ 1.56, 6.82 ]
Total events: 90 (Certolizumab pegol), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.15 (P = 0.0017)
Total (95% CI) 783 199 100.0 % 3.14 [ 1.86, 5.29 ]
Total events: 173 (Certolizumab pegol), 14 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 4.29 (P = 0.000017)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
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Analysis 8.1. Comparison 8 Safety, certolizumab 200 mg, Outcome 1 Any adverse event.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 1 Any adverse event
Study or subgroup
Certolizumab








CERTAIN 2008 37/96 41/98 7.4 % 0.92 [ 0.65, 1.30 ]
NCT00791921 HIKARI (1) 59/116 44/114 9.5 % 1.32 [ 0.98, 1.77 ]
NCT00791999 JRAPID 48/82 31/77 8.0 % 1.45 [ 1.05, 2.02 ]
NCT00993317 60/85 21/42 7.8 % 1.41 [ 1.01, 1.97 ]
RAPID1 2005 293/392 115/199 24.4 % 1.29 [ 1.13, 1.48 ]
RAPID2 2007 139/248 66/125 16.2 % 1.06 [ 0.87, 1.30 ]
REALISTIC 2008 571/846 129/209 26.7 % 1.09 [ 0.97, 1.23 ]
Total (95% CI) 1865 864 100.0 % 1.19 [ 1.07, 1.32 ]
Total events: 1207 (Certolizumab pegol 200 mg), 447 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 9.80, df = 6 (P = 0.13); I2 =39%
Test for overall effect: Z = 3.29 (P = 0.00099)
Test for subgroup differences: Not applicable
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(1) UCB provides us different number of AE that appears in clinicaltrials.org. 67 in CZP 200 mg and 83 in control groups Check with UCB again
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Analysis 8.2. Comparison 8 Safety, certolizumab 200 mg, Outcome 2 Adverse events Intensity mild.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 2 Adverse events Intensity mild
Study or subgroup
Certolizumab








NCT00791921 HIKARI (1) 29/116 33/114 12.7 % 0.86 [ 0.56, 1.32 ]
RAPID1 2005 244/392 90/199 37.2 % 1.38 [ 1.16, 1.63 ]
RAPID2 2007 108/248 45/125 23.6 % 1.21 [ 0.92, 1.59 ]
REALISTIC 2008 248/846 56/209 26.5 % 1.09 [ 0.85, 1.40 ]
Total (95% CI) 1602 647 100.0 % 1.18 [ 1.00, 1.41 ]
Total events: 629 (Certolizumab pegol 200 mg), 224 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.26, df = 3 (P = 0.15); I2 =43%
Test for overall effect: Z = 1.94 (P = 0.053)
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 Safety, certolizumab 200 mg, Outcome 3 Adverse events Intensity moderate.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 3 Adverse events Intensity moderate
Study or subgroup
Certolizumab








NCT00791921 HIKARI 36/116 44/114 20.2 % 0.80 [ 0.56, 1.15 ]
RAPID1 2005 174/392 66/199 30.9 % 1.34 [ 1.07, 1.68 ]
RAPID2 2007 61/248 32/125 19.4 % 0.96 [ 0.66, 1.39 ]
REALISTIC 2008 257/846 58/209 29.5 % 1.09 [ 0.86, 1.39 ]
Total (95% CI) 1602 647 100.0 % 1.07 [ 0.86, 1.32 ]
Total events: 528 (Certolizumab pegol 200 mg), 200 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.36, df = 3 (P = 0.10); I2 =53%
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 8.4. Comparison 8 Safety, certolizumab 200 mg, Outcome 4 Adverse events Intensity severe.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 4 Adverse events Intensity severe
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00791921 HIKARI 2/116 6/114 7.0 % 0.35 [ 0.09, 1.43 ]
REALISTIC 2008 66/846 15/209 42.8 % 1.09 [ 0.62, 1.93 ]
RAPID1 2005 32/392 13/199 33.5 % 1.26 [ 0.66, 2.40 ]
RAPID2 2007 17/248 5/125 16.7 % 1.67 [ 0.67, 4.16 ]
Total (95% CI) 1602 647 100.0 % 1.14 [ 0.78, 1.65 ]
Total events: 117 (Certolizumab pegol 200 mg), 39 (Control)
Heterogeneity: Chi2 = 3.49, df = 3 (P = 0.32); I2 =14%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 8.5. Comparison 8 Safety, certolizumab 200 mg, Outcome 5 Adverse events related to study drug.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 5 Adverse events related to study drug
Study or subgroup
Certolizumab








RAPID1 2005 167/392 50/199 72.2 % 1.70 [ 1.30, 2.21 ]
RAPID2 2007 61/248 23/125 27.8 % 1.34 [ 0.87, 2.05 ]
Total (95% CI) 640 324 100.0 % 1.59 [ 1.27, 1.99 ]
Total events: 228 (Certolizumab pegol 200 mg), 73 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 4.01 (P = 0.000062)
Test for subgroup differences: Not applicable
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Analysis 8.6. Comparison 8 Safety, certolizumab 200 mg, Outcome 6 Serious Adverse Events (SAE).
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 6 Serious Adverse Events (SAE)
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CERTAIN 2008 5/96 7/98 8.1 % 0.72 [ 0.22, 2.30 ]
REALISTIC 2008 52/846 12/209 27.3 % 1.07 [ 0.57, 2.02 ]
RAPID1 2005 45/392 11/199 32.4 % 2.00 [ 1.12, 3.58 ]
RAPID2 2007 18/248 4/125 13.2 % 2.07 [ 0.83, 5.16 ]
NCT00791999 JRAPID 4/82 1/77 3.5 % 3.21 [ 0.54, 19.00 ]
NCT00791921 HIKARI 13/116 3/114 10.7 % 3.74 [ 1.36, 10.31 ]
NCT00993317 8/85 0/42 4.8 % 4.86 [ 1.07, 22.14 ]
Total (95% CI) 1865 864 100.0 % 1.77 [ 1.27, 2.46 ]
Total events: 145 (Certolizumab pegol 200 mg), 38 (Control)
Heterogeneity: Chi2 = 9.21, df = 6 (P = 0.16); I2 =35%
Test for overall effect: Z = 3.38 (P = 0.00074)
Test for subgroup differences: Not applicable
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Analysis 8.7. Comparison 8 Safety, certolizumab 200 mg, Outcome 7 Serious Infections.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 7 Serious Infections
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 16/392 2/199 69.1 % 2.83 [ 1.05, 7.63 ]
RAPID2 2007 8/248 0/125 30.9 % 4.63 [ 1.05, 20.39 ]
Total (95% CI) 640 324 100.0 % 3.30 [ 1.45, 7.51 ]
Total events: 24 (Certolizumab pegol 200 mg), 2 (Control)
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.84 (P = 0.0046)
Test for subgroup differences: Not applicable
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Analysis 8.8. Comparison 8 Safety, certolizumab 200 mg, Outcome 8 Adverse events leading to death.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 8 Adverse events leading to death
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CERTAIN 2008 0/96 0/98 Not estimable
NCT00791921 HIKARI (1) 1/116 0/114 17.1 % 7.26 [ 0.14, 366.07 ]
RAPID1 2005 2/392 1/199 45.8 % 1.02 [ 0.09, 11.18 ]
RAPID2 2007 1/248 0/125 15.3 % 4.50 [ 0.07, 286.06 ]
REALISTIC 2008 2/846 0/209 21.8 % 3.48 [ 0.11, 112.96 ]
Total (95% CI) 1698 745 100.0 % 2.34 [ 0.46, 11.84 ]
Total events: 6 (Certolizumab pegol 200 mg), 1 (Control)
Heterogeneity: Chi2 = 0.93, df = 3 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
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(1) 1 patient died of a rupture of a dissecting aortic aneurysm in the thoracic region, but UCB considered that in unlikely to have beeen related to study medication
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Analysis 8.9. Comparison 8 Safety, certolizumab 200 mg, Outcome 9 Adverse events leading to withdrawal.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 9 Adverse events leading to withdrawal
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CERTAIN 2008 6/96 6/98 12.5 % 1.02 [ 0.32, 3.28 ]
NCT00791921 HIKARI 8/116 2/114 10.6 % 3.42 [ 0.97, 12.13 ]
NCT00791999 JRAPID 3/82 3/77 6.4 % 0.94 [ 0.18, 4.77 ]
NCT00993317 4/85 2/42 5.6 % 0.99 [ 0.17, 5.60 ]
RAPID1 2005 17/392 3/199 19.1 % 2.37 [ 0.92, 6.09 ]
RAPID2 2007 12/248 2/125 13.3 % 2.45 [ 0.79, 7.57 ]
REALISTIC 2008 40/846 8/209 32.3 % 1.23 [ 0.60, 2.54 ]
Total (95% CI) 1865 864 100.0 % 1.62 [ 1.07, 2.44 ]
Total events: 90 (Certolizumab pegol 200 mg), 26 (Control)
Heterogeneity: Chi2 = 4.38, df = 6 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.28 (P = 0.022)
Test for subgroup differences: Not applicable
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Analysis 8.10. Comparison 8 Safety, certolizumab 200 mg, Outcome 10 Death.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CERTAIN 2008 0/96 0/98 Not estimable
NCT00791921 HIKARI (1) 1/116 0/114 14.9 % 7.26 [ 0.14, 366.07 ]
RAPID1 2005 (2) 3/392 1/199 52.9 % 1.48 [ 0.18, 11.81 ]
RAPID2 2007 1/246 0/125 13.3 % 4.52 [ 0.07, 285.66 ]
REALISTIC 2008 2/846 0/209 18.9 % 3.48 [ 0.11, 112.96 ]
Total (95% CI) 1696 745 100.0 % 2.56 [ 0.56, 11.59 ]
Total events: 7 (Certolizumab pegol 200 mg), 1 (Control)
Heterogeneity: Chi2 = 0.64, df = 3 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
(1) 1 patient died of a rupture of a dissecting aortic aneurysm in the thoracic region, but UCB considered that in unlikely to have beeen related to study medication
(2) One patient died of hepatic neoplam and other for cardiac arrest. One patient died in placebo group of a myocardial infarction
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Analysis 8.11. Comparison 8 Safety, certolizumab 200 mg, Outcome 11 Tuberculosis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CERTAIN 2008 0/96 0/98 Not estimable
NCT00993317 2/85 0/42 28.3 % 4.51 [ 0.23, 86.80 ]
RAPID1 2005 2/392 0/199 28.8 % 4.53 [ 0.24, 85.22 ]
RAPID2 2007 3/248 0/125 42.9 % 4.54 [ 0.41, 50.19 ]
REALISTIC 2008 0/846 0/209 Not estimable
Total (95% CI) 1667 673 100.0 % 4.53 [ 0.94, 21.85 ]
Total events: 7 (Certolizumab pegol 200 mg), 0 (Control)
Heterogeneity: Chi2 = 0.00, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.88 (P = 0.060)
Test for subgroup differences: Not applicable
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Analysis 8.12. Comparison 8 Safety, certolizumab 200 mg, Outcome 12 Malignancies included lymphoma.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 12 Malignancies included lymphoma
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CERTAIN 2008 0/96 2/98 12.7 % 0.14 [ 0.01, 2.20 ]
NCT00791921 HIKARI 0/116 1/114 6.4 % 0.13 [ 0.00, 6.70 ]
NCT00993317 (1) 0/85 0/42 Not estimable
RAPID1 2005 (2) 7/392 1/199 45.2 % 2.61 [ 0.60, 11.41 ]
RAPID2 2007 1/248 1/125 11.4 % 0.48 [ 0.03, 9.01 ]
REALISTIC 2008 4/846 2/209 24.3 % 0.43 [ 0.06, 3.18 ]
Total (95% CI) 1783 787 100.0 % 0.79 [ 0.29, 2.12 ]
Total events: 12 (Certolizumab pegol 200 mg), 7 (Control)
Heterogeneity: Chi2 = 5.32, df = 4 (P = 0.26); I2 =25%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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system], one adrenal adenoma, one hepatic neoplasm one esophageal carcinoma, and uterine cancer
(1) Data provided by UCB
(2) One patient in the arm of placebo suffered a thyroid neoplasm and 7 in the arm of certolizumab 200 mg sc suffered: three basal cell carcinomas [one with metastasis
to the central nervous
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Analysis 8.13. Comparison 8 Safety, certolizumab 200 mg, Outcome 13 Injection site pain.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 13 Injection site pain
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00993317 0/85 2/42 19.9 % 0.05 [ 0.00, 0.91 ]
RAPID1 2005 8/392 0/199 80.1 % 4.60 [ 1.05, 20.10 ]
RAPID2 2007 0/248 0/125 Not estimable
Total (95% CI) 725 366 100.0 % 1.85 [ 0.49, 6.92 ]
Total events: 8 (Certolizumab pegol 200 mg), 2 (Control)
Heterogeneity: Chi2 = 7.36, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 8.14. Comparison 8 Safety, certolizumab 200 mg, Outcome 14 Injection side reactions.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 14 Injection side reactions
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00791999 JRAPID 1/82 0/77 2.4 % 6.95 [ 0.14, 351.04 ]
RAPID1 2005 9/392 0/199 18.7 % 4.61 [ 1.15, 18.55 ]
RAPID2 2007 3/248 0/125 6.3 % 4.54 [ 0.41, 50.19 ]
REALISTIC 2008 49/846 2/209 72.7 % 2.86 [ 1.41, 5.79 ]
Total (95% CI) 1568 610 100.0 % 3.28 [ 1.80, 5.99 ]
Total events: 62 (Certolizumab pegol 200 mg), 2 (Control)
Heterogeneity: Chi2 = 0.59, df = 3 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 3.87 (P = 0.00011)
Test for subgroup differences: Not applicable
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Analysis 8.15. Comparison 8 Safety, certolizumab 200 mg, Outcome 15 Neutralising Anti-certolizumab
pegol antibodies.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 15 Neutralising Anti-certolizumab pegol antibodies
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 5/248 0/125 100.0 % 4.57 [ 0.71, 29.59 ]
Total (95% CI) 248 125 100.0 % 4.57 [ 0.71, 29.59 ]
Total events: 5 (Certolizumab pegol 200 mg), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 8.16. Comparison 8 Safety, certolizumab 200 mg, Outcome 16 Systemic lupus erythematosus.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 16 Systemic lupus erythematosus
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CERTAIN 2008 0/96 0/98 Not estimable
RAPID2 2007 1/248 0/125 100.0 % 4.50 [ 0.07, 286.06 ]
Total (95% CI) 344 223 100.0 % 4.50 [ 0.07, 286.06 ]
Total events: 1 (Certolizumab pegol 200 mg), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 8.17. Comparison 8 Safety, certolizumab 200 mg, Outcome 17 Prolonged activated partial
thromboplastin time (aPTT).
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 17 Prolonged activated partial thromboplastin time (aPTT)
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00993317 3/85 0/42 17.8 % 4.56 [ 0.40, 51.56 ]
RAPID2 2007 12/248 2/125 82.2 % 2.45 [ 0.79, 7.57 ]
Total (95% CI) 333 167 100.0 % 2.73 [ 0.98, 7.61 ]
Total events: 15 (Certolizumab pegol 200 mg), 2 (Control)
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.92 (P = 0.054)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
112Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 8.18. Comparison 8 Safety, certolizumab 200 mg, Outcome 18 Urinary tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 18 Urinary tract infection
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CERTAIN 2008 6/96 5/98 16.6 % 1.24 [ 0.37, 4.17 ]
NCT00993317 1/85 0/42 1.4 % 4.46 [ 0.07, 287.18 ]
RAPID1 2005 23/392 13/199 48.1 % 0.89 [ 0.44, 1.82 ]
RAPID2 2007 11/248 9/125 26.9 % 0.58 [ 0.22, 1.51 ]
REALISTIC 2008 5/846 2/209 7.0 % 0.57 [ 0.09, 3.70 ]
Total (95% CI) 1667 673 100.0 % 0.83 [ 0.51, 1.36 ]
Total events: 46 (Certolizumab pegol 200 mg), 29 (Control)
Heterogeneity: Chi2 = 1.77, df = 4 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 8.19. Comparison 8 Safety, certolizumab 200 mg, Outcome 19 Upper respiratory tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 19 Upper respiratory tract infection
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CERTAIN 2008 6/96 4/98 6.7 % 1.55 [ 0.44, 5.53 ]
NCT00791921 HIKARI 3/116 4/114 4.8 % 0.73 [ 0.16, 3.29 ]
NCT00791999 JRAPID 2/82 3/77 3.4 % 0.62 [ 0.11, 3.67 ]
NCT00993317 12/85 5/42 9.2 % 1.21 [ 0.41, 3.56 ]
RAPID1 2005 24/392 5/199 17.2 % 2.16 [ 0.98, 4.77 ]
RAPID2 2007 11/248 2/125 7.8 % 2.32 [ 0.72, 7.47 ]
REALISTIC 2008 112/846 19/209 51.0 % 1.46 [ 0.93, 2.32 ]
Total (95% CI) 1865 864 100.0 % 1.51 [ 1.08, 2.09 ]
Total events: 170 (Certolizumab pegol 200 mg), 42 (Control)
Heterogeneity: Chi2 = 3.35, df = 6 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours certolizumab pego Favours control
114Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 8.20. Comparison 8 Safety, certolizumab 200 mg, Outcome 20 Lower respiratory tract infection/
lung infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 20 Lower respiratory tract infection/ lung infection
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CERTAIN 2008 0/96 1/98 6.9 % 0.14 [ 0.00, 6.96 ]
NCT00791921 HIKARI (1) 2/116 0/114 13.8 % 7.33 [ 0.46, 117.85 ]
NCT00791999 JRAPID 1/82 1/77 13.7 % 0.94 [ 0.06, 15.16 ]
NCT00993317 2/85 0/42 12.2 % 4.51 [ 0.23, 86.80 ]
RAPID1 2005 3/392 0/199 18.5 % 4.54 [ 0.41, 49.96 ]
REALISTIC 2008 7/846 1/209 34.9 % 1.59 [ 0.28, 9.09 ]
Total (95% CI) 1617 739 100.0 % 2.12 [ 0.76, 5.95 ]
Total events: 15 (Certolizumab pegol 200 mg), 3 (Control)
Heterogeneity: Chi2 = 3.70, df = 5 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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(1) 2(1 pneumonia neumococcal and 1 pneumocystis jirobenzi pneumonia)
115Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 8.21. Comparison 8 Safety, certolizumab 200 mg, Outcome 21 Headache.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CERTAIN 2008 1/96 5/98 7.6 % 0.26 [ 0.05, 1.31 ]
NCT00791999 JRAPID 0/82 0/77 Not estimable
RAPID1 2005 22/392 11/199 36.1 % 1.02 [ 0.48, 2.13 ]
RAPID2 2007 9/248 1/125 11.3 % 2.95 [ 0.78, 11.14 ]
REALISTIC 2008 47/846 11/209 45.1 % 1.06 [ 0.54, 2.05 ]
Total (95% CI) 1664 708 100.0 % 1.05 [ 0.67, 1.64 ]
Total events: 79 (Certolizumab pegol 200 mg), 28 (Control)
Heterogeneity: Chi2 = 5.18, df = 3 (P = 0.16); I2 =42%
Test for overall effect: Z = 0.22 (P = 0.82)
Test for subgroup differences: Not applicable
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Analysis 8.22. Comparison 8 Safety, certolizumab 200 mg, Outcome 22 Bacteriuria.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 8/248 4/125 100.0 % 1.01 [ 0.30, 3.40 ]
Total (95% CI) 248 125 100.0 % 1.01 [ 0.30, 3.40 ]
Total events: 8 (Certolizumab pegol 200 mg), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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117Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 8.23. Comparison 8 Safety, certolizumab 200 mg, Outcome 23 Nasopharyngitis/Pharyngitis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CERTAIN 2008 10/96 11/98 15.8 % 0.92 [ 0.37, 2.27 ]
NCT00791921 HIKARI 26/116 21/114 31.5 % 1.28 [ 0.67, 2.42 ]
NCT00791999 JRAPID 16/82 12/77 19.5 % 1.31 [ 0.58, 2.95 ]
NCT00993317 10/85 4/42 9.3 % 1.25 [ 0.39, 4.06 ]
RAPID1 2005 21/392 3/199 17.3 % 2.68 [ 1.13, 6.36 ]
RAPID2 2007 8/248 1/125 6.6 % 2.79 [ 0.69, 11.32 ]
Total (95% CI) 1019 655 100.0 % 1.46 [ 1.02, 2.09 ]
Total events: 91 (Certolizumab pegol 200 mg), 52 (Control)
Heterogeneity: Chi2 = 4.04, df = 5 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 2.05 (P = 0.040)
Test for subgroup differences: Not applicable
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118Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 8.24. Comparison 8 Safety, certolizumab 200 mg, Outcome 24 Hypertension.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00791921 HIKARI 4/116 1/114 13.0 % 3.33 [ 0.57, 19.54 ]
NCT00791999 JRAPID 3/82 0/77 7.8 % 7.13 [ 0.73, 69.59 ]
RAPID1 2005 25/392 2/199 60.8 % 3.42 [ 1.51, 7.74 ]
RAPID2 2007 6/248 2/125 18.4 % 1.48 [ 0.34, 6.50 ]
Total (95% CI) 838 515 100.0 % 3.09 [ 1.64, 5.84 ]
Total events: 38 (Certolizumab pegol 200 mg), 5 (Control)
Heterogeneity: Chi2 = 1.54, df = 3 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 3.48 (P = 0.00051)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 8.25. Comparison 8 Safety, certolizumab 200 mg, Outcome 25 Hematuria.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 4/248 5/125 100.0 % 0.36 [ 0.09, 1.47 ]
Total (95% CI) 248 125 100.0 % 0.36 [ 0.09, 1.47 ]
Total events: 4 (Certolizumab pegol 200 mg), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable
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119Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 8.26. Comparison 8 Safety, certolizumab 200 mg, Outcome 26 Hepatic enzyme increased.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 26 Hepatic enzyme increased
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00791999 JRAPID 3/82 4/77 52.3 % 0.70 [ 0.15, 3.15 ]
RAPID2 2007 3/248 4/125 47.7 % 0.34 [ 0.07, 1.66 ]
Total (95% CI) 330 202 100.0 % 0.49 [ 0.17, 1.48 ]
Total events: 6 (Certolizumab pegol 200 mg), 8 (Control)
Heterogeneity: Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
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120Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 8.27. Comparison 8 Safety, certolizumab 200 mg, Outcome 27 AST increased.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 27 AST increased
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 2/248 5/125 100.0 % 0.18 [ 0.04, 0.86 ]
Total (95% CI) 248 125 100.0 % 0.18 [ 0.04, 0.86 ]
Total events: 2 (Certolizumab pegol 200 mg), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.032)
Test for subgroup differences: Not applicable
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Analysis 8.28. Comparison 8 Safety, certolizumab 200 mg, Outcome 28 ALT increased.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 28 ALT increased
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 1/248 6/125 100.0 % 0.09 [ 0.02, 0.45 ]
Total (95% CI) 248 125 100.0 % 0.09 [ 0.02, 0.45 ]
Total events: 1 (Certolizumab pegol 200 mg), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.95 (P = 0.0032)
Test for subgroup differences: Not applicable
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121Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 8.29. Comparison 8 Safety, certolizumab 200 mg, Outcome 29 Back pain.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 29 Back pain
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 17/392 2/199 100.0 % 2.91 [ 1.11, 7.65 ]
Total (95% CI) 392 199 100.0 % 2.91 [ 1.11, 7.65 ]
Total events: 17 (Certolizumab 200 mg pegol), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.17 (P = 0.030)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 8.30. Comparison 8 Safety, certolizumab 200 mg, Outcome 30 Herpes viral infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 30 Herpes viral infection
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00791921 HIKARI 1/116 0/114 52.8 % 7.26 [ 0.14, 366.07 ]
RAPID1 2005 1/392 0/199 47.2 % 4.52 [ 0.07, 285.70 ]
Total (95% CI) 508 313 100.0 % 5.80 [ 0.34, 100.23 ]
Total events: 2 (Certolizumab 200 mg pegol), 0 (Control)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
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122Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 8.31. Comparison 8 Safety, certolizumab 200 mg, Outcome 31 Bacterial peritonitis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 31 Bacterial peritonitis
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 1/392 0/199 100.0 % 4.52 [ 0.07, 285.70 ]
Total (95% CI) 392 199 100.0 % 4.52 [ 0.07, 285.70 ]
Total events: 1 (Certolizumab 200 mg pegol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Favours certolizumab pego Favours control
Analysis 8.32. Comparison 8 Safety, certolizumab 200 mg, Outcome 32 Opportunistic infections.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 32 Opportunistic infections
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CERTAIN 2008 0/96 0/98 Not estimable
NCT00791921 HIKARI (1) 2/116 0/114 100.0 % 7.33 [ 0.46, 117.85 ]
RAPID1 2005 0/392 0/199 Not estimable
REALISTIC 2008 0/846 0/209 Not estimable
Total (95% CI) 1450 620 100.0 % 7.33 [ 0.46, 117.85 ]
Total events: 2 (Certolizumab 200 mg pegol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
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Favours certolizumab pego Favours control
123Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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(1) 2 (1 Herpes Zoster and 1pneumocystis jirobenzi pneumonia)
Analysis 8.33. Comparison 8 Safety, certolizumab 200 mg, Outcome 33 Infections and infestations.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 33 Infections and infestations
Study or subgroup
Certolizumab








CERTAIN 2008 27/96 26/98 11.8 % 1.06 [ 0.67, 1.68 ]
NCT00791921 HIKARI 33/116 27/114 12.6 % 1.20 [ 0.78, 1.86 ]
NCT00791999 JRAPID 27/82 16/77 9.5 % 1.58 [ 0.93, 2.70 ]
NCT00993317 30/85 9/42 7.0 % 1.65 [ 0.86, 3.14 ]
RAPID1 2005 171/392 52/199 22.6 % 1.67 [ 1.29, 2.16 ]
RAPID2 2007 26/108 69/248 14.7 % 0.87 [ 0.59, 1.28 ]
REALISTIC 2008 245/846 48/209 21.8 % 1.26 [ 0.96, 1.65 ]
Total (95% CI) 1725 987 100.0 % 1.29 [ 1.07, 1.56 ]
Total events: 559 (Certolizumab 200 mg pegol), 247 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 9.71, df = 6 (P = 0.14); I2 =38%
Test for overall effect: Z = 2.63 (P = 0.0085)
Test for subgroup differences: Not applicable
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124Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 8.34. Comparison 8 Safety, certolizumab 200 mg, Outcome 34 Gastroenteritis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CERTAIN 2008 7/96 6/98 93.2 % 1.20 [ 0.39, 3.70 ]
RAPID1 2005 0/392 1/199 6.8 % 0.05 [ 0.00, 3.25 ]
Total (95% CI) 488 297 100.0 % 0.97 [ 0.33, 2.87 ]
Total events: 7 (Certolizumab 200 mg pegol), 7 (Control)
Heterogeneity: Chi2 = 2.07, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
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Favours certolizumab pego Favours control
Analysis 8.35. Comparison 8 Safety, certolizumab 200 mg, Outcome 35 Hematologic abnormalities.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 35 Hematologic abnormalities
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00791921 HIKARI 1/116 1/114 52.7 % 0.98 [ 0.06, 15.81 ]
RAPID1 2005 2/392 0/199 47.3 % 4.53 [ 0.24, 85.22 ]
Total (95% CI) 508 313 100.0 % 2.02 [ 0.27, 15.21 ]
Total events: 3 (Certolizumab 200 mg pegol), 1 (Control)
Heterogeneity: Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.49)
Test for subgroup differences: Not applicable
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125Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 8.36. Comparison 8 Safety, certolizumab 200 mg, Outcome 36 Decreased haemoglobin.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 36 Decreased haemoglobin
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 2/392 1/199 100.0 % 1.02 [ 0.09, 11.18 ]
Total (95% CI) 392 199 100.0 % 1.02 [ 0.09, 11.18 ]
Total events: 2 (Certolizumab 200 mg pegol), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours certolizumab pego
126Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 8.37. Comparison 8 Safety, certolizumab 200 mg, Outcome 37 Increased platelet count.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 37 Increased platelet count
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 0/392 1/199 100.0 % 0.05 [ 0.00, 3.25 ]
Total (95% CI) 392 199 100.0 % 0.05 [ 0.00, 3.25 ]
Total events: 0 (Certolizumab 200 mg pegol), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 8.38. Comparison 8 Safety, certolizumab 200 mg, Outcome 38 Pneumonia.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CERTAIN 2008 0/96 1/98 11.2 % 0.14 [ 0.00, 6.96 ]
REALISTIC 2008 7/846 1/209 56.6 % 1.59 [ 0.28, 9.09 ]
NCT00993317 1/85 0/42 9.9 % 4.46 [ 0.07, 287.18 ]
NCT00791921 HIKARI 2/116 0/114 22.3 % 7.33 [ 0.46, 117.85 ]
Total (95% CI) 1143 463 100.0 % 1.88 [ 0.51, 6.99 ]
Total events: 10 (Certolizumab 200 mg pegol), 2 (Control)
Heterogeneity: Chi2 = 2.83, df = 3 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
127Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 8.39. Comparison 8 Safety, certolizumab 200 mg, Outcome 39 Diarrhoea.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CERTAIN 2008 5/96 6/98 80.0 % 0.84 [ 0.25, 2.84 ]
NCT00993317 1/85 2/42 20.0 % 0.21 [ 0.02, 2.42 ]
Total (95% CI) 181 140 100.0 % 0.64 [ 0.22, 1.90 ]
Total events: 6 (Certolizumab 200 mg pegol), 8 (Control)
Heterogeneity: Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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128Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 8.40. Comparison 8 Safety, certolizumab 200 mg, Outcome 40 Cerebral haemorrhage including
subarachnoid.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 40 Cerebral haemorrhage including subarachnoid
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CERTAIN 2008 0/96 1/98 36.3 % 0.14 [ 0.00, 6.96 ]
NCT00993317 2/85 0/42 63.7 % 4.51 [ 0.23, 86.80 ]
Total (95% CI) 181 140 100.0 % 1.27 [ 0.12, 13.50 ]
Total events: 2 (Certolizumab 200 mg pegol), 1 (Control)
Heterogeneity: Chi2 = 1.94, df = 1 (P = 0.16); I2 =48%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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Favours certolizumab pego Favours control
Analysis 8.41. Comparison 8 Safety, certolizumab 200 mg, Outcome 41 Nausea/vomiting.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CERTAIN 2008 5/96 5/98 22.3 % 1.02 [ 0.29, 3.64 ]
REALISTIC 2008 42/846 13/209 77.7 % 0.78 [ 0.39, 1.53 ]
Total (95% CI) 942 307 100.0 % 0.83 [ 0.45, 1.50 ]
Total events: 47 (Certolizumab 200 mg pegol), 18 (Control)
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
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129Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 8.42. Comparison 8 Safety, certolizumab 200 mg, Outcome 42 Acute miocardial infarction.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 42 Acute miocardial infarction
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CERTAIN 2008 0/96 0/98 Not estimable
Total (95% CI) 96 98 Not estimable
Total events: 0 (Certolizumab 200 mg pegol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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130Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 8.43. Comparison 8 Safety, certolizumab 200 mg, Outcome 43 Constipation.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00791921 HIKARI 4/116 0/114 100.0 % 7.46 [ 1.04, 53.63 ]
Total (95% CI) 116 114 100.0 % 7.46 [ 1.04, 53.63 ]
Total events: 4 (Certolizumab 200 mg pegol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.046)
Test for subgroup differences: Not applicable
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Analysis 8.44. Comparison 8 Safety, certolizumab 200 mg, Outcome 44 Skin and subcutaneous tissue
disorders.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 44 Skin and subcutaneous tissue disorders
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00791921 HIKARI 17/116 3/114 54.3 % 4.52 [ 1.81, 11.28 ]
NCT00791999 JRAPID 10/82 4/77 38.0 % 2.38 [ 0.80, 7.10 ]
NCT00993317 3/85 0/42 7.7 % 4.56 [ 0.40, 51.56 ]
Total (95% CI) 283 233 100.0 % 3.54 [ 1.81, 6.95 ]
Total events: 30 (Certolizumab 200 mg pegol), 7 (Control)
Heterogeneity: Chi2 = 0.82, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 3.68 (P = 0.00024)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
131Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 8.45. Comparison 8 Safety, certolizumab 200 mg, Outcome 45 Cough.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00993317 4/85 1/42 100.0 % 1.84 [ 0.28, 12.22 ]
Total (95% CI) 85 42 100.0 % 1.84 [ 0.28, 12.22 ]
Total events: 4 (Certolizumab 200 mg pegol), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 8.46. Comparison 8 Safety, certolizumab 200 mg, Outcome 46 Pruritus.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00993317 3/85 0/42 100.0 % 4.56 [ 0.40, 51.56 ]
Total (95% CI) 85 42 100.0 % 4.56 [ 0.40, 51.56 ]
Total events: 3 (Certolizumab 200 mg pegol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 8.47. Comparison 8 Safety, certolizumab 200 mg, Outcome 47 Abdominal
pain/discomfort/dyspepsia.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety, certolizumab 200 mg
Outcome: 47 Abdominal pain/discomfort/dyspepsia
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00993317 12/85 2/42 100.0 % 2.58 [ 0.80, 8.35 ]
Total (95% CI) 85 42 100.0 % 2.58 [ 0.80, 8.35 ]
Total events: 12 (Certolizumab 200 mg pegol), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 8.48. Comparison 8 Safety, certolizumab 200 mg, Outcome 48 Fatigue.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00993317 3/85 1/42 100.0 % 1.45 [ 0.18, 11.96 ]
Total (95% CI) 85 42 100.0 % 1.45 [ 0.18, 11.96 ]
Total events: 3 (Certolizumab 200 mg pegol), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 8.49. Comparison 8 Safety, certolizumab 200 mg, Outcome 49 Periodontitis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00791999 JRAPID 4/85 2/77 100.0 % 1.80 [ 0.35, 9.16 ]
Total (95% CI) 85 77 100.0 % 1.80 [ 0.35, 9.16 ]
Total events: 4 (Certolizumab 200 mg pegol), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 Safety, certolizumab 400 mg, Outcome 1 Any adverse events.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 1 Any adverse events
Study or subgroup
Certolizumab








CDP870-014 2009 97/124 83/119 24.6 % 1.12 [ 0.96, 1.30 ]
FAST4WARD 2005 84/111 63/109 19.9 % 1.31 [ 1.08, 1.59 ]
NCT00791999 JRAPID 46/85 31/77 9.9 % 1.34 [ 0.96, 1.88 ]
RAPID1 2005 298/389 115/199 27.0 % 1.33 [ 1.16, 1.51 ]
RAPID2 2007 125/246 66/125 18.5 % 0.96 [ 0.78, 1.18 ]
Total (95% CI) 955 629 100.0 % 1.20 [ 1.06, 1.35 ]
Total events: 650 (Certolizumab pegol 400 mg), 358 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 8.60, df = 4 (P = 0.07); I2 =53%
Test for overall effect: Z = 2.89 (P = 0.0038)
Test for subgroup differences: Not applicable
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Analysis 9.2. Comparison 9 Safety, certolizumab 400 mg, Outcome 2 Adverse events Intensity mild.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 2 Adverse events Intensity mild
Study or subgroup
Certolizumab








CDP870-014 2009 64/124 61/119 24.7 % 1.01 [ 0.79, 1.29 ]
FAST4WARD 2005 62/111 43/109 21.2 % 1.42 [ 1.06, 1.88 ]
RAPID1 2005 254/389 90/199 32.4 % 1.44 [ 1.22, 1.71 ]
RAPID2 2007 101/246 45/125 21.8 % 1.14 [ 0.86, 1.51 ]
Total (95% CI) 870 552 100.0 % 1.25 [ 1.04, 1.50 ]
Total events: 481 (Certolizumab pegol 400 mg), 239 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.79, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 2.43 (P = 0.015)
Test for subgroup differences: Not applicable
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Analysis 9.3. Comparison 9 Safety, certolizumab 400 mg, Outcome 3 Adverse events Intensity moderate.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 3 Adverse events Intensity moderate
Study or subgroup
Certolizumab








CDP870-014 2009 59/124 45/119 24.4 % 1.26 [ 0.94, 1.69 ]
FAST4WARD 2005 52/111 40/109 21.7 % 1.28 [ 0.93, 1.75 ]
RAPID1 2005 177/389 66/199 37.9 % 1.37 [ 1.10, 1.72 ]
RAPID2 2007 57/246 32/125 16.0 % 0.91 [ 0.62, 1.32 ]
Total (95% CI) 870 552 100.0 % 1.24 [ 1.06, 1.45 ]
Total events: 345 (Certolizumab pegol 400 mg), 183 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.52, df = 3 (P = 0.32); I2 =15%
Test for overall effect: Z = 2.64 (P = 0.0082)
Test for subgroup differences: Not applicable
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Analysis 9.4. Comparison 9 Safety, certolizumab 400 mg, Outcome 4 Adverse events Intensity severe.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 4 Adverse events Intensity severe
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CDP870-014 2009 17/124 14/119 26.5 % 1.19 [ 0.56, 2.53 ]
FAST4WARD 2005 8/111 11/109 17.0 % 0.69 [ 0.27, 1.78 ]
RAPID1 2005 38/389 13/199 40.8 % 1.50 [ 0.82, 2.76 ]
RAPID2 2007 14/246 5/125 15.8 % 1.41 [ 0.53, 3.75 ]
Total (95% CI) 870 552 100.0 % 1.23 [ 0.83, 1.81 ]
Total events: 77 (Certolizumab pegol 400 mg), 43 (Control)
Heterogeneity: Chi2 = 1.93, df = 3 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 9.5. Comparison 9 Safety, certolizumab 400 mg, Outcome 5 Adverse events related to study drug.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 5 Adverse events related to study drug
Study or subgroup
Certolizumab
pegol 400 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
FAST4WARD 2005 27/111 24/109 20.0 % 1.10 [ 0.68, 1.79 ]
RAPID1 2005 166/389 50/199 54.7 % 1.70 [ 1.30, 2.22 ]
RAPID2 2007 56/246 23/125 25.2 % 1.24 [ 0.80, 1.91 ]
Total (95% CI) 746 433 100.0 % 1.46 [ 1.19, 1.80 ]
Total events: 249 (Certolizumab pegol 400 mg), 97 (Control)
Heterogeneity: Chi2 = 3.08, df = 2 (P = 0.21); I2 =35%
Test for overall effect: Z = 3.65 (P = 0.00027)
Test for subgroup differences: Not applicable
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Analysis 9.6. Comparison 9 Safety, certolizumab 400 mg, Outcome 6 Serious infections.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 6 Serious infections
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CDP870-014 2009 3/124 2/119 14.6 % 1.44 [ 0.25, 8.44 ]
FAST4WARD 2005 2/111 0/109 5.9 % 7.32 [ 0.46, 117.84 ]
RAPID1 2005 23/389 2/199 63.8 % 3.33 [ 1.43, 7.76 ]
RAPID2 2007 6/246 0/125 15.7 % 4.61 [ 0.84, 25.36 ]
Total (95% CI) 870 552 100.0 % 3.25 [ 1.65, 6.39 ]
Total events: 34 (Certolizumab pegol 400 mg), 4 (Control)
Heterogeneity: Chi2 = 1.31, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 3.42 (P = 0.00063)
Test for subgroup differences: Not applicable
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Analysis 9.7. Comparison 9 Safety, certolizumab 400 mg, Outcome 7 3Serious Adverse Events (SAE).
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 7 3Serious Adverse Events (SAE)
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CDP870-014 2009 16/124 12/119 23.2 % 1.32 [ 0.60, 2.89 ]
FAST4WARD 2005 8/111 3/109 9.8 % 2.54 [ 0.76, 8.53 ]
NCT00791999 JRAPID 5/85 1/77 5.4 % 3.59 [ 0.70, 18.26 ]
RAPID1 2005 48/389 11/199 44.4 % 2.12 [ 1.20, 3.75 ]
RAPID2 2007 18/246 4/125 17.3 % 2.09 [ 0.84, 5.19 ]
Total (95% CI) 955 629 100.0 % 1.98 [ 1.36, 2.90 ]
Total events: 95 (Certolizumab pegol 400 mg), 31 (Control)
Heterogeneity: Chi2 = 1.78, df = 4 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 3.55 (P = 0.00038)
Test for subgroup differences: Not applicable
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Analysis 9.8. Comparison 9 Safety, certolizumab 400 mg, Outcome 8 Adverse events leading to death.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 8 Adverse events leading to death
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 0/111 0/109 Not estimable
RAPID1 2005 4/389 1/199 83.3 % 1.86 [ 0.29, 11.96 ]
RAPID2 2007 1/246 0/125 16.7 % 4.52 [ 0.07, 285.66 ]
Total (95% CI) 746 433 100.0 % 2.16 [ 0.40, 11.79 ]
Total events: 5 (Certolizumab pegol 400 mg), 1 (Control)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 9.9. Comparison 9 Safety, certolizumab 400 mg, Outcome 9 Adverse events leading to withdrawal.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 9 Adverse events leading to withdrawal
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CDP870-014 2009 7/124 6/119 21.3 % 1.13 [ 0.37, 3.44 ]
FAST4WARD 2005 5/111 2/109 11.8 % 2.37 [ 0.53, 10.64 ]
NCT00791999 JRAPID 7/85 3/77 16.3 % 2.11 [ 0.59, 7.55 ]
RAPID1 2005 22/389 3/199 37.1 % 2.77 [ 1.19, 6.44 ]
RAPID2 2007 7/246 2/125 13.6 % 1.69 [ 0.42, 6.84 ]
Total (95% CI) 955 629 100.0 % 2.01 [ 1.20, 3.36 ]
Total events: 48 (Certolizumab pegol 400 mg), 16 (Control)
Heterogeneity: Chi2 = 1.69, df = 4 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 2.65 (P = 0.0081)
Test for subgroup differences: Not applicable
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Analysis 9.10. Comparison 9 Safety, certolizumab 400 mg, Outcome 10 Death.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CDP870-014 2009 0/124 0/119 Not estimable
FAST4WARD 2005 0/111 0/109 Not estimable
RAPID1 2005 4/389 1/199 83.3 % 1.86 [ 0.29, 11.96 ]
RAPID2 2007 1/246 0/125 16.7 % 4.52 [ 0.07, 285.66 ]
Total (95% CI) 870 552 100.0 % 2.16 [ 0.40, 11.79 ]
Total events: 5 (Certolizumab pegol 400 mg), 1 (Control)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 9.11. Comparison 9 Safety, certolizumab 400 mg, Outcome 11 Vomiting.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 0/111 1/109 100.0 % 0.13 [ 0.00, 6.70 ]
Total (95% CI) 111 109 100.0 % 0.13 [ 0.00, 6.70 ]
Total events: 0 (Certolizumab pegol 400 mg), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 9.12. Comparison 9 Safety, certolizumab 400 mg, Outcome 12 Pneumonitis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 0/111 1/109 100.0 % 0.13 [ 0.00, 6.70 ]
Total (95% CI) 111 109 100.0 % 0.13 [ 0.00, 6.70 ]
Total events: 0 (Certolizumab pegol 400 mg), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 9.13. Comparison 9 Safety, certolizumab 400 mg, Outcome 13 Tuberculosis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 0/111 0/109 Not estimable
RAPID1 2005 3/389 0/199 60.0 % 4.56 [ 0.42, 50.01 ]
RAPID2 2007 2/246 0/125 40.0 % 4.54 [ 0.24, 85.48 ]
Total (95% CI) 746 433 100.0 % 4.55 [ 0.71, 29.11 ]
Total events: 5 (Certolizumab pegol 400 mg), 0 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 9.14. Comparison 9 Safety, certolizumab 400 mg, Outcome 14 Arthritis bacterial.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 14 Arthritis bacterial
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 1/111 0/109 100.0 % 7.26 [ 0.14, 365.79 ]
Total (95% CI) 111 109 100.0 % 7.26 [ 0.14, 365.79 ]
Total events: 1 (Certolizumab pegol 400 mg), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 9.15. Comparison 9 Safety, certolizumab 400 mg, Outcome 15 Mastitis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 1/111 0/109 100.0 % 7.26 [ 0.14, 365.79 ]
Total (95% CI) 111 109 100.0 % 7.26 [ 0.14, 365.79 ]
Total events: 1 (Certolizumab pegol 400 mg), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 9.16. Comparison 9 Safety, certolizumab 400 mg, Outcome 16 Benign Tumour.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 16 Benign Tumour
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 2/111 0/109 100.0 % 7.32 [ 0.46, 117.84 ]
Total (95% CI) 111 109 100.0 % 7.32 [ 0.46, 117.84 ]
Total events: 2 (Certolizumab pegol 400 mg), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 9.17. Comparison 9 Safety, certolizumab 400 mg, Outcome 17 Ischaemeic stroke.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 17 Ischaemeic stroke
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 1/111 0/109 100.0 % 7.26 [ 0.14, 365.79 ]
Total (95% CI) 111 109 100.0 % 7.26 [ 0.14, 365.79 ]
Total events: 1 (Certolizumab pegol 400 mg), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 9.18. Comparison 9 Safety, certolizumab 400 mg, Outcome 18 Dizziness postural.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 18 Dizziness postural
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 1/111 0/109 100.0 % 7.26 [ 0.14, 365.79 ]
Total (95% CI) 111 109 100.0 % 7.26 [ 0.14, 365.79 ]
Total events: 1 (Certolizumab pegol 400 mg), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 9.19. Comparison 9 Safety, certolizumab 400 mg, Outcome 19 Menorrhagia.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 1/111 0/109 100.0 % 7.26 [ 0.14, 365.79 ]
Total (95% CI) 111 109 100.0 % 7.26 [ 0.14, 365.79 ]
Total events: 1 (Certolizumab pegol 400 mg), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 9.20. Comparison 9 Safety, certolizumab 400 mg, Outcome 20 Malignancies included lymphoma.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 20 Malignancies included lymphoma
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 0/111 0/109 Not estimable
RAPID1 2005 (1) 4/389 1/199 71.4 % 1.86 [ 0.29, 11.96 ]
RAPID2 2007 (2) 1/246 1/125 28.6 % 0.48 [ 0.03, 9.06 ]
Total (95% CI) 746 433 100.0 % 1.26 [ 0.26, 6.08 ]
Total events: 5 (Certolizumab pegol 400 mg), 2 (Control)
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
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one papilloma.
(1) In the placebo arm one patient suffered a thyroid neoplasm and 4 in the certolizumab 400 mg sc suffered two tongue neoplasm, 1 extranodal marginal zone B cell
limphoma and
(2) One case of malignant neoplasm was reported in each arm, namely bladder cancer in the placebo group and colon cancer in certolizumab pegol 400 mg group
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Analysis 9.21. Comparison 9 Safety, certolizumab 400 mg, Outcome 21 Injection site pain.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 21 Injection site pain
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 0/111 2/109 27.2 % 0.13 [ 0.01, 2.12 ]
RAPID1 2005 5/389 0/199 60.7 % 4.58 [ 0.71, 29.39 ]
RAPID2 2007 1/246 0/125 12.2 % 4.52 [ 0.07, 285.66 ]
Total (95% CI) 746 433 100.0 % 1.74 [ 0.41, 7.42 ]
Total events: 6 (Certolizumab pegol 400 mg), 2 (Control)
Heterogeneity: Chi2 = 4.56, df = 2 (P = 0.10); I2 =56%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 9.22. Comparison 9 Safety, certolizumab 400 mg, Outcome 22 Injection side reactions.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 22 Injection side reactions
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CDP870-014 2009 (1) 5/124 34/119 54.6 % 0.16 [ 0.08, 0.32 ]
FAST4WARD 2005 5/111 15/109 30.3 % 0.33 [ 0.13, 0.82 ]
NCT00791999 JRAPID 2/85 0/77 3.3 % 6.81 [ 0.42, 110.13 ]
RAPID1 2005 3/389 0/199 4.4 % 4.56 [ 0.42, 50.01 ]
RAPID2 2007 5/246 0/125 7.3 % 4.59 [ 0.71, 29.64 ]
Total (95% CI) 955 629 100.0 % 0.34 [ 0.20, 0.56 ]
Total events: 20 (Certolizumab pegol 400 mg), 49 (Control)
Heterogeneity: Chi2 = 20.89, df = 4 (P = 0.00033); I2 =81%
Test for overall effect: Z = 4.21 (P = 0.000025)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours certolizumab pego Favours control
(1) Authors explained that ”possibly due to the use of the sorbitol placebo”
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Analysis 9.23. Comparison 9 Safety, certolizumab 400 mg, Outcome 23 Anti-certolizumab pegol antibodies.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 23 Anti-certolizumab pegol antibodies
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 9/111 0/109 71.0 % 7.82 [ 2.07, 29.62 ]
RAPID2 2007 4/246 0/125 29.0 % 4.57 [ 0.57, 36.68 ]
Total (95% CI) 357 234 100.0 % 6.70 [ 2.18, 20.55 ]
Total events: 13 (Certolizumab pegol 400 mg), 0 (Control)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 3.32 (P = 0.00089)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 9.24. Comparison 9 Safety, certolizumab 400 mg, Outcome 24 Antinuclear antibodies (ANA).
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 24 Antinuclear antibodies (ANA)
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 19/111 12/109 100.0 % 1.65 [ 0.77, 3.53 ]
Total (95% CI) 111 109 100.0 % 1.65 [ 0.77, 3.53 ]
Total events: 19 (Certolizumab pegol 400 mg), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 9.25. Comparison 9 Safety, certolizumab 400 mg, Outcome 25 Prolonged activated partial
thromboplastin time (aPTT).
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 25 Prolonged activated partial thromboplastin time (aPTT)
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 12/246 2/125 100.0 % 2.46 [ 0.80, 7.60 ]
Total (95% CI) 246 125 100.0 % 2.46 [ 0.80, 7.60 ]
Total events: 12 (Certolizumab pegol 400 mg), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 9.26. Comparison 9 Safety, certolizumab 400 mg, Outcome 26 Urinary tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 26 Urinary tract infection
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 33/389 13/199 75.9 % 1.31 [ 0.69, 2.47 ]
RAPID2 2007 5/246 9/125 24.1 % 0.24 [ 0.08, 0.75 ]
Total (95% CI) 635 324 100.0 % 0.87 [ 0.50, 1.52 ]
Total events: 38 (Certolizumab pegol 400 mg), 22 (Control)
Heterogeneity: Chi2 = 6.54, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
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Analysis 9.27. Comparison 9 Safety, certolizumab 400 mg, Outcome 27 Back pain.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 27 Back pain
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CDP870-014 2009 7/124 2/119 31.4 % 3.03 [ 0.80, 11.43 ]
RAPID1 2005 20/389 2/199 68.6 % 3.15 [ 1.28, 7.74 ]
Total (95% CI) 513 318 100.0 % 3.11 [ 1.48, 6.55 ]
Total events: 27 (Certolizumab pegol 400 mg), 4 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 2.98 (P = 0.0028)
Test for subgroup differences: Not applicable
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Analysis 9.28. Comparison 9 Safety, certolizumab 400 mg, Outcome 28 Upper respiratory tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 28 Upper respiratory tract infection
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CDP870-014 2009 4/124 4/119 18.9 % 0.96 [ 0.23, 3.91 ]
NCT00791999 JRAPID 3/85 3/77 14.1 % 0.90 [ 0.18, 4.60 ]
RAPID1 2005 21/389 5/199 54.2 % 1.98 [ 0.86, 4.54 ]
RAPID2 2007 4/246 2/125 12.9 % 1.02 [ 0.18, 5.59 ]
Total (95% CI) 844 520 100.0 % 1.42 [ 0.77, 2.61 ]
Total events: 32 (Certolizumab pegol 400 mg), 14 (Control)
Heterogeneity: Chi2 = 1.36, df = 3 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 9.29. Comparison 9 Safety, certolizumab 400 mg, Outcome 29 Lower respiratory tract infection/
lung infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 29 Lower respiratory tract infection/ lung infection
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CDP870-014 2009 3/124 3/119 41.1 % 0.96 [ 0.19, 4.83 ]
NCT00791999 JRAPID 4/85 1/77 34.0 % 3.10 [ 0.52, 18.35 ]
RAPID1 2005 4/389 0/199 24.9 % 4.57 [ 0.57, 36.44 ]
Total (95% CI) 598 395 100.0 % 2.11 [ 0.75, 5.95 ]
Total events: 11 (Certolizumab pegol 400 mg), 4 (Control)
Heterogeneity: Chi2 = 1.63, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 9.30. Comparison 9 Safety, certolizumab 400 mg, Outcome 30 Headache.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CDP870-014 2009 12/124 9/119 35.1 % 1.31 [ 0.53, 3.19 ]
NCT00791999 JRAPID 3/85 0/77 5.4 % 6.89 [ 0.70, 67.36 ]
RAPID1 2005 18/389 11/199 45.1 % 0.83 [ 0.38, 1.82 ]
RAPID2 2007 8/246 1/125 14.4 % 2.81 [ 0.69, 11.36 ]
Total (95% CI) 844 520 100.0 % 1.30 [ 0.76, 2.20 ]
Total events: 41 (Certolizumab pegol 400 mg), 21 (Control)
Heterogeneity: Chi2 = 4.50, df = 3 (P = 0.21); I2 =33%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours certolizumab pego Favours control
Analysis 9.31. Comparison 9 Safety, certolizumab 400 mg, Outcome 31 Bacteriuria.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 6/246 4/125 100.0 % 0.75 [ 0.20, 2.82 ]
Total (95% CI) 246 125 100.0 % 0.75 [ 0.20, 2.82 ]
Total events: 6 (Certolizumab pegol 400 mg), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 9.32. Comparison 9 Safety, certolizumab 400 mg, Outcome 32 Hypertension.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00791999 JRAPID 2/85 0/77 4.9 % 6.81 [ 0.42, 110.13 ]
RAPID1 2005 32/389 2/199 71.3 % 3.76 [ 1.81, 7.80 ]
RAPID2 2007 9/246 2/125 23.7 % 2.04 [ 0.57, 7.25 ]
Total (95% CI) 720 401 100.0 % 3.35 [ 1.80, 6.20 ]
Total events: 43 (Certolizumab pegol 400 mg), 4 (Control)
Heterogeneity: Chi2 = 0.93, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 3.83 (P = 0.00013)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
159Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 9.33. Comparison 9 Safety, certolizumab 400 mg, Outcome 33 Hematuria.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 4/246 5/125 100.0 % 0.37 [ 0.09, 1.49 ]
Total (95% CI) 246 125 100.0 % 0.37 [ 0.09, 1.49 ]
Total events: 4 (Certolizumab pegol 400 mg), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 9.34. Comparison 9 Safety, certolizumab 400 mg, Outcome 34 Hepatic enzyme increased.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 34 Hepatic enzyme increased
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00791999 JRAPID 5/85 4/77 58.1 % 1.14 [ 0.30, 4.36 ]
RAPID2 2007 3/246 4/125 41.9 % 0.34 [ 0.07, 1.67 ]
Total (95% CI) 331 202 100.0 % 0.69 [ 0.25, 1.92 ]
Total events: 8 (Certolizumab pegol 400 mg), 8 (Control)
Heterogeneity: Chi2 = 1.28, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 9.35. Comparison 9 Safety, certolizumab 400 mg, Outcome 35 AST increased.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 35 AST increased
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 6/246 5/125 100.0 % 0.58 [ 0.16, 2.07 ]
Total (95% CI) 246 125 100.0 % 0.58 [ 0.16, 2.07 ]
Total events: 6 (Certolizumab pegol 400 mg), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Not applicable
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Favours certolizumab pego Favours control
Analysis 9.36. Comparison 9 Safety, certolizumab 400 mg, Outcome 36 ALT increased.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 36 ALT increased
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 8/246 6/127 100.0 % 0.67 [ 0.22, 2.05 ]
Total (95% CI) 246 127 100.0 % 0.67 [ 0.22, 2.05 ]
Total events: 8 (Certolizumab pegol 400 mg), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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161Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 9.37. Comparison 9 Safety, certolizumab 400 mg, Outcome 37 Herpes viral infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 37 Herpes viral infection
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 1/389 0/199 100.0 % 4.53 [ 0.07, 285.35 ]
Total (95% CI) 389 199 100.0 % 4.53 [ 0.07, 285.35 ]
Total events: 1 (Certolizumab pegol 400 mg), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Favours certolizumab pego Favours control
Analysis 9.38. Comparison 9 Safety, certolizumab 400 mg, Outcome 38 Bacterial peritonitis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 38 Bacterial peritonitis
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 0/389 0/199 Not estimable
Total (95% CI) 389 199 Not estimable
Total events: 0 (Certolizumab pegol 400 mg), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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162Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 9.39. Comparison 9 Safety, certolizumab 400 mg, Outcome 39 Opportunistic infections.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 39 Opportunistic infections
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 0/389 0/199 Not estimable
Total (95% CI) 389 199 Not estimable
Total events: 0 (Certolizumab pegol 400 mg), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 9.40. Comparison 9 Safety, certolizumab 400 mg, Outcome 40 Infections and infestations.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 40 Infections and infestations
Study or subgroup
Certolizumab








CDP870-014 2009 33/124 17/119 19.3 % 1.86 [ 1.10, 3.16 ]
NCT00791999 JRAPID 23/85 16/77 18.0 % 1.30 [ 0.74, 2.28 ]
RAPID1 2005 184/389 52/199 37.4 % 1.81 [ 1.40, 2.34 ]
RAPID2 2007 53/246 26/125 25.3 % 1.04 [ 0.68, 1.57 ]
Total (95% CI) 844 520 100.0 % 1.49 [ 1.11, 1.99 ]
Total events: 293 (Certolizumab pegol 400 mg), 111 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 5.84, df = 3 (P = 0.12); I2 =49%
Test for overall effect: Z = 2.67 (P = 0.0076)
Test for subgroup differences: Not applicable
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163Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 9.41. Comparison 9 Safety, certolizumab 400 mg, Outcome 41 Nasopharyngitis/Pharyngitis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CDP870-014 2009 15/124 8/119 27.6 % 1.87 [ 0.79, 4.40 ]
NCT00791999 JRAPID 15/85 12/77 29.8 % 1.16 [ 0.51, 2.64 ]
RAPID1 2005 30/389 3/199 36.8 % 3.22 [ 1.53, 6.76 ]
RAPID2 2007 4/246 1/125 5.8 % 1.86 [ 0.29, 11.99 ]
Total (95% CI) 844 520 100.0 % 1.98 [ 1.26, 3.11 ]
Total events: 64 (Certolizumab pegol 400 mg), 24 (Control)
Heterogeneity: Chi2 = 3.29, df = 3 (P = 0.35); I2 =9%
Test for overall effect: Z = 2.97 (P = 0.0029)
Test for subgroup differences: Not applicable
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164Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 9.42. Comparison 9 Safety, certolizumab 400 mg, Outcome 42 Gastrointestinal disorders.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 42 Gastrointestinal disorders
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CDP870-014 2009 22/124 19/119 97.4 % 1.13 [ 0.58, 2.22 ]
RAPID1 2005 0/389 1/199 2.6 % 0.05 [ 0.00, 3.28 ]
Total (95% CI) 513 318 100.0 % 1.05 [ 0.54, 2.03 ]
Total events: 22 (Certolizumab pegol 400 mg), 20 (Control)
Heterogeneity: Chi2 = 2.07, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 9.43. Comparison 9 Safety, certolizumab 400 mg, Outcome 43 Hematologic abnormalities.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 43 Hematologic abnormalities
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00791999 JRAPID (1) 1/85 0/77 18.3 % 6.73 [ 0.13, 340.56 ]
RAPID1 2005 3/389 2/199 81.7 % 0.76 [ 0.12, 4.86 ]
Total (95% CI) 474 276 100.0 % 1.13 [ 0.21, 6.07 ]
Total events: 4 (Certolizumab pegol 400 mg), 2 (Control)
Heterogeneity: Chi2 = 0.97, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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165Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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(1) 1 patinet with bone marrow failure
Analysis 9.44. Comparison 9 Safety, certolizumab 400 mg, Outcome 44 Decreased Haemoglobin.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 44 Decreased Haemoglobin
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 1/389 1/199 100.0 % 0.49 [ 0.03, 9.10 ]
Total (95% CI) 389 199 100.0 % 0.49 [ 0.03, 9.10 ]
Total events: 1 (Certolizumab pegol 400 mg), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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166Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 9.45. Comparison 9 Safety, certolizumab 400 mg, Outcome 45 Increased platelet count.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 45 Increased platelet count
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 2/389 1/199 100.0 % 1.02 [ 0.09, 11.23 ]
Total (95% CI) 389 199 100.0 % 1.02 [ 0.09, 11.23 ]
Total events: 2 (Certolizumab pegol 400 mg), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 9.46. Comparison 9 Safety, certolizumab 400 mg, Outcome 46 Skin and subcutaneous tissue
disorders.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 46 Skin and subcutaneous tissue disorders
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00791999 JRAPID 6/85 4/77 100.0 % 1.38 [ 0.38, 4.94 ]
Total (95% CI) 85 77 100.0 % 1.38 [ 0.38, 4.94 ]
Total events: 6 (Certolizumab pegol 400 mg), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable
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167Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 9.47. Comparison 9 Safety, certolizumab 400 mg, Outcome 47 Acute miocardial infarction.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 47 Acute miocardial infarction
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00791999 JRAPID 1/85 0/77 100.0 % 6.73 [ 0.13, 340.56 ]
Total (95% CI) 85 77 100.0 % 6.73 [ 0.13, 340.56 ]
Total events: 1 (Certolizumab pegol 400 mg), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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Favours certolizumab pego Favours control
Analysis 9.48. Comparison 9 Safety, certolizumab 400 mg, Outcome 48 Corneal Perforation.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 48 Corneal Perforation
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00791999 JRAPID 1/85 0/77 100.0 % 6.73 [ 0.13, 340.56 ]
Total (95% CI) 85 77 100.0 % 6.73 [ 0.13, 340.56 ]
Total events: 1 (Certolizumab pegol 400 mg), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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168Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
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Analysis 9.49. Comparison 9 Safety, certolizumab 400 mg, Outcome 49 Conjunctivitis allergic.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety, certolizumab 400 mg
Outcome: 49 Conjunctivitis allergic
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00791999 JRAPID 1/85 0/77 100.0 % 6.73 [ 0.13, 340.56 ]
Total (95% CI) 85 77 100.0 % 6.73 [ 0.13, 340.56 ]
Total events: 1 (Certolizumab pegol 400 mg), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 9.50. Comparison 9 Safety, certolizumab 400 mg, Outcome 50 Periodontitis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults




pegol 400 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
NCT00791999 JRAPID 2/82 2/77 100.0 % 0.94 [ 0.14, 6.50 ]
Total (95% CI) 82 77 100.0 % 0.94 [ 0.14, 6.50 ]
Total events: 2 (Certolizumab pegol 400 mg), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 9.51. Comparison 9 Safety, certolizumab 400 mg, Outcome 51 Fatigue.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CDP870-004 2001 9/124 6/119 100.0 % 1.46 [ 0.52, 4.15 ]
Total (95% CI) 124 119 100.0 % 1.46 [ 0.52, 4.15 ]
Total events: 9 (Certolizumab pegol 400 mg), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 10.1. Comparison 10 Mean HAQ-DI from baseline at week 12, Outcome 1 certolizumab pegol 200
mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 10 Mean HAQ-DI from baseline at week 12
Outcome: 1 certolizumab pegol 200 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
REALISTIC 2008 851 -0.43 (0.02) 212 -0.21 (0.04) 100.0 % -0.22 [ -0.23, -0.21 ]
Total (95% CI) 851 212 100.0 % -0.22 [ -0.23, -0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 77.70 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 11.1. Comparison 11 Mean HAQ-DI from baseline at week 24, Outcome 1 certolizumab pegol 200
mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 11 Mean HAQ-DI from baseline at week 24
Outcome: 1 certolizumab pegol 200 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
RAPID1 2005 393 -0.58 (0.59) 199 -0.17 (0.56) 33.9 % -0.41 [ -0.51, -0.31 ]
NCT00993317 81 -0.54 (0.51) 40 -0.17 (0.7) 9.6 % -0.37 [ -0.61, -0.13 ]
RAPID2 2007 246 -0.5 (0.47) 127 -0.14 (0.45) 33.7 % -0.36 [ -0.46, -0.26 ]
CERTAIN 2008 91 -0.25 (0.46) 91 -0.03 (0.49) 22.8 % -0.22 [ -0.36, -0.08 ]
Total (95% CI) 811 457 100.0 % -0.35 [ -0.43, -0.26 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.92, df = 3 (P = 0.18); I2 =39%
Test for overall effect: Z = 8.32 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 11.2. Comparison 11 Mean HAQ-DI from baseline at week 24, Outcome 2 certolizumab 400 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 11 Mean HAQ-DI from baseline at week 24
Outcome: 2 certolizumab 400 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CDP870-014 2009 (1) 124 -0.32 (0.7) 119 -0.09 (0.15) 23.2 % -0.23 [ -0.36, -0.10 ]
FAST4WARD 2005 (2) 111 -0.36 (0.51) 109 0.13 (0.51) 22.0 % -0.49 [ -0.62, -0.36 ]
RAPID1 2005 390 -0.6 (0.59) 199 -0.17 (0.56) 27.4 % -0.43 [ -0.53, -0.33 ]
RAPID2 2007 246 -0.5 (0.47) 127 -0.14 (0.45) 27.4 % -0.36 [ -0.46, -0.26 ]
Total (95% CI) 871 554 100.0 % -0.38 [ -0.48, -0.28 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 9.17, df = 3 (P = 0.03); I2 =67%
Test for overall effect: Z = 7.53 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
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(1) In CDP870-014 we have obtained standard deviations from p values according to the Handbook section 7.7.3.7. calculating t values , EE and finally SD
(2) In FAST4WARD we have obtained standard deviations from p values according to the Handbook section 7.7.3.7
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Analysis 12.1. Comparison 12 HAQ-DI at 24 weeks, any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 12 HAQ-DI at 24 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 certolizumab pegol 200 mg sc
CERTAIN 2008 91 -0.25 (0.46) 91 -0.03 (0.49) 13.3 % -0.22 [ -0.36, -0.08 ]
RAPID1 2005 393 -0.58 (0.59) 100 -0.17 (0.56) 14.7 % -0.41 [ -0.53, -0.29 ]
RAPID2 2007 246 -0.5 (0.47) 64 -0.14 (0.45) 14.6 % -0.36 [ -0.48, -0.24 ]
Subtotal (95% CI) 730 255 42.7 % -0.33 [ -0.44, -0.23 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.21, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 6.05 (P < 0.00001)
2 certolizumab pegol 400 mg sc
CDP870-014 2009 (1) 124 -0.32 (0.7) 119 -0.09 (0.15) 14.5 % -0.23 [ -0.36, -0.10 ]
FAST4WARD 2005 111 -0.36 (0.51) 109 0.13 (0.51) 13.7 % -0.49 [ -0.62, -0.36 ]
RAPID1 2005 390 -0.6 (0.59) 99 -0.17 (0.56) 14.6 % -0.43 [ -0.55, -0.31 ]
RAPID2 2007 246 -0.5 (0.47) 63 -0.14 (0.45) 14.5 % -0.36 [ -0.49, -0.23 ]
Subtotal (95% CI) 871 390 57.3 % -0.38 [ -0.48, -0.27 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 8.67, df = 3 (P = 0.03); I2 =65%
Test for overall effect: Z = 6.79 (P < 0.00001)
Total (95% CI) 1601 645 100.0 % -0.36 [ -0.43, -0.29 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 13.43, df = 6 (P = 0.04); I2 =55%
Test for overall effect: Z = 9.67 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.30, df = 1 (P = 0.59), I2 =0.0%
-0.5 -0.25 0 0.25 0.5
Favours certolizumab pego Favours control
(1) In CDP870-014 we have obtained standard deviations from p values according to the Handbook section 7.7.3.7. calculating t values , EE and finally SD
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Analysis 13.1. Comparison 13 HAQ-DI at 52 weeks, any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 13 HAQ-DI at 52 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab pegol 200 mg sc
RAPID1 2005 393 -0.6 (0.59) 100 -0.18 (0.56) 50.2 % -0.42 [ -0.54, -0.30 ]
Subtotal (95% CI) 393 100 50.2 % -0.42 [ -0.54, -0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.62 (P < 0.00001)
2 certolizumab pegol 400 mg sc
RAPID1 2005 390 -0.63 (0.59) 99 -0.18 (0.56) 49.8 % -0.45 [ -0.57, -0.33 ]
Subtotal (95% CI) 390 99 49.8 % -0.45 [ -0.57, -0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.06 (P < 0.00001)
Total (95% CI) 783 199 100.0 % -0.43 [ -0.52, -0.35 ]
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 9.68 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
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Analysis 14.1. Comparison 14 SF-36 Physical Component Summary (PCS), week 24, Outcome 1
certolizumab pegol 200 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 14 SF-36 Physical Component Summary (PCS), week 24
Outcome: 1 certolizumab pegol 200 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CERTAIN 2008 82 6 (7.5) 82 1.7 (7.56) 20.9 % 4.30 [ 2.00, 6.60 ]
RAPID1 2005 393 7.7 (7.93) 199 1.8 (8.46) 45.6 % 5.90 [ 4.49, 7.31 ]
RAPID2 2007 246 5.23 (8.31) 127 0.93 (8) 33.5 % 4.30 [ 2.56, 6.04 ]
Total (95% CI) 721 408 100.0 % 5.03 [ 3.90, 6.16 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 2.51, df = 2 (P = 0.29); I2 =20%
Test for overall effect: Z = 8.72 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 14.2. Comparison 14 SF-36 Physical Component Summary (PCS), week 24, Outcome 2
certolizumab pegol 400 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 14 SF-36 Physical Component Summary (PCS), week 24
Outcome: 2 certolizumab pegol 400 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CDP870-014 2009 (1) 124 8.44 (19.76) 119 3.44 (8.07) 12.4 % 5.00 [ 1.23, 8.77 ]
RAPID1 2005 390 8.3 (7.9) 199 1.8 (8.46) 48.5 % 6.50 [ 5.09, 7.91 ]
RAPID2 2007 246 5.46 (8.31) 127 0.93 (8) 39.1 % 4.53 [ 2.79, 6.27 ]
Total (95% CI) 760 445 100.0 % 5.54 [ 4.11, 6.97 ]
Heterogeneity: Tau2 = 0.58; Chi2 = 3.10, df = 2 (P = 0.21); I2 =36%
Test for overall effect: Z = 7.60 (P < 0.00001)
Test for subgroup differences: Not applicable
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Favours control Favours certolizumab pego
(1) Calculating SD according to Handbook from p values
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Analysis 15.1. Comparison 15 SF-36 Mental Component Summary (MCS), week 24, Outcome 1
certolizumab pegol 200 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 15 SF-36 Mental Component Summary (MCS), week 24
Outcome: 1 certolizumab pegol 200 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
RAPID1 2005 393 6.3 (11.89) 199 2.3 (11.29) 56.9 % 4.00 [ 2.04, 5.96 ]
RAPID2 2007 246 6.05 (10.82) 127 1.63 (10.36) 43.1 % 4.42 [ 2.17, 6.67 ]
Total (95% CI) 639 326 100.0 % 4.18 [ 2.70, 5.66 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 5.54 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 15.2. Comparison 15 SF-36 Mental Component Summary (MCS), week 24, Outcome 2
certolizumab pegol 400 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 15 SF-36 Mental Component Summary (MCS), week 24
Outcome: 2 certolizumab pegol 400 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CDP870-014 2009 (1) 124 4.6 (13.87) 119 1.58 (4.76) 24.7 % 3.02 [ 0.43, 5.61 ]
RAPID1 2005 390 6.5 (11.85) 199 2.3 (11.29) 43.0 % 4.20 [ 2.24, 6.16 ]
RAPID2 2007 246 6.28 (10.98) 127 1.63 (10.36) 32.2 % 4.65 [ 2.39, 6.91 ]
Total (95% CI) 760 445 100.0 % 4.05 [ 2.77, 5.34 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.90, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 6.18 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) Calculating SD according to Handbook from p values
Analysis 16.1. Comparison 16 SF-36 Physical Component Summary (PCS), week 52, Outcome 1
certolizumab 200 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 16 SF-36 Physical Component Summary (PCS), week 52
Outcome: 1 certolizumab 200 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 393 7.79 (8.72) 199 1.73 (8.61) 100.0 % 6.06 [ 4.59, 7.53 ]
Total (95% CI) 393 199 100.0 % 6.06 [ 4.59, 7.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.05 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 16.2. Comparison 16 SF-36 Physical Component Summary (PCS), week 52, Outcome 2
certolizumab 400 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 16 SF-36 Physical Component Summary (PCS), week 52
Outcome: 2 certolizumab 400 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 390 8.61 (8.49) 199 1.73 (8.61) 100.0 % 6.88 [ 5.42, 8.34 ]
Total (95% CI) 390 199 100.0 % 6.88 [ 5.42, 8.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.22 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours control Favours certolizumab pego
179Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 17.1. Comparison 17 SF-36 Mental Component Summary (MCS), week 52, Outcome 1
certolizumab pegol 200 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 17 SF-36 Mental Component Summary (MCS), week 52
Outcome: 1 certolizumab pegol 200 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 393 6.35 (11.1) 199 2.05 (11.14) 100.0 % 4.30 [ 2.40, 6.20 ]
Total (95% CI) 393 199 100.0 % 4.30 [ 2.40, 6.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.44 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 17.2. Comparison 17 SF-36 Mental Component Summary (MCS), week 52, Outcome 2
certolizumab pegol 400 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 17 SF-36 Mental Component Summary (MCS), week 52
Outcome: 2 certolizumab pegol 400 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 390 6.35 (11.06) 199 2.05 (11.14) 100.0 % 4.30 [ 2.40, 6.20 ]
Total (95% CI) 390 199 100.0 % 4.30 [ 2.40, 6.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.44 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 18.1. Comparison 18 SF-36 Physical Component Summary (PCS) at week 24, any dose, Outcome
1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 18 SF-36 Physical Component Summary (PCS) at week 24, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 certolizumab pegol 200 mg sc
CERTAIN 2008 82 6 (7.5) 82 1.7 (7.56) 15.9 % 4.30 [ 2.00, 6.60 ]
RAPID1 2005 393 7.7 (7.93) 100 1.8 (8.46) 25.1 % 5.90 [ 4.07, 7.73 ]
RAPID2 2007 246 5.23 (8.31) 64 0.93 (8) 17.2 % 4.30 [ 2.08, 6.52 ]
Subtotal (95% CI) 721 246 58.2 % 4.99 [ 3.79, 6.20 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.66, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 8.12 (P < 0.00001)
2 certolizumab pegol 400 mg sc
RAPID1 2005 390 8.3 (7.9) 99 1.8 (8.46) 24.9 % 6.50 [ 4.66, 8.34 ]
RAPID2 2007 246 5.46 (8.31) 63 0.93 (8) 17.0 % 4.53 [ 2.30, 6.76 ]
Subtotal (95% CI) 636 162 41.8 % 5.62 [ 3.70, 7.54 ]
Heterogeneity: Tau2 = 0.85; Chi2 = 1.78, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 5.74 (P < 0.00001)
Total (95% CI) 1357 408 100.0 % 5.29 [ 4.37, 6.21 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.00, df = 4 (P = 0.41); I2 =0%
Test for overall effect: Z = 11.28 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.30, df = 1 (P = 0.59), I2 =0.0%
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Analysis 19.1. Comparison 19 SF-36 Mental Component Summary (MCS) at week 24, any dose, Outcome 1
Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 19 SF-36 Mental Component Summary (MCS) at week 24, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 certolizumab pegol 200 mg sc
CERTAIN 2008 83 5.2 (8.43) 85 1.2 (7.72) 19.1 % 4.00 [ 1.55, 6.45 ]
RAPID1 2005 393 6.3 (11.89) 100 2.3 (11.29) 18.2 % 4.00 [ 1.49, 6.51 ]
RAPID2 2007 246 6.05 (10.82) 64 1.63 (10.36) 13.8 % 4.42 [ 1.54, 7.30 ]
Subtotal (95% CI) 722 249 51.2 % 4.11 [ 2.62, 5.61 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 2 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 5.39 (P < 0.00001)
2 certolizumab pegol 400 mg sc
CDP870-014 2009 (1) 124 4.6 (13.87) 119 1.58 (4.76) 17.1 % 3.02 [ 0.43, 5.61 ]
RAPID1 2005 390 6.5 (11.85) 99 2.3 (11.29) 18.1 % 4.20 [ 1.68, 6.72 ]
RAPID2 2007 246 6.28 (10.98) 63 1.63 (10.36) 13.6 % 4.65 [ 1.75, 7.55 ]
Subtotal (95% CI) 760 281 48.8 % 3.91 [ 2.38, 5.44 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.76, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 5.00 (P < 0.00001)
Total (95% CI) 1482 530 100.0 % 4.01 [ 2.94, 5.08 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 5 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 7.35 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.85), I2 =0.0%
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Analysis 20.1. Comparison 20 SF-36 Physical Component Summary (PCS) at week 52, any dose, Outcome
1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 20 SF-36 Physical Component Summary (PCS) at week 52, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab pegol 200 mg sc
RAPID1 2005 393 7.79 (8.72) 100 1.73 (8.61) 50.0 % 6.06 [ 4.17, 7.95 ]
Subtotal (95% CI) 393 100 50.0 % 6.06 [ 4.17, 7.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.27 (P < 0.00001)
2 certolizumab pegol 400 mg sc
RAPID1 2005 390 8.61 (8.49) 99 1.73 (8.61) 50.0 % 6.88 [ 4.99, 8.77 ]
Subtotal (95% CI) 390 99 50.0 % 6.88 [ 4.99, 8.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.12 (P < 0.00001)
Total (95% CI) 783 199 100.0 % 6.47 [ 5.13, 7.81 ]
Heterogeneity: Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 9.47 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.36, df = 1 (P = 0.55), I2 =0.0%
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Analysis 21.1. Comparison 21 SF-36 Mental Component Summary (MCS) at week 52, any dose, Outcome 1
Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 21 SF-36 Mental Component Summary (MCS) at week 52, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab pegol 200 mg sc
RAPID1 2005 393 6.35 (11.1) 100 2.05 (11.14) 50.2 % 4.30 [ 1.86, 6.74 ]
Subtotal (95% CI) 393 100 50.2 % 4.30 [ 1.86, 6.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.45 (P = 0.00056)
2 certolizumab pegol 400 mg sc
RAPID1 2005 390 6.35 (11.06) 99 2.05 (11.14) 49.8 % 4.30 [ 1.85, 6.75 ]
Subtotal (95% CI) 390 99 49.8 % 4.30 [ 1.85, 6.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.43 (P = 0.00059)
Total (95% CI) 783 199 100.0 % 4.30 [ 2.57, 6.03 ]
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 4.87 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 1.00), I2 =0.0%
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Analysis 22.1. Comparison 22 Disease Activity Score (DAS-28) (ESR) remission (< 2.6) at 12 weeks,
Outcome 1 Proportion of patients achieving remission 12 weeks certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 22 Disease Activity Score (DAS-28) (ESR) remission (< 2.6) at 12 weeks
Outcome: 1 Proportion of patients achieving remission 12 weeks certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
REALISTIC 2008 136/851 12/212 100.0 % 2.36 [ 1.53, 3.65 ]
Total (95% CI) 851 212 100.0 % 2.36 [ 1.53, 3.65 ]
Total events: 136 (Certolizumab pegol 200 mg), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.88 (P = 0.00010)
Test for subgroup differences: Not applicable
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Analysis 23.1. Comparison 23 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any dose, 24 weeks,
Outcome 1 Proportion of patients achieving remission 24 weeks.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 23 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any dose, 24 weeks
Outcome: 1 Proportion of patients achieving remission 24 weeks








1 certolizumab pegol 200 mg sc
CERTAIN 2008 19/96 3/98 20.8 % 6.47 [ 1.98, 21.14 ]
NCT00791921 HIKARI 19/116 1/114 7.3 % 18.67 [ 2.54, 137.17 ]
RAPID1 2005 (1) 45/391 3/100 22.1 % 3.84 [ 1.22, 12.09 ]
RAPID2 2007 (2) 23/245 1/62 7.4 % 5.82 [ 0.80, 42.27 ]
Subtotal (95% CI) 848 374 57.6 % 5.97 [ 2.93, 12.17 ]
Total events: 106 (Certolizumab pegol), 8 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.87, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 4.93 (P < 0.00001)
2 certolizumab pegol 400 mg sc
CDP870-014 2009 9/126 2/121 12.7 % 4.32 [ 0.95, 19.60 ]
RAPID1 2005 (3) 50/387 3/99 22.3 % 4.26 [ 1.36, 13.38 ]
RAPID2 2007 (4) 21/246 1/63 7.4 % 5.38 [ 0.74, 39.22 ]
Subtotal (95% CI) 759 283 42.4 % 4.46 [ 1.95, 10.21 ]
Total events: 80 (Certolizumab pegol), 6 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 3.53 (P = 0.00041)
Total (95% CI) 1607 657 100.0 % 5.28 [ 3.08, 9.05 ]
Total events: 186 (Certolizumab pegol), 14 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.19, df = 6 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 6.04 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.28, df = 1 (P = 0.60), I2 =0.0%
0.01 0.1 1 10 100
Favours control Favours certolizumab pego
(1) UCB report for NICE quoted Certolizumab n=391 and placebo n=196
(2) In NICE report UCB quoted certoluzimab n= 245 and placebo n =125
(3) In NICE report UCB quoted Certolizumab n= 387 and placebo n = 196
(4) In NICE report UCB quoted placebo n =125
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Analysis 24.1. Comparison 24 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any dose, 52 weeks,
Outcome 1 Proportion of patients achieving remission 52 weeks.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 24 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any dose, 52 weeks
Outcome: 1 Proportion of patients achieving remission 52 weeks
Study or subgroup Certolizumab pegol Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 certolizumab pegol 200 mg sc
RAPID1 2005 (1) 62/391 3/100 50.0 % 5.29 [ 1.69, 16.49 ]
Subtotal (95% CI) 391 100 50.0 % 5.29 [ 1.69, 16.49 ]
Total events: 62 (Certolizumab pegol), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.87 (P = 0.0041)
2 certolizumab pegol 400 mg sc
RAPID1 2005 (2) 74/387 3/99 50.0 % 6.31 [ 2.03, 19.59 ]
Subtotal (95% CI) 387 99 50.0 % 6.31 [ 2.03, 19.59 ]
Total events: 74 (Certolizumab pegol), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.19 (P = 0.0014)
Total (95% CI) 778 199 100.0 % 5.80 [ 2.60, 12.94 ]
Total events: 136 (Certolizumab pegol), 6 (Control)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 4.29 (P = 0.000018)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.83), I2 =0.0%
0.01 0.1 1 10 100
Favours control Favours certolizumab pego
(1) In NICE report UCB quoted placebo certoluzimab n= 391 and placebo n =196
(2) UCB report for NICE quoted Certolizumab n=387
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Analysis 25.1. Comparison 25 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time, Outcome
1 Proportion of patients achieving remission 12 weeks certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 25 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time
Outcome: 1 Proportion of patients achieving remission 12 weeks certolizumab 200 mg
Study or subgroup
Certolizumab
pegol 200 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
REALISTIC 2008 136/851 12/212 100.0 % 2.82 [ 1.60, 5.00 ]
Total (95% CI) 851 212 100.0 % 2.82 [ 1.60, 5.00 ]
Total events: 136 (Certolizumab pegol 200 mg), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.56 (P = 0.00036)
Test for subgroup differences: Not applicable
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Analysis 25.2. Comparison 25 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time, Outcome
2 Proportion of patients achieving remission 24 weeks certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 25 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time
Outcome: 2 Proportion of patients achieving remission 24 weeks certolizumab 200 mg
Study or subgroup
Certolizumab








CERTAIN 2008 19/96 3/98 36.3 % 6.47 [ 1.98, 21.14 ]
RAPID1 2005 (1) 45/391 3/196 38.1 % 7.52 [ 2.37, 23.89 ]
RAPID2 2007 (2) 23/245 1/125 12.8 % 11.73 [ 1.60, 85.89 ]
NCT00791921 HIKARI 19/116 1/114 12.8 % 18.67 [ 2.54, 137.17 ]
Total (95% CI) 848 533 100.0 % 8.47 [ 4.15, 17.28 ]
Total events: 106 (Certolizumab pegol 200 mg), 8 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.97, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 5.87 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours certolizumab pego
(1) UCB report for NICE quote Certolizumab n=391
(2) UCB report for NICE quote Certolizumab n=245
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Analysis 25.3. Comparison 25 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time, Outcome
3 Proportion of patients achieving remission 24 weeks certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 25 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time
Outcome: 3 Proportion of patients achieving remission 24 weeks certolizumab 400 mg
Study or subgroup
Certolizumab








CDP870-014 2009 9/126 2/121 30.3 % 4.32 [ 0.95, 19.60 ]
RAPID1 2005 (1) 50/387 3/196 52.2 % 8.44 [ 2.67, 26.72 ]
RAPID2 2007 21/246 1/125 17.4 % 10.67 [ 1.45, 78.41 ]
Total (95% CI) 759 442 100.0 % 7.18 [ 3.12, 16.50 ]
Total events: 80 (Certolizumab 400 mg), 6 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 4.64 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours certolizumab 400 mg sc
(1) UCB report for NICE quote Certolizumab n=387
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Analysis 25.4. Comparison 25 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time, Outcome
4 Proportion of patients achieving remission 52 weeks certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 25 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time
Outcome: 4 Proportion of patients achieving remission 52 weeks certolizumab 200 mg
Study or subgroup
Certolizumab
pegol 200 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 (1) 62/391 3/196 100.0 % 10.36 [ 3.29, 32.58 ]
Total (95% CI) 391 196 100.0 % 10.36 [ 3.29, 32.58 ]
Total events: 62 (Certolizumab pegol 200 mg), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.00 (P = 0.000064)
Test for subgroup differences: Not applicable
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(1) UCB report for NICE quote Certolizumab n=391
Analysis 25.5. Comparison 25 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time, Outcome
5 Proportion of patients achieving remission 52 weeks certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 25 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time
Outcome: 5 Proportion of patients achieving remission 52 weeks certolizumab 400 mg
Study or subgroup
Certolizumab
pegol 400 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 (1) 74/387 3/196 100.0 % 12.49 [ 3.99, 39.12 ]
Total (95% CI) 387 196 100.0 % 12.49 [ 3.99, 39.12 ]
Total events: 74 (Certolizumab pegol 400 mg), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.34 (P = 0.000015)
Test for subgroup differences: Not applicable
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(1) UCB report for NICE quote Certolizumab n=387
Analysis 26.1. Comparison 26 DAS-28 at 12 weeks, 200 mg certolizumab, Outcome 1 DAS 28 (ESR) change
from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 26 DAS-28 at 12 weeks, 200 mg certolizumab








N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
REALISTIC 2008 851 -1.64 (0) 212 -0.78 (0) Not estimable
Total (95% CI) 851 212 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 27.1. Comparison 27 DAS-28 at 24 weeks, 400 mg certolizumab, Outcome 1 DAS 28 (ESR) change
from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 27 DAS-28 at 24 weeks, 400 mg certolizumab
Outcome: 1 DAS 28 (ESR) change from baseline
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
FAST4WARD 2005 111 -1.5 (2) 109 -0.6 (2) 47.5 % -0.90 [ -1.43, -0.37 ]
RAPID2 2007 246 -2.46 (1.31) 127 -0.5 (1.05) 52.5 % -1.96 [ -2.21, -1.71 ]
Total (95% CI) 357 236 100.0 % -1.46 [ -2.49, -0.42 ]
Heterogeneity: Tau2 = 0.52; Chi2 = 12.71, df = 1 (P = 0.00036); I2 =92%
Test for overall effect: Z = 2.75 (P = 0.0059)
Test for subgroup differences: Not applicable
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Analysis 28.1. Comparison 28 DAS-28 at week 52, certolizumab 200 mg, Outcome 1 DAS 28 (ESR) Change
from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 28 DAS-28 at week 52, certolizumab 200 mg
Outcome: 1 DAS 28 (ESR) Change from baseline
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 393 -3.3 (1.3) 199 -2.4 (1.3) 100.0 % -0.90 [ -1.12, -0.68 ]
Total (95% CI) 393 199 100.0 % -0.90 [ -1.12, -0.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.96 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 29.1. Comparison 29 DAS-28 at week 52, certolizumab 400 mg, Outcome 1 DAS 28 (ESR) Change
from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 29 DAS-28 at week 52, certolizumab 400 mg
Outcome: 1 DAS 28 (ESR) Change from baseline
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 390 -3.4 (1.4) 199 -2.4 (1.3) 100.0 % -1.00 [ -1.23, -0.77 ]
Total (95% CI) 390 199 100.0 % -1.00 [ -1.23, -0.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.60 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 30.1. Comparison 30 DAS-28 at 24 weeks, any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 30 DAS-28 at 24 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 certolizumab pegol 200 mg sc
RAPID2 2007 246 -2.27 (1.38) 64 -0.5 (1.05) 35.7 % -1.77 [ -2.08, -1.46 ]
Subtotal (95% CI) 246 64 35.7 % -1.77 [ -2.08, -1.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 11.20 (P < 0.00001)
2 certolizumab pegol 400 mg sc
FAST4WARD 2005 111 -1.5 (2) 109 -0.6 (2) 28.6 % -0.90 [ -1.43, -0.37 ]
RAPID2 2007 246 -2.46 (1.31) 63 -0.5 (1.05) 35.8 % -1.96 [ -2.27, -1.65 ]
Subtotal (95% CI) 357 172 64.3 % -1.45 [ -2.49, -0.41 ]
Heterogeneity: Tau2 = 0.51; Chi2 = 11.56, df = 1 (P = 0.00067); I2 =91%
Test for overall effect: Z = 2.74 (P = 0.0061)
Total (95% CI) 603 236 100.0 % -1.59 [ -2.10, -1.08 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 11.70, df = 2 (P = 0.003); I2 =83%
Test for overall effect: Z = 6.07 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.33, df = 1 (P = 0.57), I2 =0.0%
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Analysis 31.1. Comparison 31 DAS-28 at 52 weeks, any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 31 DAS-28 at 52 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab pegol 200 mg sc
RAPID1 2005 393 -3.3 (1.3) 100 -2.4 (1.3) 51.0 % -0.90 [ -1.19, -0.61 ]
Subtotal (95% CI) 393 100 51.0 % -0.90 [ -1.19, -0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.18 (P < 0.00001)
2 certolizumab pegol 400 mg sc
RAPID1 2005 390 -3.4 (1.4) 99 -2.4 (1.3) 49.0 % -1.00 [ -1.29, -0.71 ]
Subtotal (95% CI) 390 99 49.0 % -1.00 [ -1.29, -0.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.73 (P < 0.00001)
Total (95% CI) 783 199 100.0 % -0.95 [ -1.15, -0.75 ]
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 9.12 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.23, df = 1 (P = 0.63), I2 =0.0%
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Analysis 32.1. Comparison 32 DAS-28 at 24 weeks, 200 mg certolizumab, Outcome 1 DAS 28 (ESR) change
from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 32 DAS-28 at 24 weeks, 200 mg certolizumab
Outcome: 1 DAS 28 (ESR) change from baseline
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID2 2007 246 -2.27 (1.38) 127 -0.5 (1.05) 100.0 % -1.77 [ -2.02, -1.52 ]
Total (95% CI) 246 127 100.0 % -1.77 [ -2.02, -1.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 13.81 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 33.1. Comparison 33 Erosion score (ES), Outcome 1 Change from the baseline mean ES at week
24, certolizumab pegol 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 33 Erosion score (ES)
Outcome: 1 Change from the baseline mean ES at week 24, certolizumab pegol 200 mg
Study or subgroup
Certolizumab







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 353 0 (1.5) 180 0.7 (2.1) 61.6 % -0.41 [ -0.59, -0.22 ]
RAPID2 2007 214 0.1 (2) 112 0.7 (2.6) 38.4 % -0.27 [ -0.50, -0.04 ]
Total (95% CI) 567 292 100.0 % -0.35 [ -0.50, -0.21 ]
Heterogeneity: Chi2 = 0.83, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 4.86 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours certolizumab pego Favours control
197Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 33.2. Comparison 33 Erosion score (ES), Outcome 2 Change from the baseline mean ES at week
24, certolizumab pegol 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 33 Erosion score (ES)
Outcome: 2 Change from the baseline mean ES at week 24, certolizumab pegol 400 mg





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
RAPID1 2005 355 0.1 (2.4) 180 0.7 (2.1) 60.7 % -0.60 [ -1.00, -0.20 ]
RAPID2 2007 222 -0.3 (1.8) 112 0.7 (2.6) 39.3 % -1.00 [ -1.54, -0.46 ]
Total (95% CI) 577 292 100.0 % -0.76 [ -1.14, -0.37 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 1.38, df = 1 (P = 0.24); I2 =28%
Test for overall effect: Z = 3.88 (P = 0.00011)
Test for subgroup differences: Not applicable
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Analysis 33.3. Comparison 33 Erosion score (ES), Outcome 3 Change from the baseline mean ES at week
52, certolizumab pegol 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 33 Erosion score (ES)
Outcome: 3 Change from the baseline mean ES at week 52, certolizumab pegol 200 mg





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 364 0.1 (2.5) 180 1.5 (4.3) 100.0 % -1.40 [ -2.08, -0.72 ]
Total (95% CI) 364 180 100.0 % -1.40 [ -2.08, -0.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.04 (P = 0.000053)
Test for subgroup differences: Not applicable
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Analysis 33.4. Comparison 33 Erosion score (ES), Outcome 4 Change from the baseline mean ES at week
52, certolizumab pegol 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 33 Erosion score (ES)
Outcome: 4 Change from the baseline mean ES at week 52, certolizumab pegol 400 mg





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 363 0 (3) 180 1.5 (4.3) 100.0 % -1.50 [ -2.20, -0.80 ]
Total (95% CI) 363 180 100.0 % -1.50 [ -2.20, -0.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.20 (P = 0.000027)
Test for subgroup differences: Not applicable
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Analysis 34.1. Comparison 34 Erosion score (ES) at 24 weeks, any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 34 Erosion score (ES) at 24 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 certolizumab pegol 200 mg sc
RAPID1 2005 353 0 (1.5) 91 0.7 (2.1) 37.9 % -0.70 [ -1.16, -0.24 ]
RAPID2 2007 214 0.1 (2) 56 0.7 (2.6) 14.9 % -0.60 [ -1.33, 0.13 ]
Subtotal (95% CI) 567 147 52.8 % -0.67 [ -1.06, -0.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 3.39 (P = 0.00071)
2 certolizumab pegol 400 mg sc
RAPID1 2005 355 0.1 (2.4) 90 0.7 (2.1) 31.9 % -0.60 [ -1.10, -0.10 ]
RAPID2 2007 222 -0.3 (1.8) 56 0.7 (2.6) 15.4 % -1.00 [ -1.72, -0.28 ]
Subtotal (95% CI) 577 146 47.2 % -0.73 [ -1.14, -0.32 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.80, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 3.48 (P = 0.00050)
Total (95% CI) 1144 293 100.0 % -0.70 [ -0.98, -0.42 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.89, df = 3 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 4.85 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
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Analysis 35.1. Comparison 35 Erosion score (ES) at 52 weeks, any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 35 Erosion score (ES) at 52 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab pegol 200 mg sc
RAPID1 2005 364 0.1 (2.5) 91 1.5 (4.3) 51.1 % -1.40 [ -2.32, -0.48 ]
Subtotal (95% CI) 364 91 51.1 % -1.40 [ -2.32, -0.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.98 (P = 0.0029)
2 certolizumab pegol 400 mg sc
RAPID1 2005 363 0 (3) 90 1.5 (4.3) 48.9 % -1.50 [ -2.44, -0.56 ]
Subtotal (95% CI) 363 90 48.9 % -1.50 [ -2.44, -0.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.13 (P = 0.0018)
Total (95% CI) 727 181 100.0 % -1.45 [ -2.11, -0.79 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 4.32 (P = 0.000016)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
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Analysis 36.1. Comparison 36 Joint space narrowing (JSN), Outcome 1 Change from the baseline mean JSN
24 weeks, certolizumab pegol 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 36 Joint space narrowing (JSN)
Outcome: 1 Change from the baseline mean JSN 24 weeks, certolizumab pegol 200 mg
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
RAPID1 2005 355 0.2 (2.5) 180 0.7 (2.4) 53.2 % -0.50 [ -0.94, -0.06 ]
RAPID2 2007 214 0.1 (1.4) 112 0.5 (2.3) 46.8 % -0.40 [ -0.87, 0.07 ]
Total (95% CI) 569 292 100.0 % -0.45 [ -0.77, -0.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 2.79 (P = 0.0053)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours certolizumab pego Favours control
Analysis 36.2. Comparison 36 Joint space narrowing (JSN), Outcome 2 Change from the baseline mean JSN
24 weeks,certolizumab pegol 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 36 Joint space narrowing (JSN)
Outcome: 2 Change from the baseline mean JSN 24 weeks,certolizumab pegol 400 mg
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
RAPID1 2005 355 0.2 (2.4) 180 0.7 (2.4) 51.8 % -0.50 [ -0.93, -0.07 ]
RAPID2 2007 222 -0.1 (1) 112 0.5 (2.3) 48.2 % -0.60 [ -1.05, -0.15 ]
Total (95% CI) 577 292 100.0 % -0.55 [ -0.86, -0.24 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 3.47 (P = 0.00052)
Test for subgroup differences: Not applicable
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Analysis 36.3. Comparison 36 Joint space narrowing (JSN), Outcome 3 Change from the baseline mean JSN
52 weeks,certolizumab pegol 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 36 Joint space narrowing (JSN)
Outcome: 3 Change from the baseline mean JSN 52 weeks,certolizumab pegol 200 mg





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 367 0.4 (4.2) 181 1.4 (5) 100.0 % -1.00 [ -1.85, -0.15 ]
Total (95% CI) 367 181 100.0 % -1.00 [ -1.85, -0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.020)
Test for subgroup differences: Not applicable
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Analysis 36.4. Comparison 36 Joint space narrowing (JSN), Outcome 4 Change from the baseline mean JSN
52 weeks, certolizumab pegol 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 36 Joint space narrowing (JSN)
Outcome: 4 Change from the baseline mean JSN 52 weeks, certolizumab pegol 400 mg





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 363 0.2 (2.8) 181 1.4 (5) 100.0 % -1.20 [ -1.98, -0.42 ]
Total (95% CI) 363 181 100.0 % -1.20 [ -1.98, -0.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Not applicable
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Analysis 37.1. Comparison 37 Joint space narrowing (JSN) at 24 weeks, any dose, Outcome 1 Change from
baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 37 Joint space narrowing (JSN) at 24 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 certolizumab pegol 200 mg sc
RAPID1 2005 355 0.2 (2.5) 91 0.7 (2.4) 27.7 % -0.50 [ -1.06, 0.06 ]
RAPID2 2007 214 0.1 (1.4) 56 0.5 (2.3) 21.6 % -0.40 [ -1.03, 0.23 ]
Subtotal (95% CI) 569 147 49.4 % -0.46 [ -0.87, -0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 2.14 (P = 0.032)
2 certolizumab pegol 400 mg sc
RAPID1 2005 355 0.2 (2.4) 90 0.7 (2.4) 28.0 % -0.50 [ -1.06, 0.06 ]
RAPID2 2007 222 -0.1 (1) 56 0.5 (2.3) 22.7 % -0.60 [ -1.22, 0.02 ]
Subtotal (95% CI) 577 146 50.6 % -0.54 [ -0.96, -0.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 2.59 (P = 0.0097)
Total (95% CI) 1146 293 100.0 % -0.50 [ -0.79, -0.21 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 3.35 (P = 0.00082)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.77), I2 =0.0%
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Analysis 38.1. Comparison 38 Joint space narrowing (JSN) at 52 weeks, any dose, Outcome 1 Change from
baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 38 Joint space narrowing (JSN) at 52 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab pegol 200 mg sc
RAPID1 2005 367 0.4 (4.2) 91 1.4 (5) 48.1 % -1.00 [ -2.11, 0.11 ]
Subtotal (95% CI) 367 91 48.1 % -1.00 [ -2.11, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.078)
2 certolizumab pegol 400 mg sc
RAPID1 2005 363 0.2 (2.8) 90 1.4 (5) 51.9 % -1.20 [ -2.27, -0.13 ]
Subtotal (95% CI) 363 90 51.9 % -1.20 [ -2.27, -0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.028)
Total (95% CI) 730 181 100.0 % -1.10 [ -1.88, -0.33 ]
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.80 (P = 0.0051)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.80), I2 =0.0%
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Analysis 39.1. Comparison 39 Modified Total Sharp Scores (mTSS) at 24 weeks, any dose, Outcome 1
Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 39 Modified Total Sharp Scores (mTSS) at 24 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 certolizumab pegol 200 mg sc
RAPID1 2005 353 0.2 (3.2) 90 1.3 (3.8) 32.6 % -1.10 [ -1.95, -0.25 ]
RAPID2 2007 214 0.2 (2.7) 56 1.2 (4.1) 18.5 % -1.00 [ -2.13, 0.13 ]
Subtotal (95% CI) 567 146 51.1 % -1.06 [ -1.75, -0.38 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
2 certolizumab pegol 400 mg sc
RAPID1 2005 355 0.2 (4.2) 91 1.3 (3.8) 29.6 % -1.10 [ -1.99, -0.21 ]
RAPID2 2007 222 -0.4 (2.1) 56 1.2 (4.1) 19.3 % -1.60 [ -2.71, -0.49 ]
Subtotal (95% CI) 577 147 48.9 % -1.30 [ -1.99, -0.60 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 3.65 (P = 0.00026)
Total (95% CI) 1144 293 100.0 % -1.18 [ -1.67, -0.69 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.71, df = 3 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 4.74 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.22, df = 1 (P = 0.64), I2 =0.0%
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Analysis 40.1. Comparison 40 Modified Total Sharp Scores (mTSS) at 52 weeks, any dose, Outcome 1
Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 40 Modified Total Sharp Scores (mTSS) at 52 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab pegol 200 mg sc
RAPID1 2005 364 0.4 (5.7) 91 2.8 (7.8) 49.4 % -2.40 [ -4.11, -0.69 ]
Subtotal (95% CI) 364 91 49.4 % -2.40 [ -4.11, -0.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.76 (P = 0.0058)
2 certolizumab pegol 400 mg sc
RAPID1 2005 363 0.2 (4.8) 90 2.8 (7.8) 50.6 % -2.60 [ -4.29, -0.91 ]
Subtotal (95% CI) 363 90 50.6 % -2.60 [ -4.29, -0.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.02 (P = 0.0025)
Total (95% CI) 727 181 100.0 % -2.50 [ -3.70, -1.30 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 4.09 (P = 0.000043)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
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Analysis 41.1. Comparison 41 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm), Outcome 1
Mean change at 24 weeks certolizumab pegol 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 41 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm)
Outcome: 1 Mean change at 24 weeks certolizumab pegol 200 mg
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
RAPID1 2005 393 -29.6 (21.81) 199 -8.1 (22.57) 59.7 % -21.50 [ -25.31, -17.69 ]
RAPID2 2007 246 -23.7 (22) 127 -4.7 (21.41) 40.3 % -19.00 [ -23.63, -14.37 ]
Total (95% CI) 639 326 100.0 % -20.49 [ -23.43, -17.55 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.67, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 13.66 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 41.2. Comparison 41 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm), Outcome 2
Mean change at 24 weeks certolizumab pegol 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 41 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm)
Outcome: 2 Mean change at 24 weeks certolizumab pegol 400 mg
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
FAST4WARD 2005 (1) 111 -20.6 (42) 109 1.7 (42) 6.6 % -22.30 [ -33.40, -11.20 ]
RAPID1 2005 (2) 390 -31.7 (21.72) 199 -8.1 (22.57) 55.8 % -23.60 [ -27.41, -19.79 ]
RAPID2 2007 246 -26.1 (22) 127 -4.7 (21.41) 37.7 % -21.40 [ -26.03, -16.77 ]
Total (95% CI) 747 435 100.0 % -22.69 [ -25.53, -19.84 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.52, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 15.65 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) In FAST4WARD we have obtained standard deviations from p values according to the Handbook section 7.7.3.7
(2) Data in RAPID1 from NICE report
Analysis 41.3. Comparison 41 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm), Outcome 3
Mean change at 52 weeks certolizumab pegol 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 41 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm)
Outcome: 3 Mean change at 52 weeks certolizumab pegol 200 mg





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 393 -31 (22.57) 199 -8.8 (23.79) 100.0 % -22.20 [ -26.19, -18.21 ]
Total (95% CI) 393 199 100.0 % -22.20 [ -26.19, -18.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 10.91 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours certolizumab pego Favours control
210Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 41.4. Comparison 41 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm), Outcome 4
Mean change at 52 weeks certolizumab pegol 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 41 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm)
Outcome: 4 Mean change at 52 weeks certolizumab pegol 400 mg





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 390 -33.5 (23.7) 199 -8.8 (22.57) 100.0 % -24.70 [ -28.62, -20.78 ]
Total (95% CI) 390 199 100.0 % -24.70 [ -28.62, -20.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 12.35 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 42.1. Comparison 42 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm) at 24 weeks,
any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 42 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm) at 24 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 certolizumab pegol 200 mg sc
RAPID1 2005 (1) 393 -29.6 (21.81) 100 -8.1 (22.57) 26.2 % -21.50 [ -26.42, -16.58 ]
RAPID2 2007 246 -23.7 (22) 64 -4.7 (21.41) 18.1 % -19.00 [ -24.92, -13.08 ]
Subtotal (95% CI) 639 164 44.3 % -20.48 [ -24.26, -16.69 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 10.60 (P < 0.00001)
2 certolizumab pegol 400 mg sc
CDP870-014 2009 (2) 124 -21.8 (51.4) 119 -8.5 (19.92) 6.7 % -13.30 [ -23.03, -3.57 ]
FAST4WARD 2005 111 -20.6 (42) 109 1.7 (42) 5.1 % -22.30 [ -33.40, -11.20 ]
RAPID1 2005 390 -31.7 (21.72) 99 -8.1 (22.57) 26.0 % -23.60 [ -28.54, -18.66 ]
RAPID2 2007 246 -26.1 (22) 63 -4.7 (21.41) 17.9 % -21.40 [ -27.36, -15.44 ]
Subtotal (95% CI) 871 390 55.7 % -21.35 [ -25.08, -17.61 ]
Heterogeneity: Tau2 = 2.00; Chi2 = 3.44, df = 3 (P = 0.33); I2 =13%
Test for overall effect: Z = 11.20 (P < 0.00001)
Total (95% CI) 1510 554 100.0 % -21.07 [ -23.59, -18.55 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.01, df = 5 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 16.39 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
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Analysis 43.1. Comparison 43 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm) at 52 weeks,
any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 43 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm) at 52 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab pegol 200 mg sc
RAPID1 2005 (1) 393 -31 (22.57) 100 -8.8 (23.79) 48.6 % -22.20 [ -27.37, -17.03 ]
Subtotal (95% CI) 393 100 48.6 % -22.20 [ -27.37, -17.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.42 (P < 0.00001)
2 certolizumab pegol 400 mg sc
RAPID1 2005 390 -33.5 (23.7) 99 -8.8 (22.57) 51.4 % -24.70 [ -29.73, -19.67 ]
Subtotal (95% CI) 390 99 51.4 % -24.70 [ -29.73, -19.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.62 (P < 0.00001)
Total (95% CI) 783 199 100.0 % -23.48 [ -27.09, -19.88 ]
Heterogeneity: Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 12.77 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.46, df = 1 (P = 0.50), I2 =0.0%
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Analysis 44.1. Comparison 44 Modified total Sharp scores (mTSS), Outcome 1 Change from the baseline
mean mTSS 24 weeks, certolizumab pegol 200 mg..
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 44 Modified total Sharp scores (mTSS)
Outcome: 1 Change from the baseline mean mTSS 24 weeks, certolizumab pegol 200 mg.
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
RAPID1 2005 353 0.2 (3.2) 180 1.3 (3.8) 62.8 % -1.10 [ -1.75, -0.45 ]
RAPID2 2007 214 0.2 (2.7) 112 1.2 (4.1) 37.2 % -1.00 [ -1.84, -0.16 ]
Total (95% CI) 567 292 100.0 % -1.06 [ -1.58, -0.55 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 4.06 (P = 0.000049)
Test for subgroup differences: Not applicable
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Analysis 44.2. Comparison 44 Modified total Sharp scores (mTSS), Outcome 2 Change from the baseline
mean mTSS 24 weeks, certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 44 Modified total Sharp scores (mTSS)
Outcome: 2 Change from the baseline mean mTSS 24 weeks, certolizumab 400 mg
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
RAPID1 2005 355 0.2 (4.2) 180 1.3 (3.8) 56.7 % -1.10 [ -1.81, -0.39 ]
RAPID2 2007 222 -0.4 (2.1) 112 1.2 (4.1) 43.3 % -1.60 [ -2.41, -0.79 ]
Total (95% CI) 577 292 100.0 % -1.32 [ -1.85, -0.78 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.83, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 4.85 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 44.3. Comparison 44 Modified total Sharp scores (mTSS), Outcome 3 Change from the baseline
mean mTSS 52 weeks, certolizumab pegol 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 44 Modified total Sharp scores (mTSS)








N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 364 0.4 (5.7) 181 2.8 (7.8) 100.0 % -2.40 [ -3.68, -1.12 ]
Total (95% CI) 364 181 100.0 % -2.40 [ -3.68, -1.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.68 (P = 0.00023)
Test for subgroup differences: Not applicable
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Analysis 44.4. Comparison 44 Modified total Sharp scores (mTSS), Outcome 4 Change from the baseline
mean mTSS 52 weeks, certolizumab pegol 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 44 Modified total Sharp scores (mTSS)
Outcome: 4 Change from the baseline mean mTSS 52 weeks, certolizumab pegol 400 mg
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 363 0.2 (4.8) 181 2.8 (7.8) 100.0 % -2.60 [ -3.84, -1.36 ]
Total (95% CI) 363 181 100.0 % -2.60 [ -3.84, -1.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.11 (P = 0.000039)
Test for subgroup differences: Not applicable
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Analysis 45.1. Comparison 45 Certolizumab pegol 1mg/kg/day sc, Outcome 1 Headache.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults




pegol 1 mg control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 3/8 1/12 100.0 % 4.50 [ 0.56, 35.98 ]
Total (95% CI) 8 12 100.0 % 4.50 [ 0.56, 35.98 ]
Total events: 3 (certolizumab pegol 1 mg), 1 (control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 45.2. Comparison 45 Certolizumab pegol 1mg/kg/day sc, Outcome 2 Lower respiratory tract
infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 45 Certolizumab pegol 1mg/kg/day sc
Outcome: 2 Lower respiratory tract infection
Study or subgroup
certolizumab
pegol 1 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 0/8 1/12 100.0 % 0.48 [ 0.02, 10.54 ]
Total (95% CI) 8 12 100.0 % 0.48 [ 0.02, 10.54 ]
Total events: 0 (certolizumab pegol 1 mg), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 45.3. Comparison 45 Certolizumab pegol 1mg/kg/day sc, Outcome 3 Adverse events Intensity
severe.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 45 Certolizumab pegol 1mg/kg/day sc
Outcome: 3 Adverse events Intensity severe
Study or subgroup
certolizumab
pegol 1 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 1/8 0/12 100.0 % 4.33 [ 0.20, 94.83 ]
Total (95% CI) 8 12 100.0 % 4.33 [ 0.20, 94.83 ]
Total events: 1 (certolizumab pegol 1 mg), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 45.4. Comparison 45 Certolizumab pegol 1mg/kg/day sc, Outcome 4 Antinuclear antibodies
(ANA).
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 45 Certolizumab pegol 1mg/kg/day sc
Outcome: 4 Antinuclear antibodies (ANA)
Study or subgroup
certolizumab
pegol 1 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 2/8 1/12 100.0 % 3.00 [ 0.32, 27.83 ]
Total (95% CI) 8 12 100.0 % 3.00 [ 0.32, 27.83 ]
Total events: 2 (certolizumab pegol 1 mg), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 45.5. Comparison 45 Certolizumab pegol 1mg/kg/day sc, Outcome 5 Urinary tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 45 Certolizumab pegol 1mg/kg/day sc
Outcome: 5 Urinary tract infection
Study or subgroup
certolizumab
pegol 1 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 1/8 0/12 100.0 % 4.33 [ 0.20, 94.83 ]
Total (95% CI) 8 12 100.0 % 4.33 [ 0.20, 94.83 ]
Total events: 1 (certolizumab pegol 1 mg), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 46.1. Comparison 46 Certolizumab 5 mg/kg/day sc, Outcome 1 Lower respiratory tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 46 Certolizumab 5 mg/kg/day sc
Outcome: 1 Lower respiratory tract infection
Study or subgroup
certolizumab
pegol 5 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 1/8 1/12 100.0 % 1.50 [ 0.11, 20.68 ]
Total (95% CI) 8 12 100.0 % 1.50 [ 0.11, 20.68 ]
Total events: 1 (certolizumab pegol 5 mg), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 46.2. Comparison 46 Certolizumab 5 mg/kg/day sc, Outcome 2 Urinary tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 46 Certolizumab 5 mg/kg/day sc
Outcome: 2 Urinary tract infection
Study or subgroup
certolizumab
pegol 5 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 1/8 0/12 100.0 % 4.33 [ 0.20, 94.83 ]
Total (95% CI) 8 12 100.0 % 4.33 [ 0.20, 94.83 ]
Total events: 1 (certolizumab pegol 5 mg), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 47.1. Comparison 47 Certolizumab 20 mg/kg/day sc, Outcome 1 Headache.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults




pegol 20 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 3/8 1/12 100.0 % 4.50 [ 0.56, 35.98 ]
Total (95% CI) 8 12 100.0 % 4.50 [ 0.56, 35.98 ]
Total events: 3 (certolizumab pegol 20 mg), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 47.2. Comparison 47 Certolizumab 20 mg/kg/day sc, Outcome 2 Lower respiratory tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 47 Certolizumab 20 mg/kg/day sc
Outcome: 2 Lower respiratory tract infection
Study or subgroup
certolizumab
pegol 20 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 2/8 1/12 100.0 % 3.00 [ 0.32, 27.83 ]
Total (95% CI) 8 12 100.0 % 3.00 [ 0.32, 27.83 ]
Total events: 2 (certolizumab pegol 20 mg), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 47.3. Comparison 47 Certolizumab 20 mg/kg/day sc, Outcome 3 Death.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults




pegol 20 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 1/8 0/12 100.0 % 4.33 [ 0.20, 94.83 ]
Total (95% CI) 8 12 100.0 % 4.33 [ 0.20, 94.83 ]
Total events: 1 (certolizumab pegol 20 mg), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 47.4. Comparison 47 Certolizumab 20 mg/kg/day sc, Outcome 4 Antinuclear antibodies (ANA).
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 47 Certolizumab 20 mg/kg/day sc
Outcome: 4 Antinuclear antibodies (ANA)
Study or subgroup
certolizumab
pegol 20 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 1/8 1/12 100.0 % 1.50 [ 0.11, 20.68 ]
Total (95% CI) 8 12 100.0 % 1.50 [ 0.11, 20.68 ]
Total events: 1 (certolizumab pegol 20 mg), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 47.5. Comparison 47 Certolizumab 20 mg/kg/day sc, Outcome 5 Urinary tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 47 Certolizumab 20 mg/kg/day sc
Outcome: 5 Urinary tract infection
Study or subgroup
certolizumab
pegol 20 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 1/8 0/12 100.0 % 4.33 [ 0.20, 94.83 ]
Total (95% CI) 8 12 100.0 % 4.33 [ 0.20, 94.83 ]
Total events: 1 (certolizumab pegol 20 mg), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 48.1. Comparison 48 Withdrawals, Outcome 1 All Withdrawn: any doses any follow up.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 48 Withdrawals
Outcome: 1 All Withdrawn: any doses any follow up








CDP870-014 2009 28/126 56/121 9.5 % 0.48 [ 0.33, 0.70 ]
CERTAIN 2008 12/96 18/98 4.6 % 0.68 [ 0.35, 1.34 ]
Choy 2002 2/24 6/12 1.3 % 0.17 [ 0.04, 0.71 ]
FAST4WARD 2005 35/111 81/109 11.8 % 0.42 [ 0.32, 0.57 ]
NCT00791921 HIKARI 34/116 96/114 11.9 % 0.35 [ 0.26, 0.47 ]
NCT00791999 JRAPID (1) 36/167 52/77 10.9 % 0.32 [ 0.23, 0.44 ]
NCT00993317 25/85 21/42 8.0 % 0.59 [ 0.38, 0.92 ]
RAPID1 2005 254/783 156/199 17.0 % 0.41 [ 0.37, 0.47 ]
RAPID2 2007 137/492 110/127 16.1 % 0.32 [ 0.27, 0.38 ]
REALISTIC 2008 80/851 28/212 9.0 % 0.71 [ 0.48, 1.07 ]
Total (95% CI) 2851 1111 100.0 % 0.42 [ 0.36, 0.50 ]
Total events: 643 (certolizumab pegol), 624 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 26.60, df = 9 (P = 0.002); I2 =66%
Test for overall effect: Z = 10.16 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 48.2. Comparison 48 Withdrawals, Outcome 2 Withdrawn due to lack of efficacy: any doses any
follow up.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 48 Withdrawals
Outcome: 2 Withdrawn due to lack of efficacy: any doses any follow up








CDP870-014 2009 16/126 45/121 10.8 % 0.34 [ 0.20, 0.57 ]
FAST4WARD 2005 24/111 75/109 16.6 % 0.31 [ 0.22, 0.46 ]
NCT00993317 18/85 18/42 10.0 % 0.49 [ 0.29, 0.85 ]
RAPID1 2005 151/783 125/199 32.4 % 0.31 [ 0.26, 0.37 ]
RAPID2 2007 95/492 101/127 30.2 % 0.24 [ 0.20, 0.30 ]
Total (95% CI) 1597 598 100.0 % 0.30 [ 0.25, 0.37 ]
Total events: 304 (certolizumab pegol), 364 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 7.90, df = 4 (P = 0.10); I2 =49%
Test for overall effect: Z = 12.04 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 48.3. Comparison 48 Withdrawals, Outcome 3 Withdrawals due to adverse events.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 48 Withdrawals
Outcome: 3 Withdrawals due to adverse events





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CDP870-014 2009 7/126 6/121 10.4 % 1.13 [ 0.37, 3.44 ]
CERTAIN 2008 6/96 6/98 9.5 % 1.02 [ 0.32, 3.28 ]
FAST4WARD 2005 5/111 2/109 5.7 % 2.37 [ 0.53, 10.64 ]
NCT00791921 HIKARI 8/116 2/114 8.1 % 3.42 [ 0.97, 12.13 ]
NCT00791999 JRAPID 13/239 3/77 9.5 % 1.38 [ 0.43, 4.44 ]
NCT00993317 4/85 2/42 4.3 % 0.99 [ 0.17, 5.60 ]
RAPID1 2005 39/783 3/199 22.0 % 2.33 [ 1.08, 5.03 ]
RAPID2 2007 17/492 2/127 10.2 % 1.88 [ 0.61, 5.82 ]
REALISTIC 2008 33/851 6/212 20.3 % 1.34 [ 0.60, 2.99 ]
Total (95% CI) 2899 1099 100.0 % 1.66 [ 1.15, 2.37 ]
Total events: 132 (Certolizumab pegol), 32 (Control)
Heterogeneity: Chi2 = 4.11, df = 8 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.74 (P = 0.0061)
Test for subgroup differences: Not applicable
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Analysis 49.1. Comparison 49 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 1 ACR 50 200 mg certolizumab 24 weeks.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 49 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 1 ACR 50 200 mg certolizumab 24 weeks
Study or subgroup
Certolizumab








CERTAIN 2008 20/96 7/98 16.7 % 2.92 [ 1.29, 6.58 ]
NCT00791999 JRAPID 45/82 13/77 24.4 % 3.25 [ 1.91, 5.54 ]
NCT00993317 35/85 8/42 20.2 % 2.16 [ 1.10, 4.24 ]
RAPID1 2005 144/393 15/199 25.3 % 4.86 [ 2.94, 8.04 ]
RAPID2 2007 80/246 4/127 13.4 % 10.33 [ 3.87, 27.54 ]
Total (95% CI) 902 543 100.0 % 3.80 [ 2.42, 5.95 ]
Total events: 324 (Certolizumab pegol 200 mg), 47 (Placebo)
Heterogeneity: Tau2 = 0.14; Chi2 = 9.05, df = 4 (P = 0.06); I2 =56%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 49.2. Comparison 49 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 2 HAQ change from baseline 200 mg certolizumab 24 weeks.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 49 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 2 HAQ change from baseline 200 mg certolizumab 24 weeks





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CERTAIN 2008 91 -0.25 (0.46) 91 -0.03 (0.49) 22.8 % -0.22 [ -0.36, -0.08 ]
NCT00993317 81 -0.54 (0.51) 40 -0.17 (0.7) 9.6 % -0.37 [ -0.61, -0.13 ]
RAPID1 2005 393 -0.58 (0.59) 199 -0.17 (0.56) 33.9 % -0.41 [ -0.51, -0.31 ]
RAPID2 2007 246 -0.5 (0.47) 127 -0.14 (0.45) 33.7 % -0.36 [ -0.46, -0.26 ]
Total (95% CI) 811 457 100.0 % -0.35 [ -0.43, -0.26 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.92, df = 3 (P = 0.18); I2 =39%
Test for overall effect: Z = 8.32 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 49.3. Comparison 49 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 3 Serious adverse events certolizumab 200 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 49 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 3 Serious adverse events certolizumab 200 mg sc





n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 certolizumab 200 mg
CERTAIN 2008 5/96 7/98 8.7 % -0.02 [ -0.09, 0.05 ]
REALISTIC 2008 52/846 12/209 30.1 % 0.00 [ -0.03, 0.04 ]
NCT00791999 JRAPID 4/82 1/77 7.1 % 0.04 [ -0.02, 0.09 ]
RAPID2 2007 18/248 4/125 14.9 % 0.04 [ 0.00, 0.09 ]
RAPID1 2005 45/392 11/199 23.7 % 0.06 [ 0.01, 0.10 ]
NCT00791921 HIKARI 13/116 3/114 10.3 % 0.09 [ 0.02, 0.15 ]
NCT00993317 8/85 0/42 5.1 % 0.09 [ 0.02, 0.16 ]
Total (95% CI) 1865 864 100.0 % 0.04 [ 0.02, 0.06 ]
Total events: 145 (Certolizumab pegol), 38 (Control)
Heterogeneity: Chi2 = 11.67, df = 6 (P = 0.07); I2 =49%
Test for overall effect: Z = 3.62 (P = 0.00030)
Test for subgroup differences: Not applicable
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Analysis 49.4. Comparison 49 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 4 Proportion of patients achieving remission 24 weeks certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 49 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 4 Proportion of patients achieving remission 24 weeks certolizumab 200 mg
Study or subgroup
Certolizumab








CERTAIN 2008 19/96 3/98 36.3 % 6.47 [ 1.98, 21.14 ]
NCT00791921 HIKARI 19/116 1/114 12.8 % 18.67 [ 2.54, 137.17 ]
RAPID1 2005 (1) 45/391 3/196 38.1 % 7.52 [ 2.37, 23.89 ]
RAPID2 2007 (2) 23/245 1/125 12.8 % 11.73 [ 1.60, 85.89 ]
Total (95% CI) 848 533 100.0 % 8.47 [ 4.15, 17.28 ]
Total events: 106 (Certolizumab pegol 200 mg), 8 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.97, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 5.87 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) UCB report for NICE quote Certolizumab n=391
(2) UCB report for NICE quote Certolizumab n=245
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Analysis 49.5. Comparison 49 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 5 Radiological changes: Erosion Scores (ES) certolizumab 200 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 49 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 5 Radiological changes: Erosion Scores (ES) certolizumab 200 mg sc





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 certolizumab 200 mg sc 24 weeks
RAPID1 2005 353 0 (1.5) 180 0.7 (2.1) 71.9 % -0.70 [ -1.04, -0.36 ]
RAPID2 2007 214 0.1 (2) 112 0.7 (2.6) 28.1 % -0.60 [ -1.15, -0.05 ]
Total (95% CI) 567 292 100.0 % -0.67 [ -0.96, -0.38 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 4.51 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 49.6. Comparison 49 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 6 All Withdrawals:.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 49 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 6 All Withdrawals:








Choy 2002 2/24 6/12 1.3 % 0.17 [ 0.04, 0.71 ]
NCT00791999 JRAPID (1) 36/167 52/77 10.9 % 0.32 [ 0.23, 0.44 ]
RAPID2 2007 137/492 110/127 16.1 % 0.32 [ 0.27, 0.38 ]
NCT00791921 HIKARI 34/116 96/114 11.9 % 0.35 [ 0.26, 0.47 ]
RAPID1 2005 254/783 156/199 17.0 % 0.41 [ 0.37, 0.47 ]
FAST4WARD 2005 35/111 81/109 11.8 % 0.42 [ 0.32, 0.57 ]
CDP870-014 2009 28/126 56/121 9.5 % 0.48 [ 0.33, 0.70 ]
NCT00993317 25/85 21/42 8.0 % 0.59 [ 0.38, 0.92 ]
CERTAIN 2008 12/96 18/98 4.6 % 0.68 [ 0.35, 1.34 ]
REALISTIC 2008 80/851 28/212 9.0 % 0.71 [ 0.48, 1.07 ]
Total (95% CI) 2851 1111 100.0 % 0.42 [ 0.36, 0.50 ]
Total events: 643 (Certolizumab pegol), 624 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 26.60, df = 9 (P = 0.002); I2 =66%
Test for overall effect: Z = 10.16 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 49.7. Comparison 49 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 7 Withdrawals due to adverse events.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 49 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 7 Withdrawals due to adverse events





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CDP870-014 2009 7/126 6/121 10.4 % 1.13 [ 0.37, 3.44 ]
CERTAIN 2008 6/96 6/98 9.5 % 1.02 [ 0.32, 3.28 ]
FAST4WARD 2005 5/111 2/109 5.7 % 2.37 [ 0.53, 10.64 ]
NCT00791921 HIKARI 8/116 2/114 8.1 % 3.42 [ 0.97, 12.13 ]
NCT00791999 JRAPID 13/239 3/77 9.5 % 1.38 [ 0.43, 4.44 ]
NCT00993317 4/85 2/42 4.3 % 0.99 [ 0.17, 5.60 ]
RAPID1 2005 39/783 3/199 22.0 % 2.33 [ 1.08, 5.03 ]
RAPID2 2007 17/492 2/127 10.2 % 1.88 [ 0.61, 5.82 ]
REALISTIC 2008 33/851 6/212 20.3 % 1.34 [ 0.60, 2.99 ]
Total (95% CI) 2899 1099 100.0 % 1.66 [ 1.15, 2.37 ]
Total events: 132 (Certolizumab pegol), 32 (Control)
Heterogeneity: Chi2 = 4.11, df = 8 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.74 (P = 0.0061)
Test for subgroup differences: Not applicable
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Analysis 49.8. Comparison 49 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 8 Deaths.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 49 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 8 Deaths





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Certolizumab pegol 200 mg
CERTAIN 2008 0/96 0/98 Not estimable
NCT00791921 HIKARI (1) 1/116 0/114 10.4 % 7.26 [ 0.14, 366.07 ]
NCT00791999 JRAPID 0/82 0/25 Not estimable
RAPID1 2005 (2) 3/392 1/100 26.8 % 0.75 [ 0.07, 8.60 ]
RAPID2 2007 (3) 1/246 0/63 6.8 % 3.51 [ 0.03, 455.29 ]
REALISTIC 2008 (4) 2/846 0/209 13.2 % 3.48 [ 0.11, 112.96 ]
Subtotal (95% CI) 1778 609 57.2 % 1.94 [ 0.36, 10.32 ]
Total events: 7 (Certolizumab pegol), 1 (Placebo)
Heterogeneity: Chi2 = 1.19, df = 3 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
2 Certolizumab pegol 400 mg
CDP870-014 2009 0/124 0/119 Not estimable
FAST4WARD 2005 0/111 0/109 Not estimable
NCT00791999 JRAPID 0/65 0/25 Not estimable
RAPID1 2005 (5) 4/389 0/99 26.8 % 3.53 [ 0.31, 40.72 ]
RAPID2 2007 (6) 1/246 0/62 6.7 % 3.50 [ 0.03, 464.09 ]
Subtotal (95% CI) 935 414 33.5 % 3.53 [ 0.40, 31.39 ]
Total events: 5 (Certolizumab pegol), 0 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
3 Other doses
Choy 2002 1/24 0/12 9.3 % 4.48 [ 0.07, 286.49 ]
NCT00791999 JRAPID 0/72 0/22 Not estimable
Subtotal (95% CI) 96 34 9.3 % 4.48 [ 0.07, 286.49 ]
Total events: 1 (Certolizumab pegol), 0 (Placebo)
Heterogeneity: not applicable
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n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI) 2809 1057 100.0 % 2.56 [ 0.72, 9.07 ]
Total events: 13 (Certolizumab pegol), 1 (Placebo)
Heterogeneity: Chi2 = 1.45, df = 6 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.15)
Test for subgroup differences: Chi2 = 0.26, df = 2 (P = 0.88), I2 =0.0%
0.002 0.1 1 10 500
Favours certolizumab pego Favours control
period). In Placebo 1 death (myocardial necrosis)
to CZP
(1) 1 patient died of a rupture of a dissecting aortic aneurysm in the thoracic region, but UCB considered that in unlikely to have beeen related to study medication
(2) Two deaths: one patient (hepatic neoplasm), and the other (cardiac arrest). One more died (peritonitis, cirrhosis, and general deterioration of physical health during
the posttreatment
(3) 1 patient died by myocardial infarction
(4) Two deaths in the CZP group: one case of sigmoid diverticulitis in a 73-year-old man with pancreatitis, and one of necrotizing pneumonia, both deaths were ruled as
possibly related
(5) Four deaths: 1 patient (cerebral stroke, 1 myocardial necrosis, 1 by cardiac arrest and 1 more by atrial fibrillation)
(6) 1 patient died by fracture and shock
234Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 49.9. Comparison 49 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 9 Tuberculosis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 49 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 9 Tuberculosis





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Certolizumab pegol 200 mg
CERTAIN 2008 0/96 0/98 Not estimable
NCT00993317 2/85 0/42 21.4 % 4.51 [ 0.23, 86.80 ]
RAPID1 2005 2/392 0/100 15.8 % 3.52 [ 0.11, 110.51 ]
RAPID2 2007 3/248 0/63 23.5 % 3.53 [ 0.21, 59.55 ]
REALISTIC 2008 0/846 0/209 Not estimable
Subtotal (95% CI) 1667 512 60.8 % 3.85 [ 0.66, 22.30 ]
Total events: 7 (Certolizumab pegol), 0 (Placebo)
Heterogeneity: Chi2 = 0.02, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
2 Certolizumab pegol 400 mg
FAST4WARD 2005 0/111 0/109 Not estimable
RAPID1 2005 3/389 0/99 23.6 % 3.52 [ 0.21, 59.11 ]
RAPID2 2007 2/246 0/62 15.7 % 3.51 [ 0.11, 111.96 ]
Subtotal (95% CI) 746 270 39.2 % 3.52 [ 0.40, 31.33 ]
Total events: 5 (Certolizumab pegol), 0 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
Total (95% CI) 2413 782 100.0 % 3.71 [ 0.94, 14.61 ]
Total events: 12 (Certolizumab pegol), 0 (Placebo)
Heterogeneity: Chi2 = 0.02, df = 4 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.88 (P = 0.060)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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(with or without MTX), Outcome 10 Upper respiratory tract infections.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 49 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 10 Upper respiratory tract infections





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Certolizumab pegol 200 mg
CERTAIN 2008 6/96 4/98 5.8 % 1.55 [ 0.44, 5.53 ]
NCT00791921 HIKARI 3/116 4/114 4.1 % 0.73 [ 0.16, 3.29 ]
NCT00791999 JRAPID 2/82 3/38 2.5 % 0.26 [ 0.04, 1.75 ]
NCT00993317 12/85 5/42 8.0 % 1.21 [ 0.41, 3.56 ]
RAPID1 2005 24/392 5/100 10.7 % 1.22 [ 0.48, 3.11 ]
RAPID2 2007 11/248 2/62 4.9 % 1.35 [ 0.34, 5.40 ]
REALISTIC 2008 112/846 19/209 44.3 % 1.46 [ 0.93, 2.32 ]
Subtotal (95% CI) 1865 663 80.3 % 1.28 [ 0.91, 1.80 ]
Total events: 170 (Certolizumab pegol), 42 (Placebo)
Heterogeneity: Chi2 = 3.66, df = 6 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.16)
2 Certolizumab pegol 400 mg
CDP870-014 2009 4/124 4/119 4.7 % 0.96 [ 0.23, 3.91 ]
NCT00791999 JRAPID 3/85 3/39 3.0 % 0.41 [ 0.07, 2.37 ]
RAPID1 2005 21/389 5/99 9.7 % 1.07 [ 0.40, 2.86 ]
RAPID2 2007 4/246 2/63 2.3 % 0.44 [ 0.06, 3.29 ]
Subtotal (95% CI) 844 320 19.7 % 0.81 [ 0.41, 1.61 ]
Total events: 32 (Certolizumab pegol), 14 (Placebo)
Heterogeneity: Chi2 = 1.30, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
Total (95% CI) 2709 983 100.0 % 1.17 [ 0.86, 1.59 ]
Total events: 202 (Certolizumab pegol), 56 (Placebo)
Heterogeneity: Chi2 = 6.31, df = 10 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 1.36, df = 1 (P = 0.24), I2 =26%
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 49 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 11 Lower respiratory tract infections





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Certolizumab pegol 200 mg
CERTAIN 2008 0/96 1/98 3.8 % 0.14 [ 0.00, 6.96 ]
NCT00791921 HIKARI (1) 2/116 0/114 7.6 % 7.33 [ 0.46, 117.85 ]
NCT00791999 JRAPID 1/82 1/38 6.6 % 0.43 [ 0.02, 8.48 ]
NCT00993317 2/85 0/42 6.7 % 4.51 [ 0.23, 86.80 ]
RAPID1 2005 3/392 0/100 7.4 % 3.53 [ 0.21, 59.02 ]
REALISTIC 2008 7/846 1/209 19.4 % 1.59 [ 0.28, 9.09 ]
Subtotal (95% CI) 1617 601 51.6 % 1.81 [ 0.62, 5.26 ]
Total events: 15 (Certolizumab pegol), 3 (Placebo)
Heterogeneity: Chi2 = 4.13, df = 5 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
2 Certolizumab pegol 400 mg
CDP870-014 2009 3/124 3/119 22.5 % 0.96 [ 0.19, 4.83 ]
NCT00791999 JRAPID 4/85 1/39 16.0 % 1.73 [ 0.25, 11.80 ]
RAPID1 2005 4/389 0/99 9.9 % 3.53 [ 0.31, 40.72 ]
Subtotal (95% CI) 598 257 48.4 % 1.52 [ 0.50, 4.59 ]
Total events: 11 (Certolizumab pegol), 4 (Placebo)
Heterogeneity: Chi2 = 0.79, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
Total (95% CI) 2215 858 100.0 % 1.66 [ 0.77, 3.58 ]
Total events: 26 (Certolizumab pegol), 7 (Placebo)
Heterogeneity: Chi2 = 4.96, df = 8 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.20)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.83), I2 =0.0%
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
(1) 2(1 pneumonia neumococcal and 1 pneumocystis jirobenzi pneumonia)
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(with or without MTX), Outcome 12 Malignancies including lymphoma.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 49 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 12 Malignancies including lymphoma





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Certolizumab pegol 200 mg
CERTAIN 2008 0/96 2/98 9.1 % 0.14 [ 0.01, 2.20 ]
NCT00791921 HIKARI 0/116 1/114 4.6 % 0.13 [ 0.00, 6.70 ]
NCT00993317 (1) 0/85 0/42 Not estimable
RAPID1 2005 (2) 7/392 1/199 32.3 % 2.61 [ 0.60, 11.41 ]
RAPID2 2007 1/248 1/125 8.1 % 0.48 [ 0.03, 9.01 ]
REALISTIC 2008 4/846 2/209 17.4 % 0.43 [ 0.06, 3.18 ]
Subtotal (95% CI) 1783 787 71.5 % 0.79 [ 0.29, 2.12 ]
Total events: 12 (Certolizumab pegol), 7 (Placebo)
Heterogeneity: Chi2 = 5.32, df = 4 (P = 0.26); I2 =25%
Test for overall effect: Z = 0.48 (P = 0.63)
2 Certolizumab pegol 400 mg
FAST4WARD 2005 0/111 0/109 Not estimable
RAPID1 2005 (3) 4/389 1/199 20.4 % 1.86 [ 0.29, 11.96 ]
RAPID2 2007 (4) 1/246 1/125 8.2 % 0.48 [ 0.03, 9.06 ]
Subtotal (95% CI) 746 433 28.5 % 1.26 [ 0.26, 6.08 ]
Total events: 5 (Certolizumab pegol), 2 (Placebo)
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Total (95% CI) 2529 1220 100.0 % 0.90 [ 0.39, 2.08 ]
Total events: 17 (Certolizumab pegol), 9 (Placebo)
Heterogeneity: Chi2 = 6.16, df = 6 (P = 0.41); I2 =3%
Test for overall effect: Z = 0.25 (P = 0.81)
Test for subgroup differences: Chi2 = 0.25, df = 1 (P = 0.62), I2 =0.0%
0.5 0.7 1 1.5 2
Favours certolizumab pego Favours control
system], one adrenal adenoma, one hepatic neoplasm one esophageal carcinoma, and uterine cancer
one papilloma.
(1) Data provided by UCB
(2) One patient in the arm of placebo suffered a thyroid neoplasm and 7 in the arm of certolizumab 200 mg sc suffered: three basal cell carcinomas [one with metastasis
to the central nervous
(3) In the placebo arm one patient suffered a thyroid neoplasm and 4 in the certolizumab 400 mg sc suffered two tongue neoplasm, 1 extranodal marginal zone B cell
limphoma and
(4) One case of malignant neoplasm was reported in each arm, namely bladder cancer in the placebo group and colon cancer in certolizumab pegol 400 mg group
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Analysis 50.1. Comparison 50 Analysis of sensibility ACR50, Outcome 1 Doses.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Analysis of sensibility ACR50
Outcome: 1 Doses








1 certolizumab 100 mg sc
NCT00791999 JRAPID 32/72 4/26 4.3 % 2.89 [ 1.13, 7.38 ]
Subtotal (95% CI) 72 26 4.3 % 2.89 [ 1.13, 7.38 ]
Total events: 32 (Certolizumab pegol), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.22 (P = 0.027)
2 certolizumab 200 mg sc
CERTAIN 2008 20/96 7/98 5.7 % 2.92 [ 1.29, 6.58 ]
NCT00791999 JRAPID 45/82 4/26 4.5 % 3.57 [ 1.42, 8.97 ]
NCT00993317 35/85 8/42 8.4 % 2.16 [ 1.10, 4.24 ]
RAPID1 2005 144/393 15/100 16.2 % 2.44 [ 1.50, 3.96 ]
RAPID2 2007 80/246 4/64 4.1 % 5.20 [ 1.98, 13.67 ]
REALISTIC 2008 226/851 21/212 21.4 % 2.68 [ 1.76, 4.08 ]
Subtotal (95% CI) 1753 542 60.1 % 2.73 [ 2.13, 3.51 ]
Total events: 550 (Certolizumab pegol), 59 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.79, df = 5 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 7.85 (P < 0.00001)
3 certolizumab 400 mg sc
CDP870-014 2009 22/126 7/121 5.7 % 3.02 [ 1.34, 6.81 ]
FAST4WARD 2005 25/111 4/109 3.6 % 6.14 [ 2.21, 17.05 ]
NCT00791999 JRAPID 46/85 5/25 5.8 % 2.71 [ 1.21, 6.07 ]
RAPID1 2005 155/390 15/99 16.3 % 2.62 [ 1.62, 4.25 ]
RAPID2 2007 81/246 4/63 4.1 % 5.19 [ 1.98, 13.61 ]
Subtotal (95% CI) 958 417 35.6 % 3.18 [ 2.29, 4.41 ]
Total events: 329 (Certolizumab pegol), 35 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.42, df = 4 (P = 0.49); I2 =0.0%
0.01 0.1 1 10 100
Favours control Favours certolizumab pego
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Test for overall effect: Z = 6.94 (P < 0.00001)
Total (95% CI) 2783 985 100.0 % 2.89 [ 2.38, 3.51 ]
Total events: 911 (Certolizumab pegol), 98 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.73, df = 11 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 10.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.52, df = 2 (P = 0.77), I2 =0.0%
0.01 0.1 1 10 100
Favours control Favours certolizumab pego
Analysis 50.2. Comparison 50 Analysis of sensibility ACR50, Outcome 2 Size.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Analysis of sensibility ACR50
Outcome: 2 Size








1 certolizumab < 200 patients
CERTAIN 2008 20/96 7/98 5.7 % 2.92 [ 1.29, 6.58 ]
NCT00993317 35/85 8/42 8.4 % 2.16 [ 1.10, 4.24 ]
Subtotal (95% CI) 181 140 14.1 % 2.44 [ 1.45, 4.10 ]
Total events: 55 (Certolizumab pegol), 15 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.37 (P = 0.00074)
2 certolizumab > 200 patients
CDP870-014 2009 22/126 7/121 5.7 % 3.02 [ 1.34, 6.81 ]
FAST4WARD 2005 25/111 4/109 3.6 % 6.14 [ 2.21, 17.05 ]
NCT00791999 JRAPID 32/72 4/26 4.3 % 2.89 [ 1.13, 7.38 ]
NCT00791999 JRAPID 46/85 5/25 5.8 % 2.71 [ 1.21, 6.07 ]
NCT00791999 JRAPID 45/82 4/26 4.5 % 3.57 [ 1.42, 8.97 ]
0.01 0.1 1 10 100
Favours control Favours certolizumab pego
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RAPID1 2005 144/393 15/100 16.2 % 2.44 [ 1.50, 3.96 ]
RAPID1 2005 155/390 15/99 16.3 % 2.62 [ 1.62, 4.25 ]
RAPID2 2007 80/246 4/64 4.1 % 5.20 [ 1.98, 13.67 ]
RAPID2 2007 81/246 4/63 4.1 % 5.19 [ 1.98, 13.61 ]
REALISTIC 2008 226/851 21/212 21.4 % 2.68 [ 1.76, 4.08 ]
Subtotal (95% CI) 2602 845 85.9 % 2.97 [ 2.41, 3.67 ]
Total events: 856 (Certolizumab pegol), 83 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.91, df = 9 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 10.16 (P < 0.00001)
Total (95% CI) 2783 985 100.0 % 2.89 [ 2.38, 3.51 ]
Total events: 911 (Certolizumab pegol), 98 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.73, df = 11 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 10.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.47, df = 1 (P = 0.49), I2 =0.0%
0.01 0.1 1 10 100
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Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Analysis of sensibility ACR50
Outcome: 3 Use of MTX









CDP870-014 2009 22/126 7/121 5.7 % 3.02 [ 1.34, 6.81 ]
NCT00993317 35/85 8/42 8.4 % 2.16 [ 1.10, 4.24 ]
RAPID1 2005 144/393 15/100 16.2 % 2.44 [ 1.50, 3.96 ]
RAPID1 2005 155/390 15/99 16.3 % 2.62 [ 1.62, 4.25 ]
RAPID2 2007 81/246 4/63 4.1 % 5.19 [ 1.98, 13.61 ]
RAPID2 2007 80/246 4/64 4.1 % 5.20 [ 1.98, 13.67 ]
REALISTIC 2008 226/851 21/212 21.4 % 2.68 [ 1.76, 4.08 ]
Subtotal (95% CI) 2337 701 76.1 % 2.77 [ 2.21, 3.46 ]
Total events: 743 (Certolizumab pegol), 74 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.27, df = 6 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 8.94 (P < 0.00001)
2 Without MTX
CERTAIN 2008 20/96 7/98 5.7 % 2.92 [ 1.29, 6.58 ]
FAST4WARD 2005 25/111 4/109 3.6 % 6.14 [ 2.21, 17.05 ]
NCT00791999 JRAPID 32/72 4/26 4.3 % 2.89 [ 1.13, 7.38 ]
NCT00791999 JRAPID 46/85 5/25 5.8 % 2.71 [ 1.21, 6.07 ]
NCT00791999 JRAPID 45/82 4/26 4.5 % 3.57 [ 1.42, 8.97 ]
Subtotal (95% CI) 446 284 23.9 % 3.32 [ 2.23, 4.95 ]
Total events: 168 (Certolizumab pegol), 24 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.86, df = 4 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 5.91 (P < 0.00001)
Total (95% CI) 2783 985 100.0 % 2.89 [ 2.38, 3.51 ]
Total events: 911 (Certolizumab pegol), 98 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.73, df = 11 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 10.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.62, df = 1 (P = 0.43), I2 =0.0%
0.01 0.1 1 10 100
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Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Analysis of sensibility ACR50
Outcome: 4 Population









NCT00791999 JRAPID 46/85 5/25 5.8 % 2.71 [ 1.21, 6.07 ]
NCT00791999 JRAPID 45/82 4/26 4.5 % 3.57 [ 1.42, 8.97 ]
NCT00791999 JRAPID 32/72 4/26 4.3 % 2.89 [ 1.13, 7.38 ]
NCT00993317 35/85 8/42 8.4 % 2.16 [ 1.10, 4.24 ]
Subtotal (95% CI) 324 119 22.9 % 2.66 [ 1.77, 4.00 ]
Total events: 158 (Certolizumab pegol), 21 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.80, df = 3 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 4.72 (P < 0.00001)
2 Other trials
CDP870-014 2009 22/126 7/121 5.7 % 3.02 [ 1.34, 6.81 ]
CERTAIN 2008 20/96 7/98 5.7 % 2.92 [ 1.29, 6.58 ]
FAST4WARD 2005 25/111 4/109 3.6 % 6.14 [ 2.21, 17.05 ]
RAPID1 2005 155/390 15/99 16.3 % 2.62 [ 1.62, 4.25 ]
RAPID1 2005 144/393 15/100 16.2 % 2.44 [ 1.50, 3.96 ]
RAPID2 2007 80/246 4/64 4.1 % 5.20 [ 1.98, 13.67 ]
RAPID2 2007 81/246 4/63 4.1 % 5.19 [ 1.98, 13.61 ]
REALISTIC 2008 226/851 21/212 21.4 % 2.68 [ 1.76, 4.08 ]
Subtotal (95% CI) 2459 866 77.1 % 2.96 [ 2.37, 3.70 ]
Total events: 753 (Certolizumab pegol), 77 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.71, df = 7 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 9.60 (P < 0.00001)
Total (95% CI) 2783 985 100.0 % 2.89 [ 2.38, 3.51 ]
Total events: 911 (Certolizumab pegol), 98 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.73, df = 11 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 10.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.20, df = 1 (P = 0.65), I2 =0.0%
0.01 0.1 1 10 100
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Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Analysis of sensibility ACR50
Outcome: 5 Duration of previous disease








1 Long previous disease duration (9 years or more)
CDP870-014 2009 22/126 7/121 7.2 % 3.02 [ 1.34, 6.81 ]
FAST4WARD 2005 25/111 4/109 4.6 % 6.14 [ 2.21, 17.05 ]
Subtotal (95% CI) 237 230 11.7 % 4.02 [ 2.02, 7.98 ]
Total events: 47 (Certolizumab pegol), 11 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 1.15, df = 1 (P = 0.28); I2 =13%
Test for overall effect: Z = 3.97 (P = 0.000073)
2 Short previous disease duration (less than 7 years)
NCT00993317 35/85 8/42 10.5 % 2.16 [ 1.10, 4.24 ]
RAPID1 2005 144/393 15/100 20.3 % 2.44 [ 1.50, 3.96 ]
RAPID1 2005 155/390 15/99 20.5 % 2.62 [ 1.62, 4.25 ]
RAPID2 2007 81/246 4/63 5.1 % 5.19 [ 1.98, 13.61 ]
RAPID2 2007 80/246 4/64 5.1 % 5.20 [ 1.98, 13.67 ]
REALISTIC 2008 226/851 21/212 26.8 % 2.68 [ 1.76, 4.08 ]
Subtotal (95% CI) 2211 580 88.3 % 2.75 [ 2.18, 3.47 ]
Total events: 721 (Certolizumab pegol), 67 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.23, df = 5 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 8.53 (P < 0.00001)
Total (95% CI) 2448 810 100.0 % 2.87 [ 2.31, 3.57 ]
Total events: 768 (Certolizumab pegol), 78 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.52, df = 7 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 9.47 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.05, df = 1 (P = 0.30), I2 =5%
0.01 0.1 1 10 100
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Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Analysis of sensibility ACR50
Outcome: 6 Published vs unpublished studies









CDP870-014 2009 22/126 7/121 5.7 % 3.02 [ 1.34, 6.81 ]
FAST4WARD 2005 25/111 4/109 3.6 % 6.14 [ 2.21, 17.05 ]
RAPID1 2005 144/393 15/100 16.2 % 2.44 [ 1.50, 3.96 ]
RAPID1 2005 155/390 15/99 16.3 % 2.62 [ 1.62, 4.25 ]
RAPID2 2007 81/246 4/63 4.1 % 5.19 [ 1.98, 13.61 ]
RAPID2 2007 80/246 4/64 4.1 % 5.20 [ 1.98, 13.67 ]
REALISTIC 2008 226/851 21/212 21.4 % 2.68 [ 1.76, 4.08 ]
Subtotal (95% CI) 2363 768 71.3 % 2.97 [ 2.36, 3.73 ]
Total events: 733 (Certolizumab pegol), 70 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.71, df = 6 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 9.25 (P < 0.00001)
2 Unpublished studies
CERTAIN 2008 20/96 7/98 5.7 % 2.92 [ 1.29, 6.58 ]
NCT00791999 JRAPID 45/82 4/26 4.5 % 3.57 [ 1.42, 8.97 ]
NCT00791999 JRAPID 46/85 5/25 5.8 % 2.71 [ 1.21, 6.07 ]
NCT00791999 JRAPID 32/72 4/26 4.3 % 2.89 [ 1.13, 7.38 ]
NCT00993317 35/85 8/42 8.4 % 2.16 [ 1.10, 4.24 ]
Subtotal (95% CI) 420 217 28.7 % 2.71 [ 1.89, 3.90 ]
Total events: 178 (Certolizumab pegol), 28 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.83, df = 4 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 5.38 (P < 0.00001)
Total (95% CI) 2783 985 100.0 % 2.89 [ 2.38, 3.51 ]
Total events: 911 (Certolizumab pegol), 98 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.73, df = 11 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 10.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.17, df = 1 (P = 0.68), I2 =0.0%
0.01 0.1 1 10 100
Favours control Favours certolizumab pego
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1.5 (0.64) CZP plus
MTX 1.4
(0.6)
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Notes: CZP = certolizumab pegol; CV = coefficient of variation; DAS = disease activity score; DMARD = disease-modifying an-
tirheumatic drug; ESR = erythrocyte sedimentation rate; IU = international units; L = litre; mg = milligrams; mL = millilitres; RF=
rheumatoid factor; SD = standard deviation; Y = years; NC = not calculated; N/A = not applicable. All randomised subjects; the
actual numbers vary slightly across parameters
Notes: CZP = cer
gol; CV = coefficient





litre; mg = milligrams;
millilitres; RF= rheumatoid
tor; SD = standar
Y = years; NC




Table 2. Flow of patients in the phase III trials retrieved








ITT n = 199
Safety n = 199
ITT n = 393
Safety a n = 392
ITT n = 390
Safety n = 389
Withdrawn at week 16
due to lack of efficacy
n = 125 (62.8%)
Withdrawn at week 16
due to lack of efficacy
n = 83 (21.1%)
Withdrawn at week 16
due to lack of efficacy
n = 68 (17.4%)
All withdrawn
n = 156 (78.4%)
All withdrawn
n = 138 (35.1)
All withdrawn
n = 116 (39.7%)
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Table 2. Flow of patients in the phase III trials retrieved (Continued)
Completed
n = 43 (21.6%)
Completed
n = 255 (64.9%)
Completed
n = 274 (70.3%)
RAPID2
n = 619
ITT n = 127c
Safety n = 125
ITT n = 246
Safety n = 248
ITT n = 246
Safety n = 246
Withdrawn at week 16
due to lack of efficacy
n = 103 (81%)
Withdrawn at week 16
due to lack of efficacy
n = 52 (21.1%)
Withdrawn at week 16
due to lack of efficacy
n = 52 (21.1%)
All withdrawn
n = 110 (86%)
All withdrawn
n = 72 (29.3%)
All withdrawn
n = 65 (26.4%)
Completed
n = 17 (13.4%)
Completed
n = 174 (70.7%)
Completed
n = 181 (73.6%)
FAST4WARD ITT n = 109
Safety n = 109
ITT n = 111
Safety n = 111
All withdrawn
n = 81 (74%)
75 (68.8%) Lack of effi-
cacy
2 (1.8%) Adverse event
1 (0.9%) Protocol viola-
tion
3 (2.8) Lost to follow-up
All withdrawn
n = 35 (31.5%)
24 (21.6%) Lack of effi-
cacy
5 (4.5%) Adverse event
4 (3.6%) Protocol viola-
tion
2 (1.8%) Consent with-
drawn
Completed
n = 28 (25.7%)
Completed
n = 76 (68.5%)
CDP870-014 ITT n = 121d
Safety n = 119
ITT n = 126d
Safety n = 124
All withdrawn
n = 56 (46.3%)
45 (37.2%) Lack of effi-
cacy
6 (5%) Adverse event
5 (4.1%) Other reasons
All withdrawn
n = 28 (22.2%)
16 (12.7%) Lack of effi-
cacy
7 (5.6%) Adverse event
5 (4%) Other reasons
Completed
n = 65 (53.7%)
Completed
n = 98 (77.8%)
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Table 2. Flow of patients in the phase III trials retrieved (Continued)
NCT00993317 ITT n =42
Safety n = 42
ITT n = 85
Safety n = 85
All withdrawn
n = 21 (50%)
18 (42%) Lack of efficacy
2 (4.76%) Adverse event
1 (2.38%) Other reasons
All withdrawn
n = 25 (29.41%)
18 (21.8%) Lack of effi-
cacy
4 (4.70%) Adverse event
3 (3.52%) Other reasons
Completed
n = 21 (50%)
Completed
n = 60 (70.58%)
CERTAIN ITT n = 98
Safety n = 98
ITT n = 96
Safety n = 96
All withdrawn
n = 18 (18.36%)
7 (7.14%) Lack of efficacy
6 (6.12 %) Adverse event
5 (5.10%) Other reasons
All withdrawn
n = 12 (12.5%)
2 (2.08%) Lack of efficacy
6 (6.25%) Adverse event
4 (4.16%) Other reasons
Completed
n = 80 (81.63%)
Completed
n = 84 (87.5%)
REALISTIC ITT n = 212
Safety n =
ITT n = 851
Safety n =
All withdrawn
n = 28 (13.20%)
6 (2.83%) Lack of efficacy
6 (2.83%) Adverse event
16 (7.54%) Other reasons
All withdrawn
n = 80 (9.41%)
6 (0.70%) Lack of efficacy
33 (3.87%) Adverse event
41 (4.81%) Other reasons
Completed
n = 184 (86.79%)
Completed
n = 771 (90.59%)
HIKARI ITT n = 114
Safety n = 114
ITT n = 116
Safety n = 116
All withdrawn
n = 96 (84.2%)
2 (1.75%) Lack of efficacy
2 (1.75%) Adverse event
94 (82%) Other reasons
(protocol planned n =88)
All withdrawn
n = 34 (29.31%)
0 (0%) Lack of efficacy
8 (6.9%) Adverse event
26 (22.4%) Other reasons
(protocol planned n =24)
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Table 2. Flow of patients in the phase III trials retrieved (Continued)
Completed
n = 18 (15.8%)
Completed
n = 82 (70.69%)
JRAPID ITT n = 77
Safety n = 77
ITT n = 72
Safety n = 72
ITT n = 82
Safety n = 82
ITT n = 85
Safety n = 85
All withdrawn
n = 52 (67.53%)
2 (2.98%) Lack of efficacy
3 (3.90%) Adverse event




n = 21 (29.17%)
3 (4.17%) Lack of efficacy
0 (0%) Adverse event




n = 16 (19.51%)
1 (1.22%) Lack of efficacy
3 (3.66%) Adverse event




n = 20 (23.53%)
0 (0%) Lack of efficacy
7 (8.23%) Adverse event




n = 25 (32.47%)
Completed
n = 51 (70.83%)
Completed
n = 66 (80.49%)
Completed
n = 65 (76.47%)
a One patient withdrew by her own decision
b One patient was discontinued due to the ESR/CRP not meeting criteria
c Two patients in the placebo group received certolizumab pegol and were included for safety in the 200 mg group
d Two patients in the each of treatment groups did not take study medication. Manufactures reported efficacy calculations from
placebo n = 119 and certolizumab pegol n = 124













= 119 and certolizumab
124
Table 3. Beneficial ACR50





RR (IC95%) % RD NNT
ACR50






36% 9% 3.80 (2.42 to 5.
95)
27 (20 to 33) 4 (3 to 8)
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Table 3. Beneficial ACR50 (Continued)
RAPID1 2005;
RAPID2 2007









34% 7% 4.65 (3.09 to 6.
99)
27 (17 to 34) 4 (3 to 7)
Analysis 5.2 52 weeks 200 mg/
RAPID1 2005,
38% 8% 5.03 (3.04 to 8.
32)
30 (24 to 36) 4 (2 to 7)
Analysis 6.2 52 weeks 400 mg/
RAPID1 2005
40% 8% 5.27 (3.19 to 8.
71)
32 (26 to 38) 3 (2 to 6)
Table 4. Health-related quality of life
Follow-up Doses/study Mean differences
HAQ (0-3)
(Best=0; Worst 3)
Analysis 11.1 24 weeks 200
mg/ CERTAIN 2008; NCT00993317;
RAPID1 2005; RAPID2 2007
-0.35 (-0.43 to -0.26)
Analysis 11.2 24 weeks 400
mg/ CDP870-014 2009; FAST4WARD
2005; RAPID1 2005; RAPID2 2007
-0.38 (-0.48 to -0.28)
52 weeks 200 mg/ RAPID1 2005 -0.42 (-0.54 to -0.30)
52 weeks 400 mg/ RAPID1 2005 -0.45 (-0.57 to -0.33)
SF-36 PCS (0-100)
(Worst=0; Best=100)
Analysis 14.1 24 weeks 200mg/CERTAIN2008;RAPID12005;
RAPID2 2007
5.03 (3.90 to 6.16)
Analysis 14.2 24 weeks 400 mg/ CDP870-014 2009; RAPID1
2005; RAPID2 2007
5.54 (4.11 to 6.97)
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Table 4. Health-related quality of life (Continued)
SF-36 MCS (0-100)
(Worst=0; Best=100)
Analysis 15.1 24 weeks 200 mg/ RAPID1 2005; RAPID2 2007 4.18 (2.70 to 5.66)
Analysis 15.2 24 weeks 400 mg/ CDP870-014 2009; RAPID1
2005; RAPID2 2007
4.05 (2.77 to 5.34)
SF-36 PCS
Analysis 16.1 52 weeks 200 mg/ RAPID1 2005 6.06 (4.59 to 7.53)
Analysis 16.2 52 weeks 400 mg/ RAPID1 2005 6.88 (5.42 to 8.34)
SF-36 MCS (0-100)
(Worst=0; Best=100)
52 weeks 200 mg/ RAPID1 2005 4.3 (2.4 to 6.2)
52 weeks 400 mg/ RAPID1 2005 4.3 (2.4 to 6.2)
Patients VAS score (0-100)
24 weeks 200 mg/ RAPID1 2005; RAPID2 2007 -20.48 (-24.26 to -16.69)
400 mg/ RAPID1 2005; RAPID2 2007;
FAST4WARD 2005
-21.35 (-25.08 to -17.61)
52 weeks 200 mg/ RAPID1 2005 -22.20 (-27.37 to -17.03)
400 mg/ RAPID1 2005 -24.70 (-29.73 to -19.67)
DAS-28 remission (< 2.6)
Analysis 25.2 24 weeks 200
mg/CERTAIN 2008; NCT00791921
HIKARI; RAPID1 2005; RAPID2 2007
8.47 (4.15 to 17.28)
Analysis 25.3 400 mg/ CDP870-014 2009; RAPID1
2005; RAPID2 2007
7.18 (3.12 to 16.50)
Analysis 25.4 52 weeks 200 mg/ RAPID1 2005 10.36 (3.29 to 32.58)
Analysis 25.5 400 mg/ RAPID1 2005 12.49 (3.99 to 39.12)
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Table 5. Radiological changes
Follow up Doses/study Mean differences
Modified Total Sharp Scores
(mTTS) is the sum of the ero-
sion score (ES) and the joint
space narrowing (JSN) score
and has a range of 0 to 398
Analysis 44.1 24 weeks 200 mg/ RAPID1 2005; RAPID2 2007 -1.06 (-1.58 to -0.55)
Analysis 44.2 24 weeks 400 mg/ RAPID1 2005; RAPID2 2007 -1.32 (-1.85 to -0.78)
52 weeks 200 mg/ RAPID1 2005 -2.4 (-4.11 to -0.69)
52 weeks 400 mg/ RAPID1 2005 -2.6 (-4.29 to -0.91)
ErosionScore is the sumof joint
scores collected for 46 joints
and has a range of 0 to 230
Analysis 33.1 24 weeks 200 mg/ RAPID1 2005; RAPID2 2007 -0.67 (-0.96 to -0.38)
Analysis 33.2 24 weeks 400 mg/ RAPID1 2005; RAPID2 2007 -0.76 (-1.14 to -0.37)
52 weeks 200 mg/ RAPID1 2005 -1.4 (-2.32 to -0.48)
52 weeks 400 mg/ RAPID1 2005 -1.5 (-2.44 to -0.56)
Joint space narrowing (JSN) is
the sum of joint scores collected
for 42 joints and has a range of
0 to 168
Analysis 36.1 24 weeks 200 mg/ RAPID1 2005; RAPID2 2007 -0.45 (-0.77 to -0.13)
Analysis 36.2 24 weeks 400 mg/ RAPID1 2005; RAPID2 2007 -0.55 (- 0.86 to -0.24)
52 weeks 200 mg/ RAPID1 2005 -1 (-1.85 to -0.15)
52 weeks 400 mg/ RAPID1 2005 -1.2 (-1.98 to -0.42)
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Table 6. Adverse events
Studies Response





rate in % (num-
ber of events)
placebo



















7% (145) 4% (38) 1.77 (1.27 to 2.
46)














10% (95) 4% (31) 1.98 (1.36 to 2.
9)




















4% (90) 3% (26) 1.62 (1.07 to 2.
44)







5% (48) 2% (16) 2.01 (1.20 to 3.
36)
3 (1 to 5) 52 (23 to 257)
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0.3% (6) 0.1% (1) 2.56 (0.56 to 11.
6)











0.5% (5) 0% (0) 2.16 (0.40 to 11.
79)







0.01 (1) 0% (0) 4.48 (0.07 to
286.49)
























0.6% (12) 0.9% (7) 0.79 (0.29 to 2.
12)








0.6 % (5) 0.4% (2) 1.26 (0.26 to 6.
08)
0 (-1 to 1) NS
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32% (559) 25% (247) 1.29 (1.07 to 1.
56)












34% (293) 21% (111) 1.49 (1.11 to 1.
99)
10 (1 to 20) 10 (5 to 44)
Tuberculosis Peto OR 3.71
(0.94 to 14.61)
Not calculated NS

























0.6% (5) 0% (0) 4.55 (0.71 to 29.
11)
Not calculated NS
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to Present>
Search Strategy:
1 (CDP870 or CDP 870 or “certolizumab pegol” or certolizumab or CDP-870 or cimzia).mp. (393)
2 (“Rheumatoid Arthritis” or (Caplan$ and Syndrome?) or (Felty$ and S?ndrome) or (Rheumatoid and Nodule?) or (Sjogren$ and S?
ndrome?) or (Sicca$ and S?ndrome?) or (Ankylos$ and Spondylit$) or (Spondylarthritis and Ankylopoietica) or (Rheumatoid$ and
Spondylit$) or (Bechterew$ and Disease?) or (Marie-Struempell and Disease?) or (Adult and Onset and Still$ and Disease?)).mp.
(98824)
3 exp Arthritis, Rheumatoid/ (94528)
4 2 or 3 (126632)
5 1 and 4 (131)








14 5 and 13 (114)
15 limit 14 to yr=“2009 -Current” (99)
Search date: 2009-February 12, 2013
Appendix 2. EMBASE search strategy
1. ’rheumatoid arthritis’/exp/
2. ’certolizumab pegol’/exp/
3. (CDP870 OR ’CDP 870’ OR CDP-870 OR ’certolizumab pegol’ OR certolizumab OR cimzia).mp.
4. 2 OR 3
5. 4 AND 1
6. random:.tw.
7. clinical trial:.mp.
8. exp health care quality
9. or/6-8
10. 5 AND 9
Search date: 2009-February 12, 2013
Appendix 3. CINAHL search strategy
1.’rheumatoid arthritis’/exp/
2.“rheumatoid arthritis”.mp.
3. (CDP870 OR ’CDP 870’ OR CDP-870 OR ’certolizumab pegol’ OR certolizumab OR cimzia).mp.






Search date: 2009-February 12, 2013
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Appendix 4. Search strategy for CDSR and CENTRAL, HTA, DARE, NHS EED
Last search on November 2009
#1 certolizumab or cimzia
#2 cdp870
#3 cdp next 870
#4 (#1 OR #2 OR #3)
#5 rheumatoid next arthritis
#6 MeSH descriptor Arthritis, Rheumatoid explode all trees
#7 (#5 OR #6)
#8 (#4 AND #7)
Search date: 2009-February 12, 2013
Appendix 5. SCOPUS search strategy
Search strategy for benefits:
SCOPUS will be searched up to August of 2007, without limits of years:
KEY((certolizumab OR cimzia OR CDP-870 OR CDP870 OR “CDP 870”) AND (“rheumatoid arthritis” ))
Web of Knowledge (WOK), was searched up to August of 2007, without limits of years. The search strategy is as follows:
topic=((certolizumab OR cimzia OR CDP-870 OR CDP870 OR “CDP 870”) AND (“rheumatoid arthritis” )
Databases=MEDLINE, Current Contents Connect, Web of Science, Derwent Innovations Index, ISI Proceedings; Timespan=All Years
Search date: 2009-February 12, 2013
Appendix 6. TOXLINE (TOXNET) search strategy
Search strategy for safety:
TOXLINE (TOXNET) will be searched up to October 2007. The search strategy will combine index and text terms for CDP870:
#1. certolizumab OR “certolizumab pegol” OR CDP870 OR CDP-870 OR “CDP 870” OR cimzia
Search date: 2009-February 12, 2013
Appendix 7. Web of Knowledge
Web of Knowledge (Science Citation Index and Social Science Citation Index) 1900 - February 2013
Search terms: TS= (certolizumab OR cimzia OR or CDP870 OR cdp 870) and (“rheumatoid arthritis”)
Search date: 2009-February 12, 2013
Appendix 8. Results of searches
Database name and coverage Search date Total Retrieved
Ovid MEDLINE(R) In-Process & Other
Non-Indexed Citations and Ovid MED-
LINE(R) 1946 to present
2009-February 12, 2013 315
Ovid Embase Classic+Embase
1947 to 2013 January 16
2009- February 12, 2013 1365
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(Continued)
Wiley Cochrane Library - CENTRAL
Issue 1 of 12- Jan. 2013
2009- February 12, 2013 11
EbscoHost CINAHL
1982-January 2013
2009- February 12, 2013 32
Toxline (TOXNET) 2007- February 12,
2013
34




1966 to 2013 January
2009- February 12, 2013 814
Total 2760
Total without Duplicates 1300
Appendix 9. Searches updated to June 2014
Database name and coverage Search date Total Retrieved Total without Duplicates
Ovid MEDLINE(R) In-Pro-
cess & Other Non-Indexed Ci-
tations and Ovid MEDLINE
(R)
2013-2014
June 5, 2014 29 28
Ovid Embase Classic+Embase
2013-2014
June 5, 2014 208 192
EbscoHost CINAHL
2013-2014
June 5, 2014 1 1
Wiley Cochrane Library -
CENTRAL
2013-2014
June 6, 2014 4 4
SCOPUS
2013-2014
June 10, 2014 233 124
Web of Knowledge
2013-2014
June 10, 2014 94 54
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(Continued)
Total 569 403
WH A T ’ S N E W
Last assessed as up-to-date: 5 June 2014.
Date Event Description
5 June 2014 New citation required but conclusions have not changed In the current update, we changed some authors in the
team: Sylvia Bort, Paloma Vela and Francis Kynaston are
new
5 June 2014 New search has been performed • Eleven trials were included (10 trials for benefits, 5
more than previously, and 10 for harms, 4 more than
previously). We have more information regarding the
quality of trials because UCB gave us data about this.
This information has been used to update the assessment
of the quality of trials.
• New data from clinical trial 014, as Disease Activity
Score (DAS) remission and SF-36 physical and mental
domains or pain assessment, were added. We also added
more data on the quality of the two phase II (004 and
Choy) trials.
• We got unpublished information on new trials for
quality and results including withdrawals and serious
adverse events from http://clinicaltrials.gov. We checked
this information with UCB.
H I S T O R Y
Protocol first published: Issue 1, 2009
Review first published: Issue 2, 2011
Date Event Description
3 April 2008 New search has been performed CMSG ID: C001-R
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C O N T R I B U T I O N S O F A U T H O R S
Design the protocol: Juan Cabello; Vicente Ruiz; Amanda Burls
Write up the background: Paloma Vela
Develop the search strategy: Tamara Rader
Trial search (2 people): Vicente Ruiz; Sylvia Bort
Obtain copies of the trials: Sylvia Bort
Selection of trials for inclusion (2 + 1): Vicente Ruiz; P Jobanputra. If data discrepancies were to be resolved by involvement of a third
person: FJB Kynaston-Pearson
Retrieval of trial data on benefits (two people): Vicente Ruiz; P Jobanputra. If data discrepancies were to be resolved by involvement
of a third person: Francis JB Kynaston-Pearson
Data input in Revman: Sylvia Bort
Carry out analyses: Vicente Ruiz;
Interpret analyses: P Jobanputra
Write up results: Vicente Ruiz; P Jobanputra; P Vela; Amanda Burls; Juan Cabello; Sylvia Bort; FJB Kynaston-Pearson
Update review: Vicente Ruiz; P Jobanputra; P Vela
D E C L A R A T I O N S O F I N T E R E S T
UCB paid Dr Vicente Ruiz’s registration for the Cochrane meeting in Madrid 2011 to. In 2011 and 2012 he attended the UCB
Advisory Board meetings in Madrid when the sponsor explained details and preliminary results for the new trials of certolizumab pegol.
He did not receive any economic or other kind of compensation for these meetings.
Paresh Jo: UCB arranged and paid for travel and accommodation for the American College for Rheumatology meeting in Philadelphia
in 2009.
Burls A: none known.
Cabello JB: none known.
Vela Casasempere P: I have participated as a member of advisory boards for Roche and Pfizer. I have also received fees for development
of educational presentations for Roche, Abbvie, UCB, BMS and MSD, and travel and accommodations expenses to attend scientific
meetings from Pfizer, Abbvie and Roche.
Bort-Marti S: none known.
Kynaston-Pearson FJB: none known.
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S O U R C E S O F S U P P O R T
Internal sources
• Grant from, Spain.
Instituto de Salud Carlos III. Ministerio de Sanidad. FIS number PI08˙90617 in the first previous systematic review.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Data synthesis
We decided to perform a random-effects model analysis despite low values of the I2 statistic. Although it was the same drug, there is
clear clinical heterogeneity (different doses, allowing MTX or not, different follow-up, different duration of RA, etc.).
Subgroup analysis
Subgroup analyses were planned for the duration of the illness (approximately three years evolution), patients’ sex, drug dose and
administration, and methodological quality; but only subgroup analysis regarding the dose of certolizumab pegol was performed. All
phase III trials were performed in patients with a long mean duration of RA (from 6.1 to 9.5 years) and we could not obtain any data
categorized by sex. All phase III trials allowed previous DMARD treatment (mean 1.2 to 2 years). All the phase III trials included in
the meta-analysis were rated as high quality and so we did not perform subgroup analysis based on methodological quality.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antibodies, Monoclonal, Humanized; Antirheumatic Agents [∗therapeutic use]; Arthritis, Rheumatoid [∗drug therapy]; Immunoglob-
ulin Fab Fragments [∗therapeutic use]; Methotrexate [therapeutic use]; Polyethylene Glycols [∗therapeutic use]; Randomized Con-
trolled Trials as Topic
MeSH check words
Adult; Humans
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